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Abstract 
 
An increased rate of cellular proliferation is a hallmark of cancer cells and may be 
accompanied by an increase in ribosome biogenesis and dysregulation in rRNA synthesis. In 
this regard CX-5461 has been developed as a novel RNA polymerase I inhibitor and is currently 
in Phase I/II clinical trials. The work described herein sets out to explore the use of this agent 
in combination with radiation therapy in solid cancer cell lines to understand the associated 
molecular mechanisms using this approach. Previous work has examined the CX-5461 in 
haematological malignancies and some solid cancers. Reports have shown that, treatment 
with CX-5461 induces potent anti-proliferative effects alongside induction of apoptosis in 
haematological malignancies.  
 
A panel of solid human tumour cell lines treated with CX-5461 indicated a broad spectrum of 
sensitivity (MTS Assay) with IC50 values ranging from 35nM to 1μM. The mode of cell death 
following CX-5461 exposure in the cancer cell lines studied was cell context dependent- either 
via autophagy (LC3I ® LC3II conversion alongside p62 sequestosome decrease) or via 
apoptosis (AnnexinV staining and late PARP cleavage). Treatment with CX-5461 also induced 
marked levels of DNA damage as detected through increased gH2AX foci staining. The 
presence of senescence marker β-galactosidase in CX-5461 treated cells indicates cell cycle 
arrest alongside the potent anti-proliferative effects of CX-5461 being highlighted through the 
clonogenic assays and decreased Ki-67 expression (flow cytometry). 
 
Through combination experiments involving CX-5461 and X-ray radiotherapy the current 
study has identified the highest levels of increased effectiveness in interactions between CX-
5461 and X-rays within the CaSki cervical cancer cell line. Highly significant effects were seen 
when low dose radiation and low dose CX-5461 were used together (combination index CI - < 
0.2 with 6.25nM CX-5461 and 2Gy X-rays) through isobologram analysis. Cell cycle analysis of 
CaSki and A375 cells treated with single dose CX-5461 resulted in G2M cell cycle arrest and 
combination treatments with X-rays indicated cell cycle disruption with prolonged S-phase. 
The work described herein identifies the synergistic role of CX-5461 in combination with X-
rays in solid cancers and may also inform the design of clinical trials of this novel agent.   
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Figure 1: Graphical abstract illustrating the increased effectiveness of combining RNA Pol I inhibition alongside X-ray radiation 
to induce cell death in solid cancer cell lines. Treatment with CX-5461 inhibits the transcription of rRNA genes which results in a 
decrease in ribosome production. Following exposure to a second agent (X-rays) DNA damage induced by X-rays exposure 
cannot be repaired as there are no viable ribosomes present to produce the necessary repair proteins required for the fulfilment 
of the DNA damage response mechanism 
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Chapter 1 
 
Introduction 
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1.1 General introduction 
 
Cancer can be defined as the abnormal growth and division of cells without control and the 
ability of these cells to invade nearby tissue (NCI dictionary of cancer terms) and is one of the 
world’s leading public health problems. It is the second leading cause of death globally and is 
responsible for some 8.8 million deaths in 2015 (World Health Organization 1st Feb 2018). 
Data collected from Cancer Research UK indicate around 14.1 million new cases worldwide in 
2012 and 8.2 million deaths globally resulting from cancers of various kinds (Cancer research 
UK 4th July 2018). In the UK, over 350,000 new cases of cancer were reported in 2015 and 
over 160,000 deaths reported in 2014 (Cancer research UK 4th July 2018). The survival rates 
in the UK show that for all cancers combined 50% of people diagnosed with cancer in England 
and Wales survive their disease for ten years or more (2010-2011). The data also highlighted 
that cancer survival is higher in women compared to men and importantly cancer survival is 
improving and has doubled in the last 40 years across the UK (Cancer Research UK, England 
and Wales Survival (2010-2011) Summary - April 2014).  
 
This reduction in cancer mortality is testimony to the numerous advancements made in the 
diagnosis and management of cancer through surgery, chemotherapy and radiation therapy. 
The causes of cancer vary greatly ranging from exposure to different kinds of radiation, 
dietary lifestyles as well as genetic predispositions. 
 
Treatment of cancer consists of three main avenues of intervention; surgery, chemotherapy 
and radiation therapy. Other methods of treatment include holistic alternative medicine and 
hormonal therapy. During 2013-2014, 27% of diagnosed patients in the UK for all cancers 
combined received curative or palliative radiotherapy (excluding Brachytherapy and Contact 
Radiotherapy). During the same time period, 28% of patients diagnosed with cancer (all 
cancers) received curative or palliative chemotherapy treatment (Chemotherapy, 
Radiotherapy and Tumour Resections in England: 2013-2014 workbook. London: NCRAS; 
2017). 
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Combination therapy (CT) is a modality which combines two or more agents to treat cancer. 
CT enhances the efficacy of anti-cancer agents compared to mono-therapy approaches due 
to the targeting of key intracellular pathways which result in synergistic or additive outcomes.  
The goal of radiation therapy is to minimise the dose delivered to the patient including healthy 
tissue whilst maximising the damage to target area. The aim of chemotherapy is to deliver 
cytotoxicity to the target tissue whilst sparing healthy cells and minimising side effects as a 
result of radiation exposure such as excess dose delivery to surrounding healthy tissue, skin 
problems, fatigue, hair loss and nausea and vomiting . Since the mechanism of action of most 
chemotherapy drugs is to kill rapidly growing and dividing cells, some healthy cells which are 
also rapidly proliferating are also affected which can lead to serious side effects. Targeted 
therapies on the other hand are drugs which act on specific molecular targets which are 
associated with cancer. The different kinds of targeted therapies approved for use in cancer 
treatment include: hormone therapies, signal transduction inhibitors, gene expression 
modulators, apoptotic inducers, angiogenesis inhibitors, immunotherapies and the use of 
monoclonal antibodies. 
 
Healthy cells which have undergone cellular transformation from a healthy state to a 
malignant cancerous phenotype display a number of cytological features exclusive to cancer 
cells, known as the hallmarks of cancer first described in 2000 (Hannahan and Weinburg 
2000). These hallmarks include resistance to cell death mechanisms through evasion of 
programmed cell death mechanisms such as apoptosis, evasion of growth suppressor 
signalling by resisting anti-survival/growth signalling which can stop the growth of a cell, 
sustained cellular proliferation signalling whereby a transformed cell can stimulate its own 
growth, replicative immortality which allows the cell unlimited replicative potential, induction 
of angiogenesis as the tumour can stimulate the growth of blood vessels to deliver oxygen 
and nutrients to the tumour site and activation of metastasis where a cancer cell gains the 
ability to spread to distant sites and invade local tissues (Figure 1.1).  
 
 
 
 
4 
 
This list was updated in 2011 to include two new hallmarks of cancer cells comprising of (1) 
abnormal metabolic pathways which are characterised by cancer cells utilising the Warburg 
effect to upregulate glycolysis and lactic acid fermentation within the cytosol and prevention 
of aerobic respiration within the mitochondria which results in low ATP:ADP ratios and (2) 
evasion of the immune system of cancer cells through disabling components of the immune 
system and by secretion of immunosuppressive factors such as TGF-β (Hannahan and 
Weinburg 2011). 
 
The updated paper also included two emerging characteristics of cancer cells whose 
acquisition leads to the development of the ‘hallmarks of cancer’ as previously discussed. 
These enabling characteristics include genome instability which refers to the high frequency 
of mutations within the genome of a cellular lineage, such mutations can include fluctuations 
in nucleic acid sequences, aneuploidy (abnormal number of chromosomes within a cell) or 
chromosomal rearrangements. The other enabling characteristic of cancer cells is tumour 
promoting inflammation, which can contribute to the proliferation, survival and migration of 
cancer cells (Hannahan & Weinburg, 2011). 
 
Of the hallmarks of cancer, sustained cellular proliferation is perhaps the most important 
hallmark of cancer cells which provides all the necessary components for cancer cells to grow 
and divide without any regulation. In normal healthy cells, the progression through the cell 
cycle to successful cell division is highly regulated by the production and release of growth 
promoting signals which govern entry and progression through the cell cycle ensuring normal 
cell division and maintenance of normal cellular function.  
 
 
 
 
 
 
 
 
 
 
 
Hallmarks of Cancer 
Resistance to cell death 
(Apoptosis) 
Induction of  
Angiogenesis 
Replicative  
Immortality 
Invasion and 
Metastasis 
Evasion of growth  
suppression 
Sustained proliferative  
signalling 
Figure 1.1: Schematic representation of the hallmarks of cancer adapted from Hannahan & 
Weinburg, 2011 
Genome 
instability and 
mutation 
Tumour promoting 
inflammation 
Evasion of immune 
destruction 
Dysregulated cellular 
energetics 
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The driving force behind this unbridled cellular proliferation are ribosomes, the protein 
manufacturing machineries common to all forms of living systems on earth. Ribosomes are 
responsible for converting the chemical messages encoded within mRNA transcripts into fully 
functioning proteins. These proteins then go on to interact in chemical processes which are 
involved in signalling pathways to support the sufficient growth of cells which is required to 
enter into S-phase, the repair of any DNA damage before replication or the induction of 
programmed cell death if the DNA damage is irreparable.  
 
The production of ribosome subunits takes place within a non-membrane bound organelle 
located within the nucleus, called the nucleolus. The nucleolus has long been described as 
being formed through ‘the act of making a ribosome’ (Melese & Xue, 1995) and more recently 
has been ascribed many new, previously unknown functions (Boisvert et al, 2007) which will 
be discussed in following sections.  
 
Polymerases I, II and III are required in all eukaryotic cells to transcribe nuclear genes. Each 
polymerase enzyme is committed to transcribing a different set of genes namely class I, class 
II and class III genes respectively. mRNA’s which encode cellular proteins and small nuclear 
RNA’s which are involved in mRNA processing are under the transcriptional control of 
polymerase II (Pol II). Transfer RNAs (tRNAs), which are required to translate the base 
sequence of messenger RNA (mRNA) into the amino acid sequence of proteins as well as 5s 
ribosomal RNA (the smallest of the rRNAs which is incorporated into the large ribosomal 
subunit) alongside other non-coding RNAs such as 7SK which can regulate Pol II transcription 
are synthesized by polymerase III. RNA Polymerase I (Pol I) exclusively transcribes ribosomal 
RNA (rRNA) which is an essential structural and catalytic component of ribosomes. Pol I 
transcribes multiple copies (̴400 copies in humans) of genes which encode the pre-rRNA 
precursor which is subsequently processed into 18s, 28s and 5.8s rRNAs (White, 2008). 
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The process of producing ribosomes within a eukaryotic cell is highly co-ordinated and energy 
dependant. Adenosine triphosphate (ATP) both promotes the initiation of ribosomal RNA 
transcription as well as the rate limiting step in ribosome biosynthesis (transcription of 45s 
pre rRNA) and is also consumed by actively translating ribosomes (Gaal et al, 1997). Sudden 
increases in levels of ATP have been shown to increase rRNA transcription resulting in increase 
in cellular ribosome content (Murray et al, 2003). The synthesis of ribosomes is strictly under 
the control of RNA polymerase I and accounts for 60% of transcriptional activity within a 
eukaryotic cell (Moss, 2002) and there is evidence that the size of the nucleolus is related to 
its function in ribosome biogenesis (Derenzini, 1998 & Hernandez-Verdun, 2006).  
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1.2  Classification of solid tumours 
 
Tumours can either be of solid or liquid (haematological) origin based on the location in which 
they grow inside the body. 80% of cancers are caused by solid cancers which grow as a mass 
of cells in a particular tissue, organ or gland. Solid cancers can be defined as an abnormal mass 
of tissue that usually does not contain cysts or any other liquid areas (NCI Dictionary of Cancer 
Terms). Solid tumours may be either benign (non-cancerous) or malignant (cancerous). Major 
sites of solid cancers include the colon, prostate, lung, breast, brain and skin amongst others. 
However, liquid cancers such as leukaemia develop in the blood and have the ability to travel 
to distant parts of the body. Since the main focus of this project is the response of solid 
tumours to combination treatment intervention, haematological malignancies such as 
leukaemias will not be discussed in detail. The different types of solid tumours are presented 
in Figure 1.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The classification of benign and malignant solid tumours. Adenoma – arise from glandular epithelial tissue, a thin layer 
of cells which cover glands and organs. Fibroma – grow on fibrous or connective tissue of any organ. Papilloma - epithelial tumor 
growing within ducts. Lipomas – soft tissue tumor consisting of fat tissue. 
Solid Tumour 
Benign 
Adenomas 
- Parathyroid adenoma 
- Fibroadenoma 
- Hepatic adenoma 
 
Fibromas 
- Angiofibroma 
- Dermatofibroma 
- Ossifying and non – 
ossifying fibroma 
Papilloma 
- Squamous cell papilloma 
- Choroids plexus papilloma 
- Laryngeal papilloma 
 
Lipomas  
- Angiolipoma 
- Myeloipoma 
- Fibriolipoma 
- Spindle cell lipoma  
Malignant 
Breast - Adenosquamous carcinoma 
Bone - Chondrosarcoma/osteosarcoma 
Brain - Glioblastoma/Astroblastoma 
Colon - Adenosquamous carcinoma 
Head - Squamous cell carcinoma 
Liver - Hepatocellular carcinoma 
Lung - Adenocarcinoma/ Non-small cell carcinoma 
Neck - Fibrous histiocytoma 
Ovary - Endometrioid adenocarcinoma 
Prostate - Mucinous adenocarcinoma 
Pancreas - Acinar cell carcinoma 
                       / Tubular adenocarcinoma 
Skin - Epithelioid cell melanoma 
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The classification of these solid tumours depends on the cell type from which they are 
composed: 
 
o Carcinomas are of two types – adenocarcinoma which develop within an organ or a 
gland and squamous cell carcinomas which develop within the epithelium (surface 
layer of cells) of sites such as breast, lung, prostate, skin and pancreas etc. 
o Sarcomas – arising from connective or supportive tissue such as bone, muscle and 
cartilage 
o Lymphoma – arising from lymphoid organs such as spleen, thymus and lymph nodes 
which produce cells of the immune system 
 
The clinical, gross and microscopic features of benign and malignant tumours are summarised 
below in table 1.1: 
 
Benign Malignant 
Clinical 
Slow growth Rapid growth 
Unusual ulceration Frequent ulcers 
Uncommon haemorrhage Frequent haemorrhage 
No metastasis Frequent metastasis 
Gross Appearance 
Smooth tumour edge (may be 
encapsulated) 
Irregular tumour edge due 
infiltrative growth 
No evidence of secondary spread Adjacent structures may be 
infiltrated 
Microscopic Features 
High resemblance to tissue origin Poor resemblance 
Uniform cell size and shape Pleomorphic 
No invasion of blood vessels Angiogenesis 
No dysplasia in adjacent tissue Possible in cervix, skin and 
stomach 
Table 1.1: Clinically relevant features that distinguish benign and malignant tumours (Lakhani et al 2010) 
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1.3 The nucleolus 
 
The nucleolus is derived from the Latin word meaning ‘true nucleus’ and it was first noted 
independently by Wagner and Valentin in the early 1800’s. It was not until the late 1800’s 
where a more detailed description was provided by Montgomery who published 346 hand-
drawn figures of nuclei and nucleoli from a wide range of biological materials. For the large 
part of the 20th century, the nucleolus held its place as the monofunctional, ribosome 
production factory of the cell and the site of rRNA synthesis (Perry, 1960, Perry et al, 1961, 
Perry, 1962 & Penman et al, 1966) which was later visualised in the classic ‘Christmas tree‘ 
image of ribosomal genes in action (Miller, 1969). It wasn’t until Pederson et al and others 
showed that that nucleolus is involved in more than just ribosome biogenesis that the 
nucleolus began to take on a more of a plurifunctional role (Figure 1.3) (Pederson et al, 1998).  
 
Currently the nucleolus is ascribed to many functions such as cell cycle progression, signal 
recognition particle production, viral protein assembly, and protein sequestration. 
Importantly the nucleolus plays a pivotal role in the nucleolar stress response which regulates 
the guardian of the genome, p53. The multiple functions of the nucleolus could result from 
the plurifunctionality of nucleolar proteins such as Nopp140 , nucleophosmin and nucleolin.  
 
In general, most tumour cells display a high number of nucleoli with a larger size compared 
to normal cells. Hypertrophied nucleoli are characteristic of a high number of proliferating 
cells and rapidly proliferating cells. The rate of cell proliferation and the number of 
proliferating cells are major factors in determining the growth rate of a tumour mass. 
Nucleolar function is influenced by the tumour suppressor proteins p53 and retinoblastoma 
protein (pRb) which control cellular proliferation through regulation of the G1 exit phase of 
the cell cycle (pRb) and inducing apoptosis and G2 cell cycle phase arrest (p53) in response to 
cellular stresses. Mutations affecting p53 and pRb can cause genome instability (Hernando et 
al, 2004) as well as influencing nucleolar function which contributes to nucleolar 
enlargement. Tumours with deleted Rb or inactivated pRb or mutated p53 exhibit significantly 
larger nucleoli compared to tumours with wild type p53 and Rb status (Trere et al, 2004). 
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Since the above-mentioned factors can affect the size of nucleoli, as a result, abnormal size 
and increased numbers of nucleoli are used as prognostic indicators for many cancers 
(Derenzini et al, 2000, Horky et al, 2002). Over 400 studies have published on the relationship 
between nucleolar size (following AgNOR staining) and tumour prognosis. In the majority of 
these studies, the nucleolar parameter was found to be a relevant prognostic factor, the 
larger the size of the nucleolus the worse the prognosis of the disease (Pich et al, 2000).  
 
Nucleoli are the most noticeable structures seen within the nucleus of a eukaryotic cell when 
observed under light microscopy (Figure 1.4). Unlike many cellular organelles, the nucleolus 
is not bound by a membrane but instead is an aggregate of macromolecules such as rRNA 
genes, precursor rRNAs, mature rRNAs, rRNA-processing enzymes, small nucleolar 
riboproteins (snoRNPs) which function as guide RNAs for sequence-specific 2’-O-ribose 
methylation and pseudouridylation of ribosomal RNAs, large groups of assembly factors such 
as ATPases and GTPases, protein kinases and RNA helicases as well as ribosomal proteins and 
partly assembled ribosomes. The close relationships of the above components ensure that 
the assembly of the nucleolus after cell division occurs in a swift and controlled manner.  
 
The nucleolus is a dynamic interphase organelle.  A typical eukaryotic cell can contain several 
nucleoli per nucleus which stem from active regions of the 47s rRNA genes (rDNA) which form 
around tandemly repeated sequences of rDNA located on five acrocentric chromosomes (13, 
14, 15, 21 and 22) called NOR (Nucleolar Organizer Regions), first noted by McClintock in 
1934, these regions house approximately 200 copies of the rDNA (Pederson, 2011). These 
NOR’s contain alternating modules of a 47s pre-rRNA coding region which includes an 
intergenic spacer that houses the 47s rRNA promotor (Grummit, 2013). The structure of a 
functional nucleolus is tricompartite, consisting of a fibrillar centre (FC) surrounded by a 
dense fibrillar centre (DFC), which is encased within a granular centre (GC) (Figure 1.5). A 
nucleus harbouring these nucleolar features is termed fibrillargranular (Wachtler and Stahl, 
1993).  
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Assembly of Ribonucleoproteins 
- Signal recognition particle 
- Rnase enzymes in tRNA processing 
- Telomerase RNP 
Sensor of cellular stress 
- JNK2-Tif-1A mediated  
       inhibition of rDNA transcription 
-      Stabilization of p53 
rRNA transcription 
rRNA processing 
Ribosomal subunit assembly  
RNA Processing 
- Some tRNAs 
- Polycistronic snoRNAs 
- Maturation of snRNAs 
Viral Replication 
- Nucleolar transport of  
HIV mRNA/Rev/Tat 
- Animal & plant virus 
protein 
Cell cycle/Apoptosis regulation 
- Nucleolar sequestration 
- Tumour suppressor proteins 
p53/MDM2/ARF 
- c-Myc oncogene – cell growth 
- PP1g - cell cycle progression 
- ReIA component NF-kB - 
apoptosis 
Figure 1.3: The multifunctional nucleolus. Canonical functions of nucleoli are shown in red. Recent functions discovered 
over the last decade illustrating the multiple roles of nucleoli. Image of CaSki cells stained for Fibrillarin (Green), DNA DAPI 
(Blue) 
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Figure 1.4: (Above) Brighfield image of CaSki cells showing individual nucleoli taken using 20x objective. (Below) 
Confocal image of  SKMEL-28 stained for nucleolar marker nucleophosmin (Magenta), a-tubulin (Green) and 
DNA counterstain DAPI (Blue) (40x obj). Red arrows are pointing towards individual nucleoli.  
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Each nucleolar compartment can be characterised through its unique biochemical 
composition. rDNA, transcription factors such as RNA Pol I and UBF as well as nascent rRNA 
are located within the FC and the inner compartment of the DFC. This makes the FC sensitive 
to silver and utilised in AgNOR staining as a prognostic cancer marker (Derenzini & Trere, 
2001).  The DFC component which also stains positive for AgNOR is the site for early pre-rRNA 
processing and modifications and contains nascent pre-rRNA and proteins such as fibrillarin, 
which is involved in the early processing of rRNA (Biggiogera, 2001 and Koberna, 2002). 
Proteins that are involved in the later steps of rRNA processing such as nucleophosmin and 
nucleolin as well as pre-ribosomes approaching the final stages of maturation can be found 
within the outer DFC and within the GC, with the GC accounting for up to 70% of total 
nucleolar mass (Thiry & Lafontaine, 2005). 
 
 
 
 
 
Nuclear Membrane 
Granular  
Component 
(GFC) 
Fibrillar Centre (FC) 
Nucleolus 
Dense  
Fibrillar  
Component 
(DFC) 
Figure 1.5: Schematic representation of a single nucleolus showing the tricompartite structure of the fibrillar centre 
FC, dense fibrillar centre DFC and granular centre GC 
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Nucleolar organiser regions (NOR) are chromosomal segments which contain tandem repeat 
sequences of rDNA genes. The NORs also contain acidic, non-histone proteins which are 
agrophillic (high affinity for silver nitrate) in nature which allows these proteins to bind to 
silver ions that permits for selective staining using silver techniques such as silver nucleolar 
organiser region (AgNOR) staining (Trere, 2000). 
 
It has been previously established that the affinity of AgNOR staining is directly related to the 
transcriptional activity of rDNA genes (Haaf et al, 1988). Since the fibrillar centre is considered 
the site of initiation of rDNA transcription (Cheutin et al, 2002) as it contains the necessary 
components to facilitate rDNA transcription such as rDNA, upstream, binding factor (UBF) and 
RNA Polymerase I (Pol I). The presence of non-histone proteins of the transcriptional 
machinery such as UBF and selectivity factor 1 (SL-1) make the fibrillar centre of the nucleolus 
highly concentrated with agrophillic proteins, making this region sensitive to AgNOR staining 
methods. Nucleolin (C23) and nucleophosmin (B23) are also prominent agrophillic nucleolar 
proteins which localise to the dense fibrillar component (DFC) and granular component (GC) 
of the nucleolus and can account for up to 75% of AgNOR protiens (Roussel & Hernandez-
Verdun, 1994). 
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1.4 rDNA organisation and transcription 
 
It is remarkable to think that the most abundant RNAs in a cell are the ribosomal RNA which 
forms the core of ribosomes. Unlike bacteria, eukaryotic cells have a dedicated RNA 
polymerase which exclusively transcribes these rRNA genes; RNA polymerase I. There are four 
types of eukaryotic rRNA, each type is present in one copy per ribosome. Three of the four 
rRNA’s (18s, 5.8s and 28s) are produced by chemically modifying and cleaving a single large 
precursor rRNA (45s rRNA). The fourth, 5S RNA is synthesised from a separate cluster of genes 
by RNA polymerase III and does not require any chemical modification or cleaving.  
 
The 45s rRNA sequence consists of 13,000 nucleotides and extensive modifications occur to 
this precursor rRNA before the rRNA subunits are cleaved out of it and assembled into 
functioning ribosomes. Each modification is made at a specific position along the 45s 
precursor rRNA specified by ‘guide RNA’s’ which position themselves along the precursor 
rRNA by base pairing and recruitment of a RNA-modifying enzyme. Other Guide RNAs are 
involved in promoting cleavage of the precursor rRNA into mature rRNA. The guide RNAs 
involved in modification of the precursor rRNA are transcribed by RNA polymerase II and 
belong to a large class of RNAs known as small nucleolar RNAs (snoRNA). 
 
The process of rDNA transcription is presented in Figure 1.6. The complete final mature 80s 
ribosome is composed of a 40s subunit which contains 18s rRNA (rRNA) and 33 ribosomal 
proteins (RP’s) connected to a 60s subunit which contains 5S, 5.8S and 28s rRNAs and 47 RP’s. 
The synthesis of ribosomes primarily takes place within the nucleolus, namely within the 
fibrillary centre, where the RNA Pol I machinery transcribe 45s precursor rRNA from rDNA 
genes. The rDNA genes contain the sequences for the 18s, 5.8s and 28s rRNAs. The 45s pre 
rRNA transcript is then processed into a 90s processome which contains 5s RNA (transcribed 
by RNA Pol III in the nucleoplasm) and ribosomal proteins (RP’s). These RP’s are transcribed 
by RNA Pol II in the nucleus, exported to the cytoplasm for translation into functioning 
proteins which are then exported back into the nucleolus.  
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Pol II also transcribes genes for approx. 200 small nucleolar RNA’s (snoRNA’s) which aid in the 
maturation process of the pre RNA into 40s and 60s ribosomal subunits within the 90s 
processome. Additional RP’s are utilised into the 40s and 60s subunits within the nucleoplasm 
and cytoplasm with the whole process of synthesising ribosomes involving several hundred 
accessory factors to give rise to the mature functioning 80s ribosome (Pellettier, et al 2018, 
Zomerdijk, et al 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18s 5.8s 28s 
Pol I 
45s Pre rRNA 
90s 
Processing 
Assembly & Modification 
Pre 60s Pre 40s 
Cytoplasm 
Nucleus 
Nucleolus 
Pol III 
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POL II 
RP mRNA 
RPL 
Import 
Late maturation & export 
Final maturation 
steps 
and protein 
synthesis 
40s 
mRNA 
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snoRNA 
5.8s 
18s 
28s 
Figure 1.6: Schematic representation of the transcription and processing of the 45s pre rRNA transcript within the 
nucleolus. Adapted from Boisvert et al, 2007. 
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1.5  Ribosome Biogenesis 
 
Ribosome biogenesis is a highly coordinated process that takes places predominantly within  
the nucleolus.  It requires the coordinated activity of all three RNA polymerases (Pol I, II and 
III) along with transcription factors, small nucleolar RNA’s and non-ribosomal RNA’s to 
facilitate the transcription, processing and maturation of rRNA. This produces a mature rRNA 
assembled with approximately 80 proteins to form the 40s and 60s ribosomal subunits of the 
functional ribosome. Cell growth (increase in cell mass) requires high amounts of ribosomes, 
which carry out the process of protein synthesis. Therefore, ribosome biogenesis underlies 
the cells capacity to grow. All cells require the basic process of transcription to meet cellular 
needs such as survival, growth and differentiation and a link has been established between 
cellular transformation and increased rates of transcription factors as well as oncogenes in 
cancer cells (Bywater et al, 2013) 
 
Eukaryotic ribosomal DNA (rDNA), which encodes a large precursor that is processed to form 
three of the four rRNA’s, is present in multiple tandem repeats. This rDNA is subject to two 
different general modes of regulation (McStay, 2008). The output of rDNA copies can be 
controlled through modulating the association of a key co-activator, TIF-1A, with the RPA43 
subunit of RNAP I. This association is mediated by mTOR phosphorylation which connects 
RNAP I activity to nutrient signals (Grummit et al, 2004) 
 
The growth regulatory pathways currently known to modulate Pol I transcription include the 
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signalling pathways. The RAS/RAF/MEK/ERK 
pathway control Pol I transcription via multiple kinases such as ERK, MAPK, RSK2 and JNK 
(Johnson et al 2003, Zhao et al 2003, Mayer et al 2005). For example, ERK can directly 
phosphorylate and activate UBF to increase Pol I transcription elongation (Stefanovsky et al, 
2001, 2008). The PI3K/AKT/mTOR pathway can modulate Pol I transcription through 
ribosomal protein S6 kinase (S6K) which enchances Pol I transcription by indirectly modulating 
UBF phosphorylation (Mayer, 2004, Hannan, 2003).  Inhibition of mTOR signalling by 
rapamycin has been shown to rapidly down regulate rRNA gene transcription and pre-rRNA 
processing (Hannan et al, 2003).   
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Conversely, PTEN, which is an upstream, negative regulator of PI3K/AKT/mTOR,  represses Pol 
I transcription through promoting dissociation of the SL-1 complex (Zhang, 2005).  Both 
pathways show cooperation with MYC signalling pathway through MYC phosphorylation by 
ERK (Sears et al, 1999) and AKT interaction with MYC to activate Pol I transcription (Chan et 
al 2011).  Various components of these pathways can act as oncoprotiens, which can amplify 
proliferative signals.  
 
The transcription factor MYC is a commonly activated oncoprotein found over-expressed in 
approximately 50% of cancers (Dang, 2012). MYC regulates the transcription of a huge variety 
of genes including those involved in cell growth, ribosome biogenesis and protein synthesis 
(Dang, 1999, Guo et al, 2000). MYC regulates Pol I transcription in several ways: MYC 
upregulates the transcription of core Pol I subunits and transcription factors (UBF/RRN3) 
(Poortinga et al, 2004) directly associates with SL-1 to stabilize the UBF-SL-1 complex as well 
as binding to the rDNA to promote Pol I recruitment. (Grandori et al, 2005, Arabi et al, 2005).  
In addition to the above, MYC also promotes the transcription of factors which are required 
for rRNA maturation and assembly (Schlosser et al, 2003) , 5S rRNA by Pol III (Gomez-Roman 
et al, 2003) as well as the ribosomal proteins by Pol II.  These roles clearly highlight the role 
of MYC as the central regulator of ribosome biogenesis. (for review please see  Gomez-Roman 
et al, 2006 & J. van Riggelen et al, 2010). 
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1.6 Diseases linked to disordered ribosome biogenesis 
 
Ribosome biogenesis is a complex process which is energy intensive and involves several 
hundred factors such as enzymes, transcription factors and chaperones whose purpose is to 
aid in ensuring that rRNA is correctly processed, folded and assembled alongside ribosomal 
proteins. The significance of ribosome synthesis in relation to the growth needs of a cell can 
be appreciated when looking at the amount of ribosomes produced across living systems, for 
example, in growing yeast cells approximately 2000 ribosomes are synthesised per minute 
which utilises 60% of its cellular transcription (Warner et al, 2001), in human HeLa cells, a rate 
of 7500 ribosomal subunits per minute has been reported (Lewis et al, 2000).  
 
Ribosome biogenesis is an integral part of cell growth and proliferation through the role it 
plays in translating mRNAs and building a wide range of cellular proteins. Disruption in any of 
the steps relating to the synthesis of ribosomes can lead to congenital disorders named 
ribosomopathies. The term ribosomopathie refers to a collection of maladies in which the 
genetic abnormalities are caused by impaired ribosome synthesis and function, the effects of 
which manifest into particular clinical phenotypes. The first discovery of ribosome 
abnormality linked to human disease was identified just under 20 years go by 
Draptchinskaia et al, 1999. The team reported regular mutations in patients with Diamond-
Blackfan anemia (DBA), these mutations were found to reside in a gene encoding for a 
ribosomal protein, RPS19. Since then, a growing number of diseases related to impairment of 
ribosome biogenesis and mutations occurring within ribosomal protein genes have been 
reported (Table 1.3 & 1.4).  
 
Since cancer cells have upregulated rates of ribosome synthesis and produce higher quantities 
of ribosomes compared to healthy cells, this makes these cancerous cells likely to be 
susceptible to reductions in ribosome production following chemical intervention (Ruggero, 
2012). A systematic investigation of thirty-six compounds belonging to different chemical 
categories which are routinely used in chemotherapeutic regimens revealed that eighteen of 
these agents showed strong inhibitory effects on ribosome biogenesis either through specific 
interference with rRNA synthesis or pre-rRNA processing (Burger et al, 2010)  
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Another rationale for pursuing ribosome synthesis as a potential target for therapeutic 
intervention comes from the observation that CX-5461, CX-3543 and BMH-21 preferentially 
kill cancer cells over normal untransformed cells. In non-transformed BJ-hTert fibroblast cells, 
CX-5461 displayed an IC50 value of 5µM compared to 3nM in EOL-1 leukaemia cancer cells 
(Drygin et al, 2011). Similar cytotoxic preference was observed in animal models in which the 
above mentioned compounds displayed efficient antitumor activity. Inhibition of tumour 
growth was observed in xenografts of pancreatic cancer cells (MIA PaCa-2 cells) exposed to 
CX-5461 and CX-3543 (Drygin et al, 2009), in A375 melanoma cells treated with CX-5461 and 
BMH-21 (Drygin et al, 2011 & Peltonen et al, 2014).   
 
Common mutations occurring in proteins involved in the synthesis of ribosomes and their 
associated diseases are presented in table 1.2: 
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Disease Gene 
(Human) 
Impaired function Clinical phenotype Reference 
Treacher Collins 
Syndrome(TCS) 
TCOF1 Impaired methylation 
of 18s rRNA and 
impaired rDNA 
transcription 
Craniofacial abnormalities Gonzales et 
al, 2005 
Bowen-Conradi 
Syndrome (BCS) 
EMG1 Impaired maturation of 
the 40s ribosomal 
subunit 
Growth retardation, 
skeletal abnormalities, can 
be lethal by early 
childhood 
Armistead, 
2009 
ANE Syndrome 
(Alopecia, 
neurological 
defects and 
endocrinopathy 
syndrome) 
RBM28 Improper maturation 
of the 60s ribosomal 
subunit 
Growth retardation, hair 
loss, central adrenal 
insufficiency, loss of motor 
ability 
Nousebeck et 
al, 2008 
Shwachman-
Diamond syndrome 
(SDS) 
SBDS Impaired maturation 
and export of the 60s 
ribosomal subunit 
Cancer predisposition, 
growth retardation, 
exocrine pancreas 
insufficiency, 
haematological defects, 
skeletal abnormalities 
Boocock et al, 
2002 
Table 1.2: Common mutations in proteins which are involved in ribosome biogenesis 
 
Mutations occurring in ribosomal proteins (RP’s), which play a key role in the processing of 
rRNA transcripts, and their associated diseases are presented below: 
 
Disease Gene (Human) Impaired function Clinical phenotype Reference 
RPS7 Diamond Blackfan 
anaemia (DBA) 
Impaired 5’ processing 
of 18s rRNA 
Anaemia, bone marrow 
failure, craniofacial 
abnormalities, cancer 
predisposition 
Lipton, 2009 
RPS17, RPS19 DBA Impaired 3’ processing 
of 18s rRNA 
As above Cmejla et al, 
2007 
Draptchinskaia et 
al, 1999 
RPS24 DBA Impaired 5’ processing 
of 18s rRNA 
As above Gazda et al, 2006 
RPL5, RPL11 DBA Impaired processing of 
pre rRNA of the large 
ribosomal subunit 
As above Gazda et al, 2008  
Table 1.3: Common mutations occurring in ribosomal proteins (RP's) involved in rRNA processing 
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1.7 RNA Polymerase 1 Transcription Machinery 
 
rRNA genes are located within the nucleolus around nucleolar organizer regions (NOR’s). 
Mammalian cells contain several hundred copies of tandemly repeated rRNA genes that are 
transcribed within the nucleolus with very high efficiency to meet the cells metabolic activity 
and demand for ribosomes.  
 
The mammalian rDNA clusters can be characterized by multiple alternating modules of a long 
intergenic spacer of approximately 30 kb and a precursor rRNA (pre-rRNA) coding region of 
around 14 kb. Each active rRNA gene is transcribed by a specialized nucleolar DNA-dependent 
RNA polymerase, Pol I, to generate a 47S pre-rRNA. After synthesis, this primary transcript is 
then processed and modified to generate one molecule each of mature 18S, 5.8S and 28S 
rRNA, which together which 5S rRNA (transcribed by Pol III) forms the RNA backbone of the 
ribosome. 
 
Initiation of rDNA transcription requires assembly of a specific multiprotein complex at the 
rDNA promoter containing RNA Pol I and a number of auxiliary proteins.  In mammalian cells, 
two specific factors bind the rDNA promoter site, the upstream binding factor (UBF) and the 
promoter selectivity factor (SL1), which together form the preinitiation complex (PIC) and 
recruit RNAP1 as well as various accessory factors to the rRNA gene, for a detailed review see 
(Grummit, 2003, Drygin, 2010). The expression of rRNA is a process which is highly regulated 
in response to a variety of environmental conditions, nutrient availability and various forms 
of cellular stress. It is important to note modulating the synthesis of rRNA requires the 
involvement of several signalling pathways that regulate cell growth and proliferation, such 
as c-Myc (Drygin et al, 2010) 
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1.8 Targeting the nucleolus for cancer intervention 
 
The nucleolus is a dynamic interphase organelle, disassembling at the onset of mitosis and 
reassembling towards the end of telophase, ready to enter into the cell cycle. It is well 
established that nucleoli act as central hubs specialising in co-ordinating the synthesis of the 
protein producing machinery of the cell, the ribosome.  
 
The nucleolus as a target for cancer intervention has attracted a great deal of interest over 
the last decade with several reviews highlighting the role of nucleoli in cancer and potential 
therapeutic avenues of mediation, for an in depth review the reader is referred to the 
following reviews (Orselic & Jurada, 2016, Hannan et al, 2014, Cann & Dellaire, 2010). The 
observation that cancer cells contain enlarged nucleoli as well as increased number of nucleoli 
has been observed in a number of different cancer types such as breast, liver and large-cell 
lung carcinoma as well as Hodgkins disease (Montanaro et al, 2008).  
 
Conversely, Zink et al reported that small nucleoli have also been observed in small cell 
anaplastic lung cancer and also in haematological malignancies with irregular shaped nucleoli 
also seen in malignant cells (Zink et al, 2004). The concept that tumour cells may require 
higher rates of protein synthesis was first proposed 70 years ago using C14-amino acid labelling 
techniques in normal vs malignant tissues (Zamecnik et al, 1948). It is now well established 
that increased rRNA transcription mediated by Pol I and increased expression of ribosomal 
proteins is a signature of cancer cell (White, 2005 & Ruggerro, 2003) 
 
A pioneering proteomic study by the Lamond laboratory identified over 4500 proteins which 
are associated with the nucleolus, 70% of which have a function which is not related to 
ribosome synthesis (Ahmad et al, 2008). These proteins are instead attributed to other 
important previously uninscribed functions such as regulation of cell cycle progression, DNA 
damage sensing, genomic organisation and signal recognition particle production (Diesch et 
al, 2014) 
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It has recently been proposed how several dysregulated nucleolar functions could lead to the 
establishment of a malignant phenotype. These functions include up and downregulation of 
ribosome synthesis, nucleolar degradation of c-Myc and cyclin E, epigenetic regulation of 
rRNA genes and regulation of telomere function (Orsolic et al, 2016).  
 
The controversial nature of targeting the nucleolus and ribosome biogenesis in cancer is owed 
largely to the role nucleoli and riboproteins (Rp) play in sustaining the growth of normal 
healthy cells as it was previously thought that that drugs which targeted the nucleolus and 
ribosome biogenesis (RB) would not be able to distinguish between normal and cancerous 
cells. Burger et al at showed that out of a screen of 36 agents, 21 drugs were found to interact 
with RB at several levels including rDNA transcription and early and late rRNA processing 
(Burger et al, 2010).  
 
Over the last decade there has been significant interest in developing drugs that can 
selectively target Pol I transcription in vivo and induce cytotoxic effects. Initially, the Pol 1 
inhibitor CX-3543 was developed (Quarfloxin, Cylene Pharmaceuticals). This drug exerted its 
effects by binding to G-quadruplex DNA structures that are found within the G-C rich region 
of the rDNA repeat sequence thus preventing the nucleolin G-quadruplex complex formation 
(Drygin et al, 2009) similar to the manner in which Actinomycin D intercalates into GC –rich 
islands commonly found at rDNA repeat sites. Actinomycin D is an intercalating agent which 
at low doses has been shown to be an inhibitor of rDNA transcription dude to its ability to 
bind to GC rich regions and stabilize topoisomerase-I DNA covalent complexes which prevent 
the progression of RNA polymerase enzymes (Trask & Muller, 1988). Exposure to ActD has 
been shown to affect all three eukaryotic polymerases with class I genes, under the control 
of Pol I being the most sensitive (0.05 µg/ml) followed class two genes controlled by RNA Pol 
II (0.5 µg/ml) and class three genes under the control of RNA Pol III being the most resistant 
(5µg/ml) (Perry & Kelley, 1970). However, ActD displays limited selectivity as an rDNA 
transcription inhibitor as it will also bind to other locations within the genome which are also 
rich in GC sequences.  
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CX-3543’s mechanism of action involves inhibiting Pol 1 transcription at the elongation stage 
which then causes subnuclear translocation of nucleolin which is not bound to any rDNA, to 
move to the nucleoplasm resulting in apoptosis in human cancer cell lines (Drygin et al, 2009; 
Feterston et al, 1984 and Sobel et al, 1985). CX-3543 has shown to be therapeutically 
advantageous and well tolerated in patients exhibiting carcinoid/neuroendocrine tumours in 
separate phase 1 clinical trials (Drygin et al, 2010). CX-3543 has been assessed in solid and 
neuroendocrine tumours as well as lymphomas as phase I/II studies within the US (2008), no 
other trial is currently active using CX-3543. 
 
The next generation of Pol I inhibitors introduces a small molecule, CX-5461 (Cylene 
Pharmaceuticals/Senhwa), as a promising candidate for the inhibition of Pol I transcription. 
CX-5461 works by preventing the Pol I transcription initiation factor SL-1 from binding to the 
rDNA promoter. Drygin et al showed how selective CX5461 was for RNA Pol I machinery by 
comparing the rates of transcription of two genes, one under the control of RNA Pol I – the 
45s rRNA precursor gene and the other under the control of RNA Pol II – the proto-oncogene 
c-Myc. CX5461 was shown to be 300-400 fold more selective towards RNA Pol I compared to 
RNA Pol II/III (Drygin et al, 2011). 
 
Drygin et al found very high anti-proliferative effects of CX5461 at very low nanomolar doses 
(58nM A375 melanoma cell line) as well as in a panel of cancer cell lines with wild type and 
mutated p53 status. The cytotoxic effects induced by CX5461 included autophagy in solid 
cancers and apoptosis, in a p53 dependent manner, in haematological malignancies showing 
that sensitivity towards Pol inhibition varied greatly between different cell lines with 
haematological malignancies being amongst the most sensitive to Pol 1 inhibition (Drygin et 
al, 2011).  
 
The in vitro efficacy of CX5461 was assessed to see if it could be translated into any in vivo 
therapeutic benefit by using a mouse model of MYC-driven B cell lymphoma (Eu-Myc 
lymphoma). The results showed that continuous treatment with CX5461 did not affect normal 
B cell population. This resulted in disease remission with reports of extended survival in their 
MYC-driven B cell lymphoma model.  
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This effect was attributed not to the insufficiency of ribosomes or a decrease in protein 
translation but instead to p53 activation and tumour specific induction of apoptosis (Bywater 
et al, 2012).  The induction of p53 in response to Pol I inhibition was linked to the activation 
of the nucleolar stress response, leading to nucleolar disruption and release of 
ribonucleoprotiens RPL5 and RPL11, both of which are known to bind to MDM2.   
 
 
The use of Pol I inhibitors may have some distinct advantages over current methods used to 
activate a p53 response in cancers. Inhibiting pol I transcription is non-genotoxic, meaning 
that its use does not damage the DNA in healthy cells and also reduces the chances of 
secondary cancer formation (Godley et al, 2008). This is supported by the work of Bywater et 
al (2012) showing that p53 was not activated and apoptosis was not induced in normal B cell 
populations treated with CX5461 even though RNA pol I as a target was inhibited in both cell 
populations. These findings indicate that normal cells may have a higher threshold for the 
activation of the nucleolar stress response and p53 stabilization in response to pol I inhibition 
compared to tumour cells.  
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1.9  Non-ribosomal role of nucleolar proteins 
 
The extra non-ribosomal functions of ribosomal proteins such as RPL11 have suggested the 
role that they may play in co-ordinating the nucleolar stress response.  These functions of 
RPL11 would be in agreement with the notion that ribosomal proteins may play extra-
ribosomal roles in gene regulation (Wool, 1996, Lindstom, 2009).  Since c-Myc is a master 
regulator and inducer of ribosome biogenesis and protein synthesis, current data places 
RPL11 in a position where it can oversee and modify the entire process of ribosome biogenesis 
and cell growth. 
 
Since RPL11 does not only regulate p53 and MDM2, it also regulates c-Myc mRNA turnover 
and c-Myc protein activity. RPL11 has also been shown to inhibit c-Myc activity through 
blocking recruitment of c-Myc’s co-activator TRRAP to the promoter regions of c-Myc target 
genes that are transcribed by RNA POL I & III and the 5S rRNA genes transcribed by RNA Pol 
III, all targets of the c-Myc protein. In response to nucleolar stress, binding of RPL11 to these 
genes was increase and TRRAP binding was decreased.  As well as RPL11 being recruited to 
promoter sites of genes that are under the regulation of p53 upon nucleolar stress (Mahata 
et al, 2011) RPL11 also binds to c-Myc mRNA at its 3’ untranslated region which leads to a 
reduction in c-Myc’s mRNA levels. Nucleolar stress decreases c-Myc mRNA levels in a RPL11 
dependent manner (Challagundla et al, 2011). 
 
The activation of ‘nucleolar stress’ causes the translocation of many nucleolar proteins from 
the nucleolus to the nucleoplasm such as nucleophosmin, nucleostemin and various 
ribosomal proteins such as RPL5, RPL11 and RPL23 (Kurki et al, 2004, Zhou et al, 2012).  These 
translocation can activate p53 through inhibition of HMD2 (Zhou et al, 2012).  Katagiri et al 
showed that inhibition of Pol I transcription through specific inhibitors (Adriamycin (ADR )and 
Actinomycin D (ActD)) and siRNA induced nucleolar disruption and autophagy. The authors 
found that nucleophosmin played a key role in the activation of autophagy induced by 
nucleolar disruption. However the authors showed that nucleophosmin was not essential for 
canonical autophagy induced by nutrient starvation but not accompanied by nucleolar 
disruption (Katagiri et al, 2015). 
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The functions of the chaperone nucleophosmin (NPM1) include ribosome biogenesis, 
intracellular support, apoptosis and mRNA splicing (Lindstrom, 2011, Grisendi, 2006).  High 
levels of NPM1 have been reported in breast (Karhemo, 2011) , colon (Nozawa, 1996) , and 
bladder cancer (Tsui, 2004).  NPM1 has also been found to be overexpressed in gliomas at 
both the mRNA and protein level when compared to normal brain (Kuo et al, 2015, Gimenez 
et al, 2010 and Chen et al, 2015).  Lindstrom et al showed that depletion of NPM1 had modest 
effects on the viability of U251MG, U1242MG and U343MGa Cl2:6 glioma cells, although 
nucleolar morphology alteration was observed. The study also showed that cells depleted of 
NPM1 that were exposed to low doses of Actinomycin D were more prone to cell death 
(apoptosis) compared to wild type NPM1 cells (Lindström ,2015) 
 
Small interfering RNAs (siRNA) are small strands of double stranded RNA, usually around 21 
nucleotides in length and are used to interfere with the translation of proteins by binding to 
specific mRNA sequences and promoting their degradation. siRNA gene silencing in contrast 
to pharmacological intervention (CX-5461) has several distinct differences in that siRNA 
silencing removes the target mRNA transcript (therefore its related protein) from the cell via 
degradation compared to pharmacological intervention which may only block the function of 
a protein whilst that particular protein will remain within the cell. As a result, drug inhibited 
proteins may lack certain protein activity but may still be able to interact with binding partners 
or assemble into macromolecular complexes. With respect to protein turnover rate, RNA 
interference usually takes several days to take effect compared to pharmacological 
intervention where the effect can be immediate.  
siRNA silencing is suitable for stable or transient knockdown of target genes and is relatively 
simple to perform using readily available kits for efficient knockdown however siRNA is not 
suitable for essential proteins and can also result in small off-target effects which can result 
in toxicity and activation of the innate immune response (Jackson and Linsley, 2010). 
Pharmacological intervention can be used to investigate essential proteins for functional 
analysis and therapeutic approaches but drawbacks to this technique include potential off-
target effects of the chemical agent as well as cellular uptake. 
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1.10 Nucleolus and the cell cycle 
 
The nucleolus is a dynamic interphase organelle which is disassembled at the onset of mitosis 
and reassembles along with the reinitiation of rDNA transcription during late telophase, ready 
to enter into interphase (Hernandez-Verdun, 2011). During interphase the three main 
compartments of nucleoli can be identified (FC, DFC and GC). These distinct structures reflect 
the different compartmentation of the machineries required to transcribe the rDNA, process 
the 45s pre rRNA transcript and assembly of the 40s and 60s ribosomal subunits (Hernandez-
Verdun, 2010). The functions of each of the above mentioned compartments are presented 
in Table 1.4. 
 
Nucleolar compartment Function 
Fibrillar Centre (FC) Initiation of rDNA transcription occurs at the border 
of FC and DFC 
 
Early processing of rRNA transcripts 
Dense Fibrillar Centre (DFC) 
Granular Centre (GC) Late processing of rRNA transcripts 
Table 1.4: The function of each compartment of the nucleolus in the transcription and processing of rDNA 
 
As a result, each compartment of nucleoli can be visualized using fluorescent markers which 
localise to each compartment such as PAF140 for the FC, fibrillarin for the DFC and 
B23/Nucleophomin to demarcate the GC. In eukaryotic cells, ribosome production increases 
during G1 phase of the cell cycle, is at its maximal peak during G2 (Siri et al, 2000) and is 
inhibited during prophase and mitosis (Hernandez-Verdun, 1997).  
 
A schematic representation of the dynamic structure of the nucleolus through the cell cycle 
is shown in Figure 1.7. 
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At the beginning of prophase, increased levels of cyclin B1 cause the phosphorylation of rDNA 
transcription machinery which includes SL1 and the transcription termination factor-1 (Heix 
et al, 1998). Nucleolar disassembly at the onset of mitosis may be the result of hyper-
phosphorylation of RNA Pol I transcription components. The breakdown of nucleoli begins 
with the loss of the RNA Pol I subunit RPA39 from the FC region which precedes the 
breakdown of the nuclear envelope (Leung et al, 2004).  
 
Also during prophase, the RNA Pol I transcription machinery remains associated with the 
rDNA repeats of NOR’s (Roussel et al, 1996) with the exception of some RNA Pol I subunits 
such as RPA39, RPa16, RPA20 and RPA194 which transiently disassociate from NOR’s during 
metaphase and reappear in anaphase. Transcription factors such as UBF remain in contact 
with NOR’s throughout mitosis (Leung et al, 2004, Dundr et al, 2000) in contrast to the RNA 
Pol I processing machinery which does not remain associated with NOR’s and is redistributed 
at prophase. Following the disassociation of RNA Pol I subunits, rRNA processing components 
such as fibrillarin and nucleophomsin also disassociate from the DFC and GC respectively 
(Leung et al, 2004). Gautier et al (1992) reported that although the majority of the rRNA 
processing components are redistributed from the nucleolus to the cytoplasm during mitosis, 
others become associated to the surface of condensed chromosomes known as the 
perichromosomal layer. 
 
During anaphase the majority of rRNA processing apparatus is either packaged into nucleolar 
derived foci (NDF) in the cytoplasm or remain associated with chromosomes in the 
perichromosomal layer. These NDF structures contain early and late rRNA processing proteins 
as well as U3 snoRNA’s and pre rRNA transcripts (Dundr et al, 1996). 
 
As chromosomes split during the latter half of anaphase and during the beginning of 
telophase where chromosomes cluster within the centre of each new cell, rRNA transcription 
is reactivated due to a decrease in cyclin B1-CDk levels (Siri et al, 2000). Following the 
reactivation of rRNA transcription, the NE begins to reform and the contents of NDF begin to 
disassociate and enter back into the nucleus as the number of cytoplasmic NDF decrease 
(Dundr, 2000). The contents of NDF (rRNA processing components) are transferred to 
structures that form on the surface of chromosomes known as pre nucleolar bodies (PNB) 
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(Savino, 2001), the contents of which include pre RNA transcripts and processing proteins. 
The same authors demonstrated that the PNB’s are not mobile and instead release their 
contents which translocate to the nucleolus.  
 
Both early and late rRNA processing components are released in a sequential manner from 
PNB’s. Recruitment of early rRNA processing proteins such as fibrillarin to the nucleolus 
precedes the expansion of the DFC region in early G1 phase, the progressive accumulation of 
fibrillarin at this stage has been shown to also correlate with reformation of the nuclear 
envelope (Leung, 2004). Subsequently, the proteins involved in the later stages of rRNA 
processing are released from PNB and begin to form the GC of newly assembling nucleoli 
(Leung 2004, Siri et al, 2002). As both rRNA transcription and processing machinery 
reassemble with rDNA regions, the NOR’s come together within the nucleoplasm and fuse 
together to form the typical functioning nucleolar structure observed during interphase. To 
conclude, the dynamic nature of nucleoli necessitates its breakdown and reformation upon 
entry and re-entry in the cell cycle. This is a highly complex and regulated process under the 
control of cyclin dependant kinases. The tight regulation of nucleoli is important to maintain 
the appropriate levels of ribosome subunits in order to maintain protein synthesis levels 
during cell growth and replication.   
 
Reports in the literature indicate a possible mechanism whereby abrogating ribosome 
biogenesis or disrupting nucleolar morphology activates a nucleolar stress response which 
leads to rapid activation of p53 and cell cycle arrest (Rubbi, 2003). Another aspect of nucleolar 
biology which links the nucleolus to the cell cycle are two proteins usually interacting with the 
large ribosomal subunit (RPL11 & RPL5) have also been reported to regulate p53 (Sloan et al, 
2013). 
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Reports in the literature provide evidence that treatment with CX-5461 induces cell cycle 
arrest in the G2/M phase transition (Cornelison et al, 2017, Hein et al, 2017). Previous  
experiments involving radiation and Chinese hamster V79 cells provide evidence that the 
most radiosensitive phase of the cell cycle is G2 (Marples ,2003).  
 
Taking this into account, based on the literature perpetual exposure to CX-5461 will induce 
cells in a G2M arrest, where cells will be unable to enter into the mitotic phase of the cell 
cycle. This coupled with exposure to low doses of radiation, sufficient enough to induce single 
and double stranded DNA breaks should in theory maximise cytotoxicity and induce cell 
death.  
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1.11  Nucleolus as a stress sensor 
 
1.11.1 P53 Dependent Nucleolar Stress Pathways 
 
The nucleolar stress response is triggered through the perturbation of ribosome synthesis. 
This leads to the disruption of nucleolar integrity. The key event in this process is the 
modulation of MDM2, which canonically represses the activity of the tumor repressor gene 
p53 (Olson et al, 2004, Pestov et al, 2001 and Rubbi et al, 2003). MDM2 mediates its effects 
on p53 via two mechanisms i) MDM2 directly binds p53 thus impairing its interaction with 
basal pol II transcription machinery and ii) MDM2 alters p53 stability through its E3 ubiquitin 
ligase activity and targets p53 for nuclear export and 26s proteosomal degradation. 
Under normal conditions, ribosomal proteins (RPs) are assembled with rRNA into the 40s and 
60s subunits within the nucleolus. P53 activity is maintained at a low level through MDM2 
promoted ubiquitin degradation. Under conditions of nucleolar stress, ribosome production 
is halted, RP’s, RNA’s and nucleolar proteins (NP) are released into the nucleoplasm, this 
results in the activation of p53 via the following mechanisms: 
• Riboproteins interact with MDM2 directly preventing its interaction with p53 
• RPL26 binds to p53 mRNA and enhances its transcription 
• Increase in RP11 translation results in interaction between RP11 and MDM2 which 
leads to an increase in p53 activity 
Increase in levels of p53 result in an upregulation of p53 target gene expression that manifests 
in cell cycle arrest, apoptosis or cellular senescence. Activating and stabilizing p53 is an 
important step employed by various chemotherapeutic agents in order to block cell 
proliferation and/or induce cell death in cancer cells (Johnstone et al, 2002, Vousden, 2009). 
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1.11.2 P53 Independent Nucleolar Stress Pathways 
 
It is frequently quoted in the literature that over 50% of cancer cells contain mutations in the 
p53 gene therefore it is of importance to understand how these cells respond to nucleolar 
stress. Previously it has been reported that in HeLa cells nucleolar stress induced cell cycle 
arrest and/or apoptosis [Lindstrom & Nister, 2010]. Also, inhibition of RNA pol I in p53 -/- cells 
has been shown to decrease expression levels of E2F-1 transcription factor, due to the release 
of RPL11 which consequently binds MDM2 and inactivates its E2F-1 stabilizing function 
[Donati et al, 2012]. In the same paper, the authors showed a mechanistic link between 
nucleolar stress response and cell cycle arrest that was dependent upon ribosomal proteins 
but independent of p53 activation. Ladevia et al also showed activation of cell cycle arrest 
independent of p53 function in p53 -/- TF-1 and K562 erythroid cell lines. The authors observed 
that nucleolar stress destabilized the proto-oncogene PIM1 that in turn increased the levels 
of p27kip1, which contributed to cell cycle arrest in a process that was reversed by restoring 
PIM1 levels (Iadevia et al, 2010).  It has been reported that MDM2 has many p53-independent 
effects within the cell aside from controlling E2F1 and p53 function.  
 
Pederson et al (2013) reported a connection between inducing nucleolar stress and cell cycle 
progression in HeLa cells. The authors induced nucleolar stress by briefly exposing cells to low 
concentrations of actinomycin D (ActD) which is known to selectively inhibit rRNA synthesis 
(Bensuade, 2011, Perry ,1962). They went on to find that treatment with ActD had no effect 
on the transition of G1 or S phase of the cell cycle but that cells were found to be stalled in 
late interphase. Additional experiments by the team also demonstrated that the cell cycle 
arrest was not only induced by the decline in rRNA synthesis or from ribosome starvation. 
Further work indicated that nucleolar stress induced cell cycle arrest involved the action of a 
G2 checkpoint which is mediated by the ATR-Chk1 pathway (Pederson et al, 2013)  
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1.12 Chemotherapy 
 
Chemotherapy, surgery and radiation continue to be the go to modalities for cancer 
treatment. In recent years a growing trend has emerged for the development of more specific 
targeted therapies have changed the landscape of the drug market. Currently, traditional 
chemotherapy drugs can be classified into seven major groups summarised in Table 1.5: 
 
Class Example Mechanism of action 
Platinum compounds Cisplatin, Carboplatin, Oxaliplatin Crosslinking of DNA, instrastrand 
and interstrand links, inhibit DNA 
repair and DNA synthesis 
Antimicrotubule agents Vinca alkaloids (vinblastine, 
vinorelbine) 
Stabilizing microtubule, blocking 
cell division, preventing M phase 
transition 
Antimetabolites Pyrimidine antimetabolites (5-FU, 
azacytidine (Vidaza), capecitabine 
(Xeloda), gemcitabine) 
 
Purine antimetabolites 
(mercaptopurine, fludarabine, 
pentostatin) 
 
Antifolates (methotrexate, 
pemetrexed) 
 
Thymidilate synthase inhibitors 
 
Adenosine deaminase inhibitors 
 
Ribonucleotide reductase 
inhibitors 
Similar structurers to molecules 
used in nucleic acid synthesis. 
Induce cell death during S phase, 
incorporated into RNA or DNA 
Antitumor antibiotics Actinomycin D 
Mitomycin C 
Bleomycin 
Anthracycline (doxorubicin) 
Epipodophyllotoxins (etoposide) 
Campthothecins 
Intercalating agents, block RNA or 
DNA synthesis, inhibit 
topoisomerase II causing DNA 
disruption and cell death 
Alkylating agents Cyclophosamide 
Nitrogen mustard or L-
phenylalanine agents 
Nitrosoureas – carmustine 
Alkane sulfonate - busulfan 
Introduce alky group into 
nucleophilic sites on DNA and RNA 
through covalent bonds, cause 
cross linking by reacting with the 7 
position of nitrogen bases, 
interfering with strand separation, 
preventing mitosis 
Kinase inhibitors Gleevec Inhibit tyrosine kinase, compete 
with ATP, blocks kinase receptor 
from binding ATP preventing 
phosphorylation 
Signal transduction inhibitors Tarceva 
Hormone therapeutics Tamoxifen Selective oestrogen receptor 
modulator 
Table 1.5: Classification of main chemotherapy drugs and their mechanism of action 
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1.13 RNA Polymerase inhibitors – a new class of anti-cancer agents 
 
Traditional chemotherapy drugs target fundamental cellular processes such as DNA 
replication and cell division through the use of alkylating agents (which add alkyl groups to 
guanine nucleotides) and mitotic inhibitors (used to disrupt microtubule assembly) to prevent 
the successful duplication of DNA  and inhibit complete cell division of cancer cells.  Anti-
cancer agents exhort their effects by targeting rapidly proliferating cells but are unable to 
distinguish between healthy and cancerous cells, as a result healthy rapidly diving cells such 
as those of the intestinal lining, hair and nails can also be affected. To circumvent this non-
selectivity of traditional chemotherapy agents, targeted therapy molecules provide 
alternative selective route to targeting important cellular processes for cancer intervention. 
 There is evidence in the literature to suggest that changes in rRNA synthesis could be 
considered as highly important molecular change within cancer cells to promote neoplastic 
growth with reports that pre-rRNA is overexpressed in many types of cancers and that 
overexpression of pre-rRNA correlates with poor prognosis in alveolar rhabdomysarcomas 
(Williamson et al 2006).  
Recently, targeted agents have been developed against rDNA transcription which include CX-
5461, CX-3543 (Quarfloxin) and BMH-21. BMH-21 which is a DNA intercalator that binds rDNA 
and inhibits rRNA transcription and interestingly does not induce the phosphorylation of 
gH2AX in A375 cells which is a key biomarker for DNA damage (Colis et al, 2014). CX-3543 
which was previously discussed in Section 1.8 is also a novel RNA Pol I inhibitor which 
selectively inhibits nucleolin/rDNA G-quadruplex complexes within the nucleolus in a range 
of solid and haematological cancers (Drygin et al, 2009).  
Many drugs used in chemotherapeutic intervention work by targeting DNA synthesis of a 
cancer cell but secondary effects of such drugs also show an effect on the process of ribosome 
biogenesis at various levels (Burger et al, 2010). These include DNA damaging agents, 
topoisomerase inhibitors, antimetabolites, anthracyclines and alkylating agents. Current 
chemotherapeutic strategies that have an impact upon ribosome biogenesis and their 
associated effects on the nucleolus are summarised in Table 1.6: 
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Drug Effect on 
nucleolus 
Effect on 
ribosome 
biogenesis 
Mechanism of 
action 
Cancer type 
CX5461 Nucleolar 
disintegration 
Selective 
inhibition of Pol I 
transcription 
(inhibits 
initiation) 
Inhibits SL-1 
preinitiation 
complex forming at 
the site of rDNA 
transcription 
Phase 1/2 clinical 
trial, AML, multiple 
myeloma and 
lymphoma 
CX3543 Redistribution of 
nucleolin (found 
mainly in GC) 
Selective 
inhibition of Pol I 
transcription 
(inhibits 
elongation) 
Interrupts  
nucleolin/rDNA G-
quadruplex 
complexes 
Phase 1 clinical trial, 
Carcinoid and 
neuroendocrine 
tumours 
Actinomycin D Nucleolar 
disintegration 
Pol I transcription 
inhibition at low 
nanomolar 
concentrations 
Intercalates into 
GC-rich duplex DNA 
Wilms tumour and 
Ewing sarcoma 
5-Fluorouracil No effect Impairs late 
mRNA processing 
Thymidylate 
synthase, 
incorporates into 
47S pre-RNA 
Breast, rectum, 
colon, oesophageal, 
stomach, head and 
neck, gastric, 
pancreas, biliary 
tract, renal cell and 
carcinoid cancer 
Mitomycin C Nucleolar 
disintegration 
Pol I transcription 
inhibition 
Interstrand DNA 
crosslinking via 
alkylating 5-CpG-3 
guanosine 
Non-small cell lung 
cancer, colorectal, 
head and neck, 
bladder, breast, 
anal, pancreas and 
stomach 
Cisplatin Nucleolar 
disintegration 
Pol I transcription 
inhibition 
DNA crosslinking via 
alkylation of DNA 
bases 
Stomach, ovarian, 
lung, bladder, 
testicular 
Ellipticine Not determined Pol I transcription 
initiation 
inhibition 
Impairs SL-1 rDNA 
promoter binding 
and preinitiation 
complex assembly 
Breast, Kidney and 
Liver 
Table 1.6: Chemotherapeutic agents that affect ribosome biogenesis and nucleolar morphology 
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1.14 CX-5461 
2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic 
acid (5-methyl-pyrazin- 2-ylmethyl)-amide, hereafter referred to as CX-5461 is a selective, 
potent and orally available inhibitor of Pol I transcription (Figure 1.7). The compound was first 
identified by Cylene pharmaceuticals as an inhibitor of Pol I transcription from a library of 
compounds. The team used qRT-PCR methods to measure the differential effects of new 
chemical entities on pol I and Pol II driven transcription in HCT-116 colorectal adenocarcinoma 
cells and later used a larger panel of additional cell lines (Haddach et al, 2012). Their results 
showed that CX-5461 was a highly potent and selective inhibitor of rRNA synthesis which 
suppressed Pol I transcription at the initiation stage and also displayed anti proliferative 
affects in vitro and in in vivo xenograft models displayed anti-tumour activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drygin et al (2011) further showed the selectivity of CX-5461 towards Pol I transcription in 
relation to Pol II transcription in cell based screening assays through qRT-PCR methods. The 
team used two short lived RNA transcripts, one under the control of Pol I (45s – pre rRNA) 
and the other under the transcriptional control of Pol II (the proto-oncogene c-Myc). Data 
from this experiment showed that CX-5461 was ∼ 200 fold more selective towards Pol I 
transcription relative to Pol II transcription (Table 1.7). 
 
Cell Line Pol I IC50 Pol II IC50 
HCT-116 142 nM/L > 25 μM 
A375  113 nM/L > 25 μM 
MIA PaCa-2 54 nM/L ∼ 25 μM/L 
Table 1.7: IC50 values of cell lines exposed to CX-5461 in pilot study (Drygin et al, 2011) 
 
 
Figure 1.7: Chemical structure of CX-5461 
40 
 
ChIP analysis determined that treatment with CX-5461 in either HCT-116, A375 or MIA PaCa-
2 cells resulted in 40-60% reduction of Pol I enzyme association with the rDNA promoter as 
well as depletion of binding of transcription factors to the rDNA promoter in HCT-116 cells, 
the subunits of SL-1 (TBP &TAF 110) being most affected (Drygin et al, 2011).  
 
The same team looked to see if CX-5461 could compete with SL-1 for the rDNA promoter 
region using electrophoretic mobility shift assay (EMSA) which measured the interaction of 
purified human SL-1 against a radiolabelled double stranded DNA fragment corresponding to 
the rDNA promoter region. As a negative control, CX-5447, an analogue of CX5461 was used. 
The results showed that treatment with CX-5447 did not affect the stability of SL-1/rDNA 
complex, however, treatment with CX-5461 clearly showed disruption of the complex (Drygin 
et al, 2011). Other important findings from this work showed that CX-5461 displays 250-300 
fold selectivity for inhibition of rRNA synthesis compared to DNA replication and protein 
translation, highlighting the non-genotoxic activity of this compound. Taken together, the 
work from Drygin et al (2011) shows that CX-5461 is potently selective towards polymerase I 
dependant rDNA transcription compared to genes under the control of Pol II enzymes.  
 
The assembly of the Polymerase I pre initiation complex at the rDNA promoter region is 
depicted in Figure 1.8. The process begins when upstream binding factor binds to the 
upstream control element and the core element of the rDNA promoter. This then leads to the 
recruitment of the SL-1 initiation factor which contains the TATA box binding protein (TBP) 
and several TATA-box associated factors. The stable UBF-SL-1 complex then recruits an 
initiation competent form of RNA Pol I, RRN3, responsible for mediating the interaction 
between RNA Pol I and SL-1 (Russell & Zomerdijk, 2006). CX-5461 inhibits the binding of the 
SL-1 complex to the core region along the rDNA promoter, preventing the transcription of 
rRNA. 
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Since its discovery, CX-5461 has been examined in both experimental models of 
haematological malignancies as well as solid cancers with promising results. The main findings 
of these studies are presented and summarised below in Table 1.8 with studies involving solid 
cancers annotated (S) and those involving haematological malignancies annotated (H): 
 
 
 
 
 
 
 
 
 
 
 
RNA Pol I 
TAFI12 
TAFI41 TAFIA 
TAFIB 
RRN3 
TAFIC 
TBP 
UCE CORE 
rDNA promoter 
UBF Dimer 
SL-1  
Complex 
CX-5461 
Figure 1.8: Schematic representation of how CX-5461 inhibits the pre initiation complex formation required for rRNA 
transcription. Adapted from Bywater et al, 2013. 
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Cancer type  Main Findings Reference 
Chemosensitive & Chemoresistant 
Epithelial Ovarian Cancer (S) 
qPCR analysis showed ribosomal 
components increased post 
treatment, CX-5461 induced G2M 
arrest, increased H2AX staining. 
Cornelison et al, 2017 
Multiple myeloma (H) Growth inhibition in WT and mutant 
p53 myeloma cell lines and primary 
samples. Suppression of MYC protein 
and mRNA levels – enhanced MYC 
degradation.  Increase in apoptotic 
markers. 
Lee et al, 2016 
Acute Myeloid Leukaemia (H) Cx-5461 outperformed standard 
chemotherapy agents. Induction of 
p53 dependant apoptosis.  WT and 
mut p53 activation of checkpoint 
kinase 1/2, aberrant G2M progression, 
myeloid differentiation of leukemic 
blasts 
Hein et al, 2017 
Glioblastomas, oligodendroglia’s , 
oligoastrocytomas (S) 
Cytotoxic effects of GBM cell lines, 
G2/M arrest, induction of apoptosis 
Li et al, 2018 
Osteosarcoma (S) G2M arrest, Autophagy dependant 
cell death which is also p53 dependant 
in U2-OS cell line, Induction of 
autophagy in U2-OS cells via 
AMPK/mTOR pathway and in MNNG 
cells induction of autophagy via 
AKT/mTOR pathway 
Li et al, 2016 
Advanced prostate cancer (S) G2M arrest, reduced proliferation in 
Hi-MYC tumours but not in Low-MYC 
PTEN null tumours. CX5461 combined 
with CX6258 further suppressed 
proliferation and induced cell death in 
PDX prostate cancer, increased 
caspase 3 cleavage. 
Rebello et al, 2016 
Small cell lung carcinoma (S) Suppressed proliferation in vivo, down 
regulation of MYC related genes, 
significant tumour inhibition 
Ki et al, 2016 
MYC-driven B Lymphoma (H) Nucleolar stress, p53 activation, 
dispersal of fibrillarin and loss of 
multiple nucleoli, CX-5461 induced 
p53 mediated apoptosis 
Devlin et al, 2016 
Acute lymphoblastic leukaemia (H) G2M cell cycle arrest, cell death as 
measured by PI staining. activation of 
ATM/ATR pathway, p53 independent 
apoptosis in ALL, 
induction of caspase dependant 
apoptosis 
Negi & Brown, 2015 
B cell lymphoma (H) Nucleolar disruption, p53 dependant 
activation of apoptosis, human 
hematologic cancer cells with WT p53 
significantly more sensitive to CX-5461 
(IC50 12nM) compared to mutant p53 
(IC50 230nM) in vivo. 
Bywater et al, 2012 
Table 1.8: Publications involving CX-5461 and their respective findings 
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1.15 Drug induced cytotoxicity 
Programmed cell death (PCD) can be considered as a mechanism of tumour suppression and 
is triggered in normal cells to remove unnecessary, aged or damaged cells which if not 
removed could be harmful to the living system (Fuchs et al, 2011). The three forms of 
programmed cell death include autophagy, programmed necrosis and apoptosis each of 
which can be clearly distinguished by their morphological features within a cell (Tan et al, 
2009), PCD can also be further extended to include senescence and mitotic catastrophe as 
modes of cell death in response to anticancer agents (Singh et al, 2010).  
 
Apoptosis can be activated by either intrinsic (mitochondria) or extrinsic (death receptor) 
stimuli. Both pathways converge in the activation of cysteine proteases known caspases. The 
major steps involved in apoptosis include cell shrinkage and cell fragmentation, collapse of 
cellular cytoskeleton, disassembly of nuclear envelope and release of cellular apoptotic 
bodies. Apoptosis is important in the context of cancer and cancer intervention due to the 
ability of cancer cells to evade this process and essentially resist cellular commands to self-
destruct (Hannahan & Weinburg, 2000). Autophagy is a highly conserved process in which 
cellular constituents (including organelles) are delivered to cytoplasmic lysosomes for 
degradation and the products of which are recycled by the cell. Currently there are three main 
types of autophagy reported in mammalian cells known as macroautophagy, microautophagy 
and chaperone mediated autopghagy (Glick et al, 2010). The processes of apoptosis and 
autophagy will be discussed in depth in chapter 4.  
 
Senescence refers to the limited replicative capacity of a cell which is no longer committed to 
the cell cycle but is still metabolically active. Two types of senescence prevent infinitive 
proliferation, stress induced senescence and replicative senescence. The former involves 
several stress stimuli such as DNA damage, damage to chromatin structure and oxidative 
stress as well as oncogene activation. Replicative senescence occurs due to the failure of DNA 
polymerase to successfully duplicate the ends of chromosomes known as telomeres which 
leads to telomeric DNA sequence loss as the cell cycles through each round of division This 
ability to induce growth arrest is a distinguishing feature between healthy cells and tumour 
cells presumed to function as a barrier to prevent the accumulation of mutations and possibly 
the formation of cancer. (He et al, 2017).  
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1.16 Radiotherapy 
 
Radiotherapy is a principle treatment modality for patients with solid cancers. After the 
discovery of X-rays in 1895 by Rontgen, the clinical usefulness of radiation as a means to treat 
cancer has gained considerable attention and today serves as a major medical speciality. It is 
estimated that around 50% of all cancer patients will receive radiation treatment during the 
course of their disease (Delany et al, 2005, Begg et al, 2011). To date, there is no evidence in 
the literature to describe any enhanced effects of combining radiation treatment alongside 
RNA Pol I transcription inhibition as a means of cancer treatment. Since the use of CX-5461 as 
a single agent has shown promising results in a wide range of cancers, combining this agent 
with radiotherapy could enhance its therapeutic value for the treatment and management of 
cancer. 
 
As mentioned previously, the main modalities of treatment for cancer include surgery, 
systemic therapy (chemotherapy, hormones) and radiation therapy. The latter comprises of 
either internal or external radiation. External radiation is most commonly used to treat 
cancers of the lung, head & neck, prostate, uterus, gastrointestinal tract, brain and other sites. 
Internal radiation therapy is invasive and is most commonly used to treat cancers of the 
prostate, gynaecological cancers (endometrial or cervical cancer and some breast cancers 
through the use of radioactive implants (Sadeghi et al, 2010).  
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There are various types of radiation therapy available to treat cancer patients which are 
summarised in table 1.9: 
 
Radiation therapy techniques Description 
Fractionation Based on the different radiobiological response of 
cancer and normal healthy tissue. Total radiation 
dose divided into several smaller doses over a period 
of time. Less toxic effects on healthy cells.  
3D Conformal Radiotherapy (External) Based on CT imaging.  Accurate localisation of tumour 
and critical organ structures for optimal beam 
placement.  
Intensity modulated radiation therapy (External) Allows for irregular shaped radiation doses which 
conform to tumour shape and size and spare critical 
organs (through the use of collimators)  
Image guided radiotherapy (External) Requires information from pre-radiation imaging to 
allow for the movement of organs and patient set up 
variation during treatment. Improved accuracy and 
can allow dose escalation.   
Stereotactic body radiation therapy (External) Precise delivery of high individual doses of radiation 
over few treatment fractions to destroy small, well 
defined primary and oligometastatic tumours within 
the body.  
Particle therapy (External) Uses heavier particles such as protons, neutrons and 
heavy ion beams. Neutrons produced by neutron 
generators, Protons produced by cyclotrons and 
synchrotrons and heavy ions (helium, carbon 
nitrogen etc.) produced by synchrocyclotrons and 
synchrotrons. Particle therapy can offer better dose 
distribution (Bragg Peak) which allows for maximum 
dose deposition at the tumour site whilst minimizing 
the damage to healthy tissue. Particularly useful in 
paediatric tumours and tumours close to critical 
structure such as spinal cord and brain 
Brachytherapy (Internal) Uses radioactive implant placed inside the body or 
near site of tumour. Implant can be temporary or 
permanent. Allows for higher dose delivery to smaller 
area compared to external radiation. Radiation 
source usually sealed within implant. Intracavity 
radiation is where the source is placed within a cavity 
(uterus or rectum) and interstitial radiation is where 
implant is placed within tumour tissue but not within 
a cavity. 
Table 1.9: The various radiation therapy techniques used in the treatment and management of cancer 
 
The biological effectiveness of radiation is dependent upon several factors such as total dose 
delivered, fractionation rate, the radio-sensitivity/resistance of target cells as well as the 
linear energy transfer of the particular type of radiation used (Hall, 2007). Ionizing radiation 
consists of photons (electromagnetic) or charged particles which can interact with molecules 
and break covalent bonds.  
46 
 
Radiation can be used as a curative or palliative treatment with the latter being used to 
improve quality of life under conditions where the cancer is incurable instead of to cure the 
cancer itself. Curative treatment is optimized to deliver the dose to the target tumour area 
whilst minimising the dose delivered to the surrounding normal tissues which can lead to loss 
of function of surrounding tissue and increases the risks of secondary cancers.  
 
Depending on the individual case, radiation therapy is often combined with chemotherapy. 
This can be neoadjuvant (where a therapeutic agent is administered before radiation), 
adjuvant (where an agent is applied after the initial radiation exposure) or concomitant 
treatment (where two or more agents are administered at the same time). The types of 
ionizing radiations used in the treatment of cancer are presented in Table 1.10. 
 
Radiation Type Property 
g-rays (EM Photon) Short wavelength, No mass/charge, Low LET, 
sparsely ionizing. Made from breakdown of 
radioactive isotopes such as cobalt-60 and radium. 
Used Gamma knife surgery 
X-rays (EM Photon) No mass/charge, Low LET, sparsely ionizing, 
produced from machines which excite electrons 
using cathode ray tubes or LINAC’s 
Electron (Particulate) small, –ve charge, can be accelerated to high 
speeds using betatrons or linear accelerators. 
Widely used for superficial tumours such as skin.  
Proton (Particulate) +ve charge, possess a mass approx. 2000 greater 
than that of an electron, can be accelerated to 
useful energies using cyclotrons. Used in 
specialized facilities for cancer treatment 
Neutron (Particulate) Similar mass to protons. No charge, electrically 
neutral therefore cannot be accelerated. 
Produced if charged particle such deuterium is 
accelerated and hits a target, also emitted as by-
products of nuclear fission. Not routinely used in 
cancer treatment. 
Heavy charged particles ( Carbon, neon, argon & 
Iron) 
 +ve charged nuclei of carbon, neon, argon and 
iron. Only produced in specialized facilities due to 
high amounts of energy required to accelerate. 
Not routinely used in cancer treatment. 
Table 1.10: Types of ionizing radiation used in the treatment and management of cancer 
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1.17 Effects of radiation on biological matter 
 
Living cells are exposed to a variety of different sources of environmental radiation on a daily 
basis. Although radiation may possess useful medical applications, uncontrolled exposure can 
be harmful to cellular systems (Little, 2003). Exposure to ionizing radiation may result in 
several outcomes at the cellular level; (i) the radiation may pass through the cell with no 
interaction, (ii) thereby causing no cellular damage, the cell may repair any damage inflicted 
by ionizing radiation, (iii) the radiation may elicit possible mutations within the cell which 
cause a reduction in the cells reproductive capacity, or (iv) the interaction will result in cell 
death. 
 
Ionization can be defined as the process of ejecting one or more electrons from the orbit of 
an atom. The effects of ionising radiation can either be direct or indirect. Direct ionizing 
radiation involves charged particles. With enough energy, these charged particles can disrupt 
the atomic structure of the absorbing material through which they pass and produce 
biochemical changes. Indirect ionization involves electromagnetic radiation such as X-rays 
and gamma rays. By themselves these species do not cause any biological or chemical damage 
but once they are absorbed by the material through which they pass (cell cytoplasm) they 
transfer their energy to produce charged particles which are then able to induce damage 
within their local surroundings. 
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Particulate radiation interacts with biological material either through excitation or ionization. 
The individual events of ionisation and excitation occur along the tracks of the individual 
charged particles. EM radiation, namely photons, are able to penetrate matter without 
interacting and deposit their energies in one of the following methods: 
 
• Photoelectric interaction – A photon’s energy is transferred to an orbiting electron 
usually in the outer shell of an atom. This electron is then ejected and from the atom 
and passes through the surrounding matter 
• Compton scattering – Only a portion of the photons energy is absorbed into the target 
electron and the same photon is scattered with a reduced energy. The scattered 
photon leaves in a different direction to that of the original incoming incident photon. 
As a result the target electron is ejected from its orbital position and travels in a 
separate trajectory to the scattered photon (Figure 1.9) 
• Pair production – The photon interacts with the nucleus of an atom and its energy is 
converted into mass producing an electron and a positron (Desouky et al 2015) 
 
(For an in depth review of the above processes the reader is referred to the following text 
Hobbie R.K., Roth B.J. (2007) Interaction of Photons and Charged Particles with Matter. In: 
Intermediate Physics for Medicine and Biology. Springer, New York, NY p401-435) 
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The process by which X-ray photons are absorbed depends on the energy of the photons used 
and also the chemical composition of the absorbing material. For studying the effects of 
radiation in combination with CX-5461 in solid cancer cell lines, conventional X-rays will be 
used generated from a linear accelerate at the Royal Surrey County Hospital. Since high 
energies will be used to generate the X-rays, Compton scattering process will be the dominant 
mode of interaction for the X-rays, this interaction is presented below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incident photon Scattered photon 
Fast ejected electron 
Proton 
Electron 
Neutron 
Figure 1.9: Compton scattering of X-rays. A photon interacts with an orbiting electron. Part of the photon energy is 
transferred to the orbiting electron as kinetic energy and this electron is released from the atom, the photon with 
reduced energy continues along a separate trajectory. Adapted from Hall & Garcia, 2006. 
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If either EM or particulate radiation is absorbed into biological material, there exists the 
possibility that the radiation will directly interact with critical components of the cell, such as 
DNA. The atoms within the DNA molecule itself may become ionized or excited leading to 
biological change, this is referred to as direct action of radiation. Direct action is the dominant 
interaction when considering radiation with high LET (Linear Energy Transfer). On the other 
hand, the radiation may interact with other molecules inside the cell such as water producing 
free radical molecules which also can damage biological material. This is referred to as indirect 
action of radiation. The direct and indirect action of these X-rays is presented in Figure 1.10. 
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O 
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Figure 1.10: The direct and indirect interactions of X-rays with DNA. Adapted from Hall & Garcia, 2006 
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1.18  Radiation and DNA repair 
 
Within the cell, the biological target of radiation is the nucleus, which harbours the most 
important chemical molecule inside all living cells, DNA. The direct or indirect interactions of 
radiation may induce single or double stranded breaks (SSB & DSB respectively) within the 
helical structure of DNA (Lomax et al, 2013). This detrimental effect of radiation is the 
principle which is exploited by radiotherapy. Single stranded breaks (SSB) can be repaired 
using a number of excision repair pathways which use the (undamaged) complementary 
strand as a template, these include base excision repair (BER) which repairs damage sustained 
to a single nitrogenous base through the use of glycosylase enzymes, nucleotide excision 
repair (NER) which repairs damage that causes bulky distortion to the structure of DNA such 
as pyrimidine dimerization and damage is excised using endonucleases (Reardon, 2006) and 
mismatch repair (MMR) which is responsible for correcting errors which were not detected 
by cellular proofreading mechanisms. Double stranded breaks (DSB) however are repaired by 
one of three mechanisms; non-homologous end joining (NHEJ), microhomology mediated end 
joining (MMEJ) and homologous recombination (Liang et al, 2005) 
 
1.19 Linear energy transfer 
 
LET or linear energy transfer can be described as the amount of energy that an ionising 
particle transfers per unit length of track to the medium traversed, the units of which are 
kiloelectron volt per micrometre (keV/um). LET can be defined as: 
 (𝐿) = 𝑑𝐸/𝑑𝑙 
 
Where dE = the average energy locally imparted to the medium by a charged particle of 
specified energy in traversing a distance of dl. 
 
Upon absorption of radiation by biological matter, the events (ionizations) tend to localise 
along the tracks of individual particles in a pattern which is dependent upon the type of 
radiation used.  
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The difference between high and low LET are summarised in Table 1.11: 
 
High LET Low LET 
Neutrons, alpha particles X-rays, gamma rays 
Deposit large amount of energy over a small 
distance 
Deposit low amounts of energy along track 
Ionize water into H+ and OH radicals over a short 
track 
Widely spaced ionization events 
Ionizes water over longer track 
More destructive than low LET Less destructive than high LET 
Localized DNA damage – Dense ionisations Diffuse DNA damage – sparse ionization 
Lower cell survival per absorbed dose – highly 
destructive 
Less destructive to biological material compared to 
high LET 
Table 1.11: Differences between high and low linear energy transfer radiations 
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1.20  Radio-sensitisation  
 
A radiosensitizer is a chemical agent which has the ability to increase the lethal effects of 
radiation when concomitantly administrated. A major drawback to many radiosensitizing 
candidates is a lack of differential effect between tumours and normal healthy cells. A key 
criterion of a good radiosensitiser is that the sensitivity is only markedly increased in cancer 
cells compared to normal healthy cells. 
 
Radiation therapy plays a pivotal role in the management of many cancers to the extent that 
approximately 50% of cancer patients receive some kind of radiotherapy and around 40% of 
cancer patients cured will have received some form of RT as part of their treatment (Cancer 
Research UK, 2018). Over recent years, significant advances have been made to deliver 
radiation doses to target tissues whilst limiting delivery of radiation to surrounding healthy 
tissues. 3D conformal RT, IMRT and image guided RT offer such benefits in terms of dose 
escalation within the tumour site as well as reducing dose deposition in healthy tissue (Bhide 
& Nutting, 2010). 
 
Increasing tumour control and targeting the micro-metastatic disease outside of the field of 
radiotherapy during the early treatment process can potentially be achieved by combining 
cytotoxic chemotherapy with RT (Bentzen et al, 2007) using agents such as platinum agents, 
anti-metabolites such as 5-FU and gemcitabine as well as taxanes.  
 
Data collected from studies involving squamous cell cancer of the head and neck shows that 
the greatest benefit from combining chemotherapy with RT occurs when both agents are 
administered simultaneously (Pignon et al, 2000). Other studies have reported the benefit of 
administering chemotherapy combined with radiotherapy in cancers such as glioblastoma 
multiforme (Stupp et al, 2005 & 2009) and uterine cervix (Green et al, 2001).  
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CX-5461 has the potential to act as a radiosensitizing agent to increase the cytotoxic profile 
of combining RT alongside RNA Pol I transcription inhibition due to the selectivity of CX-5461 
towards cancer cells over healthy cells. The fact that the sensitivity of a range of different 
tumours to CX-5461 is not dependent upon p53 status to induce cell death coupled with the 
lethality of radiation induced damage could provide a new avenue for the control and 
treatment of solid cancers.  
 
In the context of this project, CX-5461 has the capacity to only target cancer cells which are 
undergoing increased rates of proliferation due to their abhorrent upregulation of rDNA 
transcription, this feature of increased ribosome biogenesis has been termed ‘the Achilles 
heel of cancer’ (M van Sluis & Mcstay, 2014) and could be responsible for the selectivity of 
CX-5461 towards cancer cells over non-cancerous cells. The literature supports the 
combination of CX-5461 with other agents such doxorubicin in a synergistic manner but to 
date no data exists in the literature which shows the effects of combining the inhibition of 
rRNA synthesis alongside radiotherapy as a means of treatment for solid cancers.  
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1.21  Aims and objectives 
 
This thesis aims to investigate the effects of inhibiting RNA Pol I using CX5461 in combination 
with radiotherapy in solid cancers.  The main body of this thesis aims to address the following 
questions: 
 
1. How do cancer cells from different solid tumours respond to treatment with CX5461?  
 
Several solid cancer cell lines representing different regions of the body will be 
developed into a panel of cell lines exposed to a range of CX-5461 doses and cell 
viability will be assessed using MTS assays whilst the cancer cells proliferative capacity 
will be measured using clonogenic assays (Chapter 3). 
 
2. Are there any synergistic affects when CX-5461 is combined with radiation therapy or 
does combined treatment result in additive/antagonistic effects and does CX-5461 act 
as a radiosensitizing agent?  
 
Cell lines displaying low medium and high sensitivity towards CX-5461 will be selected 
and used in combination studies where the cells will be exposed to drug alone, 
radiation alone and combination treatments involving CX-5461 and single dose X-ray 
(0-16Gy) exposure. Cell viability following treatment will be assessed using MTS assay 
and any synergistic or additive effects of combination treatment will be determined 
using Loewe’s combination index isobologram analysis (Chapter 3).  
 
3. How does CX-5461 induce cell death in these solid cancers?  
 
CX-5461, radiation and combination treatment induced cytotoxicity will be further 
investigated to determine the mechanisms involved to induce cell death. Apoptosis 
will be measured using Annexin V-FITC assay combined with western blot analysis of 
markers of end stage caspase dependant apoptosis (cleaved caspase 3, whole and 
cleaved PARP).   
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Induction of autophagy will be determined using markers of autophagic flux (LC3II: 
LC3I ratio and p62 experession) using confocal microscopy and Western blot analysis 
coupled with detection of autophagolysosome formation using flow cytometry. 
Cellular senescence will be assessed using senescence associated β-galactosidase 
staining using bright field microscopy  
 
CX-5461 induced DNA damage following exposure to CX-5461 and combination 
treatments will be assessed using γH2AX via Western blot analysis and confocal 
microscopy (Chapter 4). 
  
4. How does CX-5461 affect progression through the cell cycle? Does CX-5461 induce any 
anti-proliferative affects?  
 
Cell cycle associated effects resulting from treatment with CX-5461 alone and in 
combination with radiation exposure will be determined using Propidium iodide 
staining via flow cytometry. The expression of markers associated with cell cycle arrest 
(p53 & p27kip1) will be assessed using Western blot analysis (Chapter 5). 
 
The effects of silencing of a prominent nucleolar protein, Nucleophosmin (NPM1), will 
be determined using Annexin V-FITC assay via flow cytometry and knockdown of 
NPM1 will be verified using Western blotting techniques. Quantitative polymerase 
chain reaction (qPCR) experiments will be used to identify changes in 45s pre-rRNA 
gene expression following exposure to CX-5461 over the course of 72hrs (Chapter 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
 
Materials & Methods 
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2. Methods & Materials 
 
2.1 CX5461 Drug preparation 
 
10mg of CX-5461 (S2684) was purchased from Selleckchem (USA) in lyophilized form. The 
powder was reconstituted in 50mM NaH2PO4 to form a final concentration of 10mM which 
was stored in 50ul aliquots at -80C. Working stock vials of 10mM CX-5461 in 50mM NaH2PO4 
pH 4.5 were kept at room temperature for two weeks and diluted directly into growth media 
prior to drug administration. DMSO as a solvent can be toxic to cells at concentrations above 
1% therefore it was important to use a solvent which would not be toxic to cells at the high 
doses of CX-5461 used to determine dose response data.  
 
CX-5461 was administered at varying concentrations which were dependent upon the type of 
experiment and exposure time. For single CX-5461 experiments, cells were exposed to 
increasing concentrations of CX-5461 ranging from 6.25nM to 3.2μM. For experiments 
involving X-rays and CX-5461 each 96-well plate received a range for CX-5461 doses (6.25nM-
3.2μM) and an individual dose of X-rays (2Gy, 4Gy, 6Gy, 8Gy and 16Gy). Cells were incubated 
following irradiation until control wells reached confluency (90%). 
 
Rapamycin (R8781, Sigma, UK) which was used as a positive control to induce autophagy was 
purchased from Sigma, UK and reconstituted in DMSO to a final stock concentration of 
2.74mM 
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2.1.1  CX-5461 solubility issues  
To prepare stock solutions of CX-5461 a suitable buffer was needed to dissolve the lyophilized 
powder. Initially we followed manufacturer’s recommendations and first attempted to 
dissolve the powdered form of the drug in laboratory reagent grade dimethyl-sulfoxide 
(DMSO) (10080110 – Fisher Scientific, UK). This resulted in precipitation of the compound 
which was not fit for subsequent experiments. 
 
Precipitation of a compound in DMSO has been reported to be an issue of compound 
solubility (Oldenburg et al 2005). Amorphous compounds (a solid which does not exhibit a 
repeating crystalline structure) can be readily dissolved in DMSO. Since information about CX-
5461s ability to form a crystalline structure is unknown, X-ray diffraction (XRD) techniques 
could be used to provide this information to confirm if this was the reason for precipitation 
of CX-5461 in DMSO. 
 
Next, we attempted to dissolve the compound in a different buffer, which was recommended 
by the manufacturer (Selleckchem, USA), namely N-N-dimethylformamide (DMF) (D4551-
250ML – Sigma, UK). Although a soluble stock solution of 10mM was achieved, high doses of 
CX-5461 prepared in DMF were toxic to cells when exposed to DMF only. Also DMF, as a 
vehicle for CX-5461 is not suitable for use in the clinical settings due to its highly toxic profile. 
The reason for CX-5461 ability to dissolve in DMF is due to similarity in structure of the DMF 
and the polarised functional amide group on CX-5461 shown in Figure 2.1 
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We then looked at dissolving the compound in sodium dihydrogen phosphate (NaH2PO4) at a 
pH of 4.5, this buffer was originally described by Drygin et al in their original paper (Drygin et 
al 2010). This buffer successfully dissolved CX-5461 and we were able to aliquot stocks of 
10mM CX-5461 in 50mM NaH2PO4 to carry out experiments. The solubility of CX-5461 in 
NaH2PO4 could be explained through the electron withdrawing characteristics of functional 
groups present within the structure of CX-5461. The red circle marks a highly electrophilic 
carbon atom within the structure of CX-5461. Since bonding electrons are attracted more 
towards the highly electronegative oxygen and nitrogen atoms, this makes this amide group 
polarised and able to attract the electrons from the nucleophilic phosphorus anion as shown 
by the green circle (Figure 2.2) 
 
 
 
 
N-N-Dimethylformamide 
CX-5461 
The nitrogen atom within the DMF is highly  
Nucleophilic due to its lone pair of electrons.  
Structure of DMF is also similar to amide group on 
CX-5461 
Nucleophile Nitrogen atom 
Electrophile Carbon atom 
Nucleophilic attack to an electron deficient carbon 
Amide function group 
Figure 2.1 Schematic representation of CX-5461's solubility in DMF buffer 
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Figure 2.2: Solubility of CX-5461 in NaH2PO4 
Electrophilic carbon atom within CX-5461 is electron deficient  
due to bonding with highly electronegative oxygen and nitrogen 
The oxygen atom within the NaH2PO4 compound is 
Highly nucleophilic due to its lone pair of electrons 
NaH2PO4 
CX-5461 
Nucleophile 
Electrophile 
Nucleophilic attach to an electron deficient carbon 
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2.2 Cell Culture 
 
All media used to maintain the culture of cell lines used in this project are described in Table 
2.1. Media was stored at 4°C and when required media was pre-heated in a water bath at 
37°C before use. 
 
Medium Supplement Supplier 
Dulbecco’s Modified 
Eagles Medium 
(DMEM) 
(D5671) 
100 U/mL penicillin (P4333) 
100ug/mL streptomycin(P4333) 
2mM L-Glutamine (G7513) 
10% Fetal Bovine Serum (FBS) 
(10500-064) 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Life Technologies, 
UK 
 
RPMI 1640 Medium 
(R0883) 
100 U/mL  Penicillin(P4333) 
100ug/mL Streptomycin(P4333) 
2mM L-Glutamine 10% (G7513) 
Fetal Bovine Serum (FBS) 
(10500-064) 
Sigma UK 
Sigma, UK 
Sigma, UK 
Life Technologies UK 
 
Mc’Coy’s 5A 
Medium 
(M8403) 
100 U/mL Penicillin(P4333) 
100ug/mL Streptomycin(P4333) 
2mM L-Glutamine(G7513) 
10% Fetal Bovine Serum (FBS) 
(10500-064) 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Life Technologies, 
UK 
 
Table 2.1: Cell culture media used in the maintenance and passaging of cell lines used  
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2.3 Cell Lines 
 
All the cell lines used in this project were adherent cell lines either purchased from ATCC or 
donated kindly Prof H Pandha and Dr Helen M Coley (University of Surrey) and are presented 
in Table 2.2. All cell lines were maintained at 37°C in an incubator with 5% CO2 atmosphere. 
Tissue culture work was performed in a sterile class II biosafety cabinet (Kendro, UK).  
Mycoplasma testing was regularly carried out once a month using MycoAlert Mycoplasma 
Detection Kit (LT07-218 -  Lonza, UK).  
 
Cell Line Culture Medium & 
Supplements 
Tissue Type 
CaSki RPMI 1640 10% FBS Epidermoid carcinoma of 
the cervix 
A375 DMEM 10% FBS Malignant melanoma of the 
skin 
LN18 DMEM 5% FBS Glioblastoma of the brain – 
right temporal lobe 
SKMEL-28 RPMI 1640 10% FBS Malignant melanoma of the 
skin 
HCT-116 McCoy’s A 10% FBS Colorectal carcinoma of the 
colon 
G361 McCoy’s A 10% FBS Malignant melanoma of the 
skin 
Panc-1 DMEM 10% FBS Epithelial carcinoma of the 
pancreas 
SCaBR EMEM 10% FBS Squamous cell carcinoma of 
the bladder 
A549 F-12K 10% FBS Epithelial carcinoma of the 
lung 
BXPC3 RPMI 1640 10% FBS Adenocarcinoma of the 
pancreas 
PSN-1 RPMI 1640 10% FBS Adenocarcinoma of the 
pancreas 
PEO1 RPMI 1640 10% FBS Adenocarcinoma of the 
ovary 
PEO1 CarbR RPMI 1640 10% FBS Adenocarcinoma of the 
ovary 
SiHa EMEM 10% FBS Squamous cell carcinoma of 
the cervix 
Table 2.2: List of solid cancer cell lines used for experimental work 
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The panel of cell lines in Table 2.2 were previously validated within the Pandha laboratory 
(Leggett Building, University of Surrey). It is important to ensure that all cell lines are validated 
since the continuous passaging of cells can result in the deviation of the cell line from its 
original phenotype and genetic sequence.  
 
Growth curves were not performed for each individual cell lines, doubling times for the 
growth of cell lines were obtained from the literature and ATCC data sheets for individual cell 
lines. It is a pre-requisite to perform growth curves on all cell lines used to determine accurate 
doubling times and to verify when cells enter into the log phase of growth for each cell line 
before performing any proliferation/cytotoxicity assays.  
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2.4 Passaging of adherent cell lines 
 
Cells were grown in either, T25 or T75 cell culture flasks (156340 and 156367 - Thermo Fisher, 
UK). Spent media was aspirated and the cell monolayer was washed briefly with Hanks 
balanced salt solution (H9269-500ML - Sigma, UK) which was then aspirated and cells then 
detached from the surface of flasks using Trypsin-EDTA (1X) solution (T4049 Sigma, UK) for 5-
10 minutes.  After cells had been observed under the microscope to be detached from the 
surface of the flasks, Tyrpsin digestion was terminated using serum containing cell media and 
the cell suspension transferred to a 20ml universal tube and centrifuged at 1500rpm for 3 
minutes. After the cells formed a pellet the supernatant was aspirated and the cell pellet re-
suspended in cell media and 1ml of cell suspension transferred to a new flask containing 11ml 
of cell media and incubated overnight to allow cells to adhere to the flask surface.  
 
2.5 Evaluation of cell numbers 
 
Depending on the type of experiment to be undertaken, cells were counted and plated out 
accordingly using a traditional haemocytometer method. 
 
A 1:10 dilution was prepared by mixing 10ul of cell suspension with 90ul of Trypan Blue 
(93595-50ML - Sigma, UK) and transferring 10ul of this dilution to a Neubauer 
haemocytometer.  Trypan blue is used to distinguish between dead and viable cells since the 
dye can only penetrate the membrane of non-viable cells. Viable cells were counted in the 
four quadrants of the haemocytometer and cell number was calculated using the following 
formula: 
 
Mean number of cells per quadrant x dilution factor x104 = number of cells/mL 
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2.6 Cryopreservation of cells and revitalisation of cryopreserved cells 
 
To store stocks of cells in a controlled manner which would not affect the integrity and 
viability of the samples, cells were harvested using traditional methods and cells re-
suspended to a concentration between 1x106  - 1x107 cells/mL in freezing media containing 
50% cell culture medium, 40% FBS (10500-064 - Life Technologies, UK) and 10% DMSO. Cell 
suspension was aliquoted into 1ml volumes in sterile Cryovial tubes and stored in a Mr Freeze 
containers at -80C to ensure a controlled decrease in temperature before being transferred 
to liquid nitrogen for long term storage.  
 
2.7 Reviving cryopreserved cells 
 
Cells stored in long term storage in liquid nitrogen were removed from storage and thawed 
rapidly in a 37°C water batch until thawed. The cells were then transferred to a universal tube 
containing 9ml of pre-warmed cell culture media to and centrifuged at 1500rpm for 3 minutes 
to remove any freezing media. The supernatant was aspirated and the cell pellet re-
suspended in 1-2 ml cell media and transferred to a T25 flask and incubated at 37°C.  
 
Also cryopreservation of cells means that cell lines can be stored at different times until they 
are required for experiments some disadvantages of thawing cryopreserved cells mean that 
some cell populations may not survive the cryopreservation process, variations in 
preservation media may adversely affect specific cell markers or specific cell populations. 
Frozen cells may also behave differently following the thawing process as they may produce 
and secrete high amounts of cytokines which has the potential to lead to scientific 
misinterpretation.  
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2.8 X-ray Irradiation of Cells 
All X-ray irradiations were performed at the Royal Surrey County Hospital using a Gulmay 
linear accelerator with a dose rate of 0.65Gy/min using 250 keV electrons which were passed 
through a 2.7mm copper filter (filter 9). Applicator I was used with a field size of 15x15cm and 
the focus surface distance was 50cm from the source of the photons to the surface if the 
target plate. Cells were seeded in 6-well plates at densities between 1x105 – 3x105 cells/ml 
depending on the experiment and time point. Cells were plated 24hrs before irradiation and 
the media was replenished prior to irradiation. The monitor units used to deliver each Gy of 
radiation are presented below: 
 
Dose Gy Monitor units (MU) 
2 192 
4 385 
6 576 
8 770 
16 770 x2 
Table 2.3: Doses of X-rays used in combination MTS experiments 
 
 
Figure 2.3: Flow diagram describing the method of plating cells in 96-well plates and exposure to single dose X-rays 
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2.9 RNA Extraction from Adherent Cells 
 
The RNeasy Plus Micro Kit (74004 - Qiagen, UK) was used to extract total RNA from cells 
according to the manufacturer’s instructions. In brief, cells were lysed using β-
mecaptoethanol (M6250-100ML -Sigma, UK) which was diluted 1:100 in RLT Plus Buffer at 
room temperature for 5 minutes. The homogenized lysate was then passed through a gDNA 
(genomic DNA) column to remove any genomic DNA. Ethanol (10048291 - Fisher Scientific, 
UK) was then added to the flow through column to provide the appropriate binding conditions 
for the RNA after which the sample was transferred to an RNeasy spin column. Any potential 
contaminations were removed by using specific buffers provided with the kit leaving behind 
only the RNA bound to the silica membrane inside the column. The isolated RNA was eluted 
20µL of RNase free water and the concentration in ng/µL of eluted RNA was measured using 
the NanoDrop ND-1000 Spectrophotometer (Labtech International, UK). RNA samples were 
either kept on ice and used immediately for cDNA library synthesis or frozen at -80°C.  
 
2.10 Complimentary DNA (cDNA) Synthesis 
 
The Cloned AMV First-Strand cDNA Synthesis Kit (12328032 – Fisher Scientific, UK) was used 
to reverse transcribe total RNA by following the manufacturer’s instructions. The RNA 
template and primer were denatured in the absence of reaction buffer and enzyme to remove 
any possible secondary structure that may impair cDNA synthesis prior to cDNA synthesis.  
 
Per reaction, 1uL 50µM Oligo (dT)20 primer, 500/1000ng RNA and 2µL 10mM dNTP were 
mixed together and made up to a volume of 12µL using DEPC-treated water and incubate at 
65°C for 5 minutes and then placed directly onto ice. 4µL 5x cDNA synthesis buffer, 1µL 0.1M 
DTT, 1µL 40U/µL RNaseOUT, 1µL DEPC-treated water and 1µL of 15U/µL Cloned AMV reverse 
transcriptase were added to each RNA reaction tube to a final volume of 20µL. The tubes were 
then transferred to a pre-heated thermos cycler (Applied Biosystems, UK) and incubated at 
60°C for 1 hour. The reaction was terminated by incubating the reaction tubes at 85°C for 5 
minutes.  
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Assuming 100% efficiency of cDNA synthesis, 1000ng cDNA was produced in 20µL to give a 
concentration of 50ng/μL which was further diluted to 2ng/μL in 480µl RNase free water. The 
cDNA was either used immediately and kept on ice or stored at -20°C. 
 
2.11 Quantitative Polymerase Chain Reaction (qPCR) 
 
qPCR analysis was performed using the Stratgene Mx3005p qPCR machine (Agllient 
Technologies, USA), using SYBR Green fluorescence to quantify the amount of PCR product. A 
qPCR master mix was prepared as follow: 12.5µL SYBR Green Jumpstart Taq Ready Mix, 
0.25µL Reference Dye (ROX) (S4438-100RXN - Sigma, UK), 5.25µl RNase-free water and 2µL 
cDNA (5ng/µL) making a total volume of 20µL per reaction. 5ul of the gene of interest primers 
were added to the corresponding wells of the 96-well qPCR plate containing the master mix 
in triplicates. GAPDH, a housekeeping gene was used as an endogenous control. The reaction 
conditions were as follows: 1x Cycle (10 minutes at 95°C), 4-x Cycles (30 seconds at 95°C, 1 
minute at 60°C and 1 minute at 72°C) 
 
Both forward and reverse primers for all human target genes used in qPCR experiments are 
displayed in table. All primers were designed using the Primer3 and BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and were purchased from Sigma (UK) and 
stored at -20C. 
 
qPCR analysis was done using MxPro software (Aglient Technologies, USA), the cycle 
threshold (cT) was determined in each sample, which is the number of cycles required for the 
fluorescent signal to exceed the background level. Ct values are inversely proportional to the 
amount of target DNA in the sample. The 2-deltact relative quantitation method was used to 
analyse the qPCR data. Each sample the expression of the gene of interest is shown relative 
to GAPDH (x1000). 
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Gene Forward primer sequence 
5’ to 3’ 
Reverse primer sequence 
  5’ to 3’ 
Accession 
number 
B-Actin CGTCACCAACTGGGACGACA 
 
CTTCTCGCGGTTGGCCTTGG NM_001101.4 
GAPDH CTCCTGTTCGACAGTCAGCC 
 
TTCCCGTTCTCAGCCTTGAC NM_002046.5 
45s rRNA CCGCGCTCTACCTTACCTACCT 
 
GCATGGCTTAATCTTTGAGACAAG NR_145819.1 
NPM1 GTTCTCTGGAGCAGCGTTCT 
 
CGGCCTTTAGTTCACAACCG NM_002520.6 
Table 2.4: Primers used for qPCR experiments to quantify the expression of 45s pre-rRNA and nucleophosmin (NPM1) gene 
transcripts following CX-5461 treatment. B-Actin and GAPDH were used as reference housekeeping genes.  
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2.12 Western Blot analysis for the detection of proteins in cell lysates 
 
Lysate Preparation and proteins separation: 
Whole cell lysates where prepared from harvested cells which were washed with 1x PBS 
(11503387 - Fisher Scientific, UK) before being lysed using radioimmunoprecipitation (RIPA) 
buffer (89900 - Life Technologies, UK) containing Halt phosphatase and protease inhibitors 
(78437 - Thermo Scientific, UK) at a working dilution of 1:100. Lysates were gently agitated 
and kept on ice for 5 minutes and then sonicated for 3x 10 second cycles and then centrifuged 
at 1300rpm for 10 minutes at 4°C. Samples were then transferred to fresh sterile 1.5ml 
Eppendorphs tubes and stored at -80°C. The total concentration of protein was determined 
using Peirce BCA Protein Assay Kit (23227 - Life Technologies, UK) by following manufacturer’s 
instructions. 10μl of sample of albumin containing standard were added in duplicates to a 96-
well plate and 200μL of working reagent was added to each well containing unknown protein 
samples and known standards and incubated (protected from light) at 37°C for 30 minutes. 
The colorimetric reaction was measured at 562nm using the Variskan Flash plate reader 
(Thermo Scientific, UK) and protein concentration in each sample was interpolated from the 
standard curve. 
 
For protein separation, sampled were diluted in RIPA buffer to the required loading 
concentration (15-20ng/ul). 30uL of the diluted lysate, 10ul of NuPAGE LDS Loading Buffer 
(NP0007 - Life Technologies, UK) and 4μl of NuPAGE sample reducing agent (NP0009 - Life 
Technologies, UK) were vortexed and denatured in a heat block at 95°C for 5 minutes.  
Samples were then again vortexed and kept on ice until loaded onto a gel. The XCell Surelock 
Mini-cell Electrophoresis apparatus (E10020 - Life Technologies, UK) was assembled 
containing nuPAGE 4-12% Bis-Tris gels (NP0336PK2 - Life Technologies, UK) and NuPage MES 
SDS running buffer (NP0002 - Life Technologies, UK) diluted 1:20 in reverse osmosis (RO) 
water. 3.5μL of pre-stained markers and 44μl of reduced lysate samples were loaded into 
each lane of the nuPAGE 4-12% Bis-Tris gel. Electrophoresis was carried out at 90 volts initially 
until the markers of the ladder could visually be identified and separated and then at 190Volts 
for 30 minutes using a PowerPac (1645070 - Bio-Rad, UK) 
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Protein Transfer, Membrane Blocking & Antibody probing and detection: 
 
Separated proteins from the gel were transferred to either 0.45μM nitrocellulose (LC2001 – 
Thermo Scientific, UK) or 0.2μM PVDF membranes (88520 – Thermo Scientific, UK) by 
electroblotting at 20 volts for 7 minutes using the iBlot gel transfer machine (IB21001 - Life 
Technologies, UK). After transfer, membranes were immediately blocked in either 5% BSA in 
TBS-0.1% Tween-20 (TBS tablets code 94158 - Sigma, UK, Tween-20 code p1379-25mL – 
Sigma, UK) or 5% Milk in TBS-0.1% Tween-20, gently shaken at room temperature for 1 hour. 
Membranes were then probed with the primary antibody which was diluted in either 5% BSA- 
TBS-0.1% Tween-20 or 5% Milk- TBS-0.1% Tween-20 overnight at 4C on a rolling machine. 
After incubation membranes were washed 3x for 5minutes in TBS-0.1% Tween-20 and 
incubated with the appropriate secondary horseradish peroxidase (HRP)-conjugated 
secondary antibody diluted in 5% Milk- TBS-0.1% Tween-20 for 1 hour at room temperature. 
Following secondary incubation membranes were again washed 3x in TBS-0.1% Tween-20 and 
the membrane covered in SuperSignal West Pico chemiluminescent substrate (Life 
Technologies, UK) for up to 3 minutes before protein bands were visualized using the 
ChemiDoc-It imager (UVP, UK). Molecular weights of proteins of interest were confirmed 
against direct comparison of pre stained marker weights in kilo Daltons (kDa). Membranes 
were stored in TBS-0.1% Tween-20 at 4°C to be stripped and re-probed.  
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Figure 2.4: Flow diagram of the western blot protocol to probe lysates obtained from CX-5461 treated samples 
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2.13 Stripping of nitrocellulose/PVDF membranes 
 
To ensure the uniform loading of protein samples in each lane, membrane blots were stripped 
using 15ml of Restore PLUS stripping buffer (46428 - Thermo Scientific, UK) and gently 
agitated for 10-15 minutes followed by 3x washes in TBS-0.1% Tween-20. Membranes were 
then again blocked to prevent any non-specific binding of antibodies for 1 hour at room 
temperature in either 5% BSA-TBS 0.1 Tween-20 or 5% Milk TBS-0.1% Tween-20 followed by 
re-probing with GAPDH primary antibodies (Cell Signalling Technologies, UK).  
 
Primary Antibodies 
Antibody Supplier Dilution Molecular Weight 
(kDa) 
Anti LC3 Rabbit 
Monoclonal 
Cell Signalling 
Technology UK 
1:1000 14,16 
Anti p62 Rabbit 
Monoclonal 
Cell Signalling 
Technology UK 
1:1000 62 
Anti pH2AX Rabbit 
Monoclonal 
Cell Signalling 
Technology UK 
1:1000 15 
Anti PARP (W&C) 
Rabbit Monoclonal 
Cell Signalling 
Technology UK 
1:1000 116, 89 
Anti Cleaved 
Caspase-3 Rabbit 
Monoclonal 
Cell Signalling 
Technology UK 
1:1000 17, 19 
Anti p-Rb Rabbit 
Monoclonal 
Cell Signalling 
Technology UK 
1:1000 110 
Anti p-
Nucleophosmin 
Rabbit Monoclonal 
Cell Signalling 
Technology UK 
1:1000 38 
Anti P53 Mouse 
polyclonal 
Santa Cruz Biotech 
USA 
1:500 53 
Anti p27kip1 Mouse 
Polyclonal 
Santa Cruz Biotech 
USA 
1:500 27 
Anti Nucleophosmin 
Mouse Polyclonal 
Santa Cruz Biotech 
USA 
1:500 38 
Anti GAPDH Mouse 
Monoclonal 
Origin Biotech USA 1:2000 37 
Secondary Antibodies 
Goat Anti Rabbit 
HRP 
Abcam, UK 1:2000  
Goat Anti Mouse 
HRP 
Abcam, UK 1:2000  
Table 2.5: Primary and secondary antibodies used for western blot analysis 
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The following positive and negative controls for the detection of apoptosis and autophagy 
 
HeLa Apoptosis Lysate Set: 
Staurosporine-Treated and 
Vehicle-Treated Control 
(ab136806) 
 
Abcam, UK 
LC3 Control Cel Extracts - 
HeLa cells, untreated (-) or 
chloroquine-treated (50 μM, 
overnight; +)  #11972 
Cell Signalling Technology, 
UK 
Table 2.6: +ve and -ve controls used for autophagy and apoptosis western blot experiments 
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2.14 Western blot troubleshooting 
 
Western blot membranes were probed for a marker of DNA damage, gH2AX. A 
phosphorylated form of gH2AX (p-gH2AX) was used to detect levels of p-gH2AX in drug treated 
lysates. Following separation of proteins and transfer onto a nitrocellulose membrane, the 
membrane was blocked in 5% non-fat dry milk in TBST20 0.1% for 1 hour at room 
temperature. Following primary and secondary antibody incubations, and subsequent 
imaging of the membrane, an irregular white smear would appear on the membrane making 
visualization of the protein bands very difficult (Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon further investigation, it was found that the non-fat milk blocking buffer used contained 
the phosphoprotein casein which is known to cross react with the phosphorylated proteins 
resulting in non-specific binding and high background noise as shown in Figure 2.5 
 
 
 
 
 
 
 
Figure 2.5: Western blot blocked in 5% non-fat dry milk in TBST20 0.1% showing a lack of clear 
visualization of protein bands 
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The membrane was then stripped and re-blocked in 5% BSA in TBST20 since BSA contains only 
one protein (albumin) in an attempt to reduce background noise. Following primary and 
secondary incubations, imaging of the membrane showed that indeed blocking in BSA 
prevented and background noise which resulted in a clearer western image (Figure 2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Western membrane from Figure 1 stripped and re-blocked in 5% BSA in TBST20 showing 
clearer visualization of protein bands and significantly lower background noise 
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2.15 Cell viability assay 
 
Cell Titre 96 Aqueous Non-Radioactive Cell Proliferation (MTS) Assay (G3582 - Promega, UK): 
The MTS assay is a colorimetric assay based on the reduction of a tetrazolium compound by 
viable cells to form a coloured formazan dye which is soluble in cell culture media.  The assay 
contains a tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-5-3(carboxymethoxyphenyl0-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt] as well as an electron coupling reagent 
(phenazine ethosulphate; PES), which when combined with MTS forms a stable solution.  
 
Figure 2.7: Structure of MTS tetrazolium and its formazan product 
The tetrazolium compound is bioreduced by cells into a coloured formazan product. This 
reaction is accomplished by NADH or NADPH which is produced by mitochondrial 
dehydrogenase enzymes within metabolically active cells. The change in colour of solution is 
directly proportional to the number of viable cells in the sample being tested.  
 
3000 Cells were seeded in a volume of 100μL and left to incubate overnight at 37°C and attach 
to the surface of 96 well plates. This cell density was chosen because it allowed enough cell 
divisions to take place for the duration of treatment without causing cell overcrowding and 
contact inhibition.  After 24 hours the media was aspirated from each well and 100uL of CX-
5461, NaH2PO4 or media alone control was added to the designated wells in triplicates 
according to the plate plan for 96hrs at 37°C. 100μL of Cell Titre 96 Aqueous Non-Radioactive 
Cell Proliferation (MTS) Assay (Promega, UK) was then diluted 1:10 using RPMI 1640 media 
and added to each well as well as empty wells for use a background control. The plates were 
protected from light and incubated for 2 hours at 37°C, each individual experiment was 
incubated for the same time period. Optical density was measured using a Variskan Flash 
plate reader (Thermo Scientific, UK) at 492nm wavelength.   
Coloured 
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The data obtained from the OD values was analysed. The average OD of the background 
control (MTS only) was subtracted from the average OD of each sample. The % survival in 
each treatment was then calculated relative to the untreated cells using the following 
formula: 
 
% cell survival = (averaged treated sample / average OD untreated sample) x 100 
 
 
 
Figure 1.8: Flow diagram showing the process of setting up the MTS assay to determine the dose response profile of solid 
cancer cell lines 
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2.16 Clonogenic Assay 
 
The clonogenic assay was used to evaluate single drug toxicity (CX-5461) and combined 
treatments (CX-5461 & X-rays and X-rays alone). Cells were grown in 6-well plates and 
following treatment incubated up to 14 days. Colonies were fixed in 50% ethanol in PBS and 
stained with 5% crystal violet in PBS (R40052 - Sigma, UK). Colonies with more than 50 cells 
were counted and survival fractions were determined taking into consideration the plating 
efficiency for all treatment modalities based on triplicate experiments. Calculations were 
based established protocols (Franken et al 2006). 
 
Plating efficiency was calculated as follows 
 
PE = # of colonies counted / # of cells seeded x 100 
 
Survival fraction was calculated as follows: 
SF = # of colonies formed after treatment (drug or radiation) / # of cells seeded x PE 
 
 
 
Figure 2.9: Flow diagram of the process of setting up a clonogenic assay to determine the proliferative capacity of single cells 
following CX-5461 treatment 
81 
 
2.17 Immunofluorescence (IF) staining & confocal microscopy 
 
IF staining was utilised to demonstrate the cellular localization of Rabbit -LC3 and Rabbit-
pH2AX proteins which are involved in autophagy and sites of DNA damage respectively.  
10,000 cells were seeded in individual chambers of 8-well tissue culture treated glass chamber 
slides (354104 - BD Bioscience, UK). Cells were incubated for 24hrs to allow cells to adhere to 
the surface before drug treatment and incubation at 37°C for either 48hrs or 72hrs.  
 
Following drug exposure, media was aspirated and cells washed with 500μL 1x PBS 0.1% 
Tween-20 3x and either permeabilised and fixed in 300μL ice cold methanol for 5 minutes at 
room temperature for microtubule-associated protein 1 light chain LC3 staining, or 
permeabilised using 300μl 4% paraformaldehyde (20ml 1x PBS & 0.8g paraformaldehyde 
powder (P6148 - Sigma, UK) – made in house on a magnetic stirrer at 60°C until completely 
dissolved) for 10 minutes at room temperature followed by 3x 500μL 1x PBS 0.1% Tween-20 
washes and then fixed using 300μL 0.1% Triton X for 10 minutes at room temperature for p-
H2AX staining and again washed 3x in 1x PBS 0.1% Tween-20. Cells were blocked to prevent 
non-specific binding in 500μL of 1% BSA in 1x PBS – 0.1% Tween-20 and 10% Goat serum for 
30 minutes at room temperature. Chambers were then aspirated and the primary antibody 
diluted in 1% BSA PBS 0.1% Tween20 was added in a volume of 300μL to each well (1:200 for 
LC3 and pH2AX), a negative control well was included which received 1% BSA PBS 0.1% 
Tween20 with no diluted primary antibody. Cells were incubated with the primary antibody 
at 4°C overnight in the cold room in a humidified chamber. For autophagy experiments 
positive controls were treated with 300μL of 10μM rapamycin.  
 
Following primary incubation cells were washed 3x in 1x PBS – 0.1% Tween-20 and incubated 
with the secondary antibody, goat anti-rabbit Alexa Flour 488 (ab150077 - Abcam, UK) diluted 
1:500 in 1%BSA PBS 0.1% Tween20 for 1 hour at room temperature after which cells were 
washed 3x in 1x PBS – 0.1% Tween-20. The plastic chamber was removed using the white 
comb provided with the chamber slides and which revealed the glass slide underneath. 
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Drops of Vectashield Hardset Mounting Media (H-1500 - Vector Laboratories, UK) containing 
DAPI were dropped onto the glass slide and a glass coverslip placed on top and allowed to 
cure for 15 minutes at room temperature. DAPI served as a counterstain to mark the nucleus 
of cells. The slide was imaged using a Nikon A1M confocal microscope and using the NIS 
element acquisition software (64-bit) (Nikon, UK).  
 
 
Figure 2.10: Schematic flow diagram showing the process of immunostaining CX-5461 treated cells in chamber slides for 
fluorescent microscopy 
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2.18 Detection of cellular Senescence in solid cancers 
 
Senescence is a state of reversible cell cycle arrest characterised by an increase in cytoplasmic 
β-galactosidase levels. To determine senescent activity in solid cancers the Cellular 
Senescence Assay Kit (KAA002 - Chemicon, USA) was used following manufacturer’s 
instructions. In brief, cells were grown to the desired confluency on 20x20mm coverslip inside 
small petri dishes and exposed to CX-5461 for the desired period of time. Following treatment 
media was aspirated and the cells washed in 1x PBS . 1ml of fixing solution was added to each 
dish and incubated at room temperature for 15 minutes. Fixing solution was removed and the 
cells washed twice in 2mls of 1x PBS and aspirated. 2ml of freshly prepared 1x SA-β-gal 
Detection Solution (KAA002 - Chemicon, USA) was added to each dish and dishes were 
wrapped in foil and incubated at 37°C overnight in 0% CO2. The following day the 1x SA-β-gal 
Detection Solution was removed and the stained cells were washed twice with 2ml 1x PBS. 
After aspiration cover slips were mounted onto glass slides (29514 - Thermo, UK) and blue 
cells were counted under phase contrast microscopy. For long term storage coverslips were 
overlayed with 70% glycerol diluted in 1x PBS and stored at 4°C.  
 
 
Figure 2.11: Flow diagram depicting the method to stain CX-5461 treated cells to detect the presence of any cells undergoing 
cellular senescence 
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2.19 Ki-67 Flow cytometry staining protocol 
 
Ki-67 is marker for cellular proliferation. Cells were seeded in 6-well plates at a density of 
1x105 – 2.5x105 cells/ml and allowed to adhere to the surface overnight at 37°C. Following 
incubation media was aspirated and cells were treated with a low and high dose of CX-5461 
(500nM &1μM) for 24hrs, 48hrs and 72hrs. After exposure cells were harvested using trypsin 
and washed in 1x PBS and centrifuged at 2000rpm for 2 minutes.  
 
The supernatant was aspirated and the cell pellet was resuspended and fixed in a volume of 
50μL at room temperature for 15 minutes using Reagent A of the Fix and Perm Kit (GAS004 - 
Life Technologies, UK) and neutralised with binding buffer and centrifuged again for 2 minutes 
at 2000rpm. The supernatant was discarded and the cell pellet resuspended in 90µl of 
Reagent B and incubated with a 1:10 dilution of Ki-67 antibody (130-100-290 - Mileni Biotec, 
UK) at room temperature for 20 minutes. Buffer was added to each well and again centrifuged 
for 2 minutes at 2000rpm, the supernatant was removed and the cell pellets resuspended in 
PBS for analysis by flow cytometry.  
 
 
Figure 2.12: Flow diagram showing the preparation of cells prior to staining for Ki-67 expression analysis using flow cytometry 
 
 
85 
 
2.20 Flow cytometry Autophagy Detection 
 
Autophagy is a catabolic process used to degrade cytoplasmic constituents and organelles 
inside of lysosomes. To detect autophagy in solid cancers, the quantitative CYTO-ID® 
Autophagy Detection Kit (Enz-51031-0050 - Enzo, UK) was used following manufacturer’s 
instructions. Cells were harvested following drug exposure using traditional methods and 
centrifuged at 1500rpm for 2 minutes. Sample cell pellets were then washed using 1X Assay 
Buffer (Enzo, UK) and again pelleted and then resuspened in in 250μL of 1x Assay Buffer (Enzo, 
UK) and 250μL of CYTO-iD Green stain solution (Enzo, UK) and mixed thoroughly and 
incubated at 37°C protected from light for 30 minutes, a mono dispersal of cells was achieved 
by pipetting the mixture up and down several times before incubation. Following incubation, 
samples were pelleted and washed with 1x Assay buffer (Enzo, UK) and re-suspended in 500μl 
1x Assay Buffer (Enzo, UK) and analysed using the FL1 (Green) channel of a flow cytometer. 
 
 
 
Figure 2.13: Flow diagram of the protocol to measure the formation of autophagolysosomes using flow cytometry 
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2.21 Flow Cytometry Annexin V-FITC/PI Apoptosis Detection 
 
The Annexin V-FITC Apoptosis Detection Kit (CBA059 - Calbiochem, USA) was used to detect 
cell membrane alterations which accompany cell death using flow cytometry. The assay was 
followed using manufacturer’s guidelines following the conventional Annexin V Binding 
protocol. Cells were seeded at the appropriate density in T25 flasks and exposed to CX-5461 
for the desired period of time.  
Cells were harvested using Trypsin and washed using 1x PBS and resuspend and transferred 
to sterile eppendorphs and again washed 2 more times in PBS at 1000rpm for 5 minutes at 
4°C.  
 
The supernatant was then aspirated and sample cell pellets re-suspended in 500μL binding 
Buffer (Calbiochem, USA) and 2uL of Annexin V-FITC (Calbiochem, USA) was added to each 
sample, vortexed and incubated at room temperature for 30 minutes protected from light. 
Following incubation the binding buffer was removed by centrifugation and 1000rpm for 5 
minutes and sample cell pellets resusupended in 500μl binding buffer and 10μL propidium 
Iodide (PI) (Calbiochem, USA) added to each sample and analysed using FL1 and FL3 channels 
for Annexin V-FITC and Propidium Iodide respectively using a Beckman Coulter Epics Flow 
Cytometer.  
 
 
Figure 2.14: Flow diagram depicting the process of determine the mode of cell death following CX-5461 treatment as 
measured by Annexin/PI assay using flow cytometry 
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2.22 Cell Cycle Flow Cytometry Analysis 
 
Cells were grown to 70-80% confluency following drug treatment and harvested using 
traditional methods 12ml universal tubes. Cells were washed with 1x PBS pelleted and the 
supernatant aspirated. Samples were either stored at this stage by resuspending pellets in 
70% Ethanol in PBS and stored at 4°C until analysis or resuspened in 1xPBS and incubated 
with Ribonuclease A for 30 minutes at 37°C. Following incubation, 33μL of propidium iodide 
was added to each sample and incubated at room temperature for 10 minutes before analysis 
by flow cytometry using the Beckman Coulter Epics Flow Cytometer. 
 
 
Figure 2.15: Schematic diagram illustrating the process of sample preparation following CX-5461 treatment for the analysis 
of cell cycle associated effects using flow cytometry 
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2.23 Combination Index (CI) analysis for combination treatment involving CX-5461 and 
radiation therapy (RT) 
 
Loewe’s combination index analysis is a contemporary method to analyze the drug-drug 
interactions or in this case drug-radiation interaction. The Loewe’s combination index (CI) is 
calculated using the following equation 
 
CI = (CA, X/ICX, A) + (CB, X/ICX, B) 
 
CA,X ,CB,X,, ICX,A and ICX,B are the concentrations of agent A and agent B used in combination and 
as individual agents respectively to achieve the same effect X 
 
In our experiments, CA,X & CB,X denote the concentration of CX-5461 and radiation dose 
respectively used in combination to achieve a ‘X’ effect.  
 
ICX,A & ICX,B, are concentrations of CX-5461 and radiation dose used as single agents to the 
achieve the same effect of ‘X’ 
 
Loewe’s Combination Index (CI) of <1 or > 1 is used to indicate synergy or antagonism 
 
Microsoft Excel and GraphPad 7 were used to indicate Loewe’s CI values. For calculating 
Loewe’s CI values, cells were cultured using standard tissue culture methods and cell viability 
post various combinations of CX-5461 and radiation treatment was measured using MTS 
assay. Normalized MTS values were calculated for each CX-5461 and radiation combination. 
 
IC50 values for CX-5461 treatment were first obtained by using non-linear regression modeling 
curve-fit analysis followed by the log IC50 values for CX-5461 using the same modelling. The 
same procedure was repeated for radiation doses and Loewe’s CI values for each combination 
of CX-5461 and radiation were obtained.  
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2.24 Transient RNA Silencing for Nucleophosmin in CaSki Cells 
 
Cells were plates into 6-well plates at a density if 1x105 cells/ml and allowed to adhere to the 
surface overnight.  Following incubation cell media was removed and cells were washed 
briefly with PBS and aspirated and replaced with either NPM1 SiRNA (Dharmacon – GE 
Healthcare, USA) reagent or Non-coding control SiRNA (Dharmacon – GE Healthcare, USA)  for 
4 hours after which the silencing media was removed  and replaced with media containing 
20% FBS and left to incubate overnight. The following day the 20% FBS media was aspirated 
and replaced with normal cell culture media (RPMI 1640 10% FBS) and incubated for a further 
48hrs. After 72hrs total incubation NPM silenced and Non-coding control silenced cells were 
harvested and plated out into T25 flasks and 6-well plates and allowed to adhere overnight. 
 
After 24hrs, the T25 flasks prepared for flow cytometry analysis were drug treated with CX-
5461 at doses of 500nM and 1μM and left to incubate for 72hrs after which the cells were 
analysed for signs of apoptosis using a flow cytometer. The cells in the 6 well plates, prepared 
for Western blot analysis were allowed to grow for 48hrs before being harvested, lysed using 
RIPA buffer and treated with Halt protease cocktail inhibitors and their protein concentration 
measured using Peirce BCA Assay (23225 – Thermo Fisher, UK). 
 
Silencing of NPM1 was confirmed using Western blots by probing membranes for NPM1 (sc-
271737 - Santa Cruz, USA).  
 
SiRNA against NPM1 and Non-coding SiRNA were purchased from Dharmacon – GE 
Healthcare, USA. The sequences of each SiRNA are shown below 
 
Human SNAI2 (6591) Non-coding siRNA 
ON-TARGETplus SMARTpool siRNA J-017386-05 SNAI2 
Target sequence - UCUCUCCUCUUUCCGGAUA 
Molecular weight – 13,429.8 g/mol 
 
Human NPM1 (4861) siRNA 
ON-TARGETplus SMARTpool siRNA J-015737-05 NPM1 
Target sequence - GUAGAAGACAUUAAAGCAA 
Molecular weight – 13.384.7 g/mol 
Table 1.7 siRNA sequences used for NPM1 silencing in CaSki cells 
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Figure 2.16: Schematic flow diagram of the process of silencing NPM1 gene in CaSki cells for analysis of CX-5461 associated 
affects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
2.25 Statistical analysis methods 
 
Statistical analysis on western blot data was performed using one-way analysis of variants 
(ANOVA) with Dunnett’s multiple comparisons test to determine statistically significant 
differences in expression of protein levels comparing controls to treated samples.  A p-value 
of less than 0.05 was considered statistically significant and a p-value above 0.05 was not 
considered statistically significant. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 
0.001 and **** = p-value < 0.0001. 
 
Statistically significant differences in Ki67 expression following CX-5461 treatment over the 
course of 72hrs was determined using two-way analysis of variants (ANOVA) with Dunnett’s 
multiple comparisons test. A p-value of less than 0.05 was considered statistically significant. 
For the analysis of autophagolysosome formation following CX-5461 treatment using flow 
cytometry, statistical analysis was performed using two-way analysis of variants (ANOVA) 
with Dunnett’s multiple comparisons test. A p-value of less than 0.05 was considered 
statistically significant.  
 
Results obtained from combination experiments to determine the mode of end stage cell 
death using Annexin V-FITC assay via flow cytometry were statistically analysed using two-
way analysis of variants (ANOVA) with Dunnett’s multiple comparisons test. A p-value of less 
than 0.05 was considered statistically significant. For experiments involving scheduled 
administration of CX-5461 following radiation treatment, results were statistically analysed 
using two-way analysis of variants (ANOVA) with Dunnett’s multiple comparisons test. A p-
value of less than 0.05 was considered statistically significant.  
 
Results obtained from SiRNA silencing experiments involving the silencing of nucleophosmin 
in CaSki cell line were statistically analysed using one-way analysis of variants (ANOVA) using 
Tukey’s multiple comparison test. A p-value of less than 0.05 was considered statistically 
significant. For qPCR experiments, statistical analysis of gene expression data was analysed 
using two-way analysis of variants (ANOVA) with Dunnett’s multiple comparisons test. A p-
value of less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
The targeting of RNA polymerase I transcription in combination with 
radiation therapy to enhance tumour cell killing effects in solid 
cancers 
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3. The targeting of RNA polymerase I transcription in combination with radiation therapy 
to enhance tumour cell killing effects in solid cancers 
 
Previous reports have shed light into the cytotoxicity associated with inhibiting RNA 
Polymerase I using agents such as CX-3543 (Quarfloxin), CX-5461 and BMH-21 (Drygin et al, 
2009, Drygin et al, 2011, Haddach et al, 2012; Peltonen et al, 2014). However, no reports in 
the literature have explored combining RNA Pol I inhibition alongside radiation therapy as a 
means for cancer treatment.  The aim of combining different treatment modalities is to 
reduce radio-resistance and improve overall therapeutic index. Using molecular targeted 
approaches such as CX-5461 can potentially enhance tumour response to radiation therapy 
by enhancing tumour cell killing and minimizing normal cell toxicity. 
 
Using potent anti-proliferative agents such as CX-5461, tumour repopulation following 
radiation therapy can be overcome and provide a means of systemic control outside of the 
radiation field. The DNA damage response (DDR) is the main response by which the cell 
responds to damaged DNA following exposure to radiation. The DDR pathways which 
include base Excision Repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), direct enzymatic repair (DR), control cell cycle arrest, repair of damaged DNA and 
cell fate (Kinsella, 2009). The most lethal forms of radiation damage include double stranded 
breaks which are repaired through either homologous recombination (HR) or non-
homologous end joining (NHEJ) pathways (Helleday et al, 2008; Bradbury et al, 2003). 
 
The above processes require the correct function of a myriad of specialised proteins 
involved in the DDR. These proteins (Ataxia telangiectasia mutated (ATM), γH2AX, p53 
binding protein 1 (53BP1), checkpoint kinase 2 (Chk2), mediator of DNA damage checkpoint 
protein 1 (MDC1), breast cancer susceptibility gene 1 (BRCA1) etc.) are produced in the 
cytoplasm through the translation of mRNA sequences by ribosomes. As cells are exposed to 
doses of CX-5461, RNA Pol I mediated transcription of 45s rRNA becomes inhibited. This 
results in a decrease in production of ribosomal subunits within the nucleolus and 
subsequently results in a decrease in fully assembled cytoplasmic ribosomes (Robledo et al, 
2008). A lack of fully functioning ribosomes entails that the necessary repair proteins 
required to repair the damage induced by X-rays cannot be produced therefore the DDR 
cannot be executed resulting in the cell committing to programmed cell death (Figure 3.1).  
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3.1 Synergistic model of combination treatment involving CX-5461 & RT 
 
 
Synergy can be defined as the interaction of two or more agents to produce a combined 
effect which is greater than the sum of their separate individual effects. In vitro, or in clinical 
settings, combining two or more agents may exhibit synergistic, additive or antagonistic 
effects. Combination treatment has been shown to be a promising approach to treating 
cancer (Feala et al, 2010).  
 
As expected, when individual agents are used in combination treatments, the outcome 
cannot always be predicted with the results showing the possibility of a variety of different 
outcomes (Yeh et al, 2009), of these interaction, drug synergy and antagonism are of 
particular interest with drug synergy being an important goal of combinational drug 
development (Fitzgerald et al, 2006).  
 
Drug combinations which show synergetic affects have been shown to be therapeutically 
more specific and highly efficacious (Lehar et al, 2009). Such therapeutic drug combinations 
include prednisolone and nortriptyline against TNF-α secretion in peripheral blood 
mononuclear cells (PBMCs) and also cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP) 4-way combination in the treatment of peripheral T-cell lymphomas 
(PTCLs) (Skarbnik et al, 2013).  
 
There is also evidence to show that drug-radiotherapy combinations improve overall patient 
survival (Lawrence et al, 2013). Radiotherapy combined alongside cetuximab compared to 
radiation alone treatment has shown improvements in median overall survival and in 
patients with advanced stage head and neck cancers (Brown et al, 2008). 
Chemoradiotherapy involving cisplatin has also been shown to significantly reduce disease 
reoccurrence and improve survival compared to radiation treatment alone in cervical cancer 
patients (Shrivastava et al, 2018). 
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As previously mentioned, treatment with CX-5461 has been reported to induce G2M cell 
cycle arrest, a phase in the cell cycle which is known to be most radiosensitive (Bernard et 
al, 1995 and Pawlik & Keyomarsi 2004). The work described in this thesis sets out to exploit 
the sensitivity of cells arrested in G2M through CX-5461 treatment by exposing drug treated 
cells to a range of doses of radiation in order to ascertain if synergetic cell death does 
indeed take place.  
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3.2 Study Objective 
 
The targeting of a subcellular organelle in combination with radiation will enhance tumour 
cell killing effects 
 
 
 
 
 
 
 
 
 
 
Aim & objectives: 
 
How do cancer cells from different solid tumours respond to treatment with CX-5461? 
 
The objective of this chapter was to determine the spectrum of sensitivity of a range of 
different solid cancer cell lines towards CX5461 alone and in combination with radiotherapy. 
In order to test this, the following experiments were conducted: 
• 96hr MTS assay involving a range of solid cancer cell lines to determine IC50 dose 
values and spectrum of sensitivity 
• MTS assay reporting the effects of combination treatment involving single dose X-
rays and CX-5461 to assess any synergistic effects  
• Clonogenic assay to determine the replicative ability of single cells to form visible 
colonies following CX-5461 treatment 
• Flow cytometry KI-67 expression profile to assess the proliferative status of CX-5461 
treated cells  
 
 
 
Figure 3.1: Schematic diagram illustrating the synergistic effects of combining RNA Pol I inhibition alongside X-ray 
radiation to induce cell death 
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3.3 CX-5461 induced cytotoxicity profile in solid cancers 
 
In order to determine the spectrum of sensitivity of solid cancer cell lines towards CX-5461, 
a panel of fifteen cell lines from several different organ sites such as the brain, skin, 
pancreas and cervix were screened using an MTS assay to assess cell viability after 96hrs 
exposure (For methods see Section 2.15). The results showed a wide spectrum of sensitivity 
to CX-5461 within the nanomolar range with the most sensitive cell lines being PANC-1 and 
A375 with IC50 values of 35nM and 53nM respectively (Figure 3.2).  On the other end of the 
spectrum the highest IC50 values obtained were still within in the nanomolar range for PSN-1 
and ZR-75-1 at 656.1nM and 506.7nM respectively with the most resistant cell line being 
PEO1CarbR (PEO1 carboplatin resistant BRCA WT) with a IC50 of > 3.2µM. CX-5461 has not 
previously been tested in any of the cell lines used in this study apart from A375 where an 
IC50 value of 58nM has been previously reported (Drygin, 2011) which is in line with the 
values obtained in the present study.  A complete list of IC50 values for each cell line 
alongside their p53 status are presented in Table 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: MTS Assay dose response curve of a panel of solid tumour cell lines exposed to a range of Cx-5461 doses 
for 96hrs, each cell line was repeated in triplicates. 
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The p53 status of cell cancer cell lines exposed to CX-5461 did not correlate with sensitivity 
to the drug. Previous studies had reported a significant association between p53 status and 
CX-5461 sensitivity only in haematological malignancies (Bywater et al, 2013) and not in 
solid cancers (Drygin, 2011). Our results show that CX-5461 displayed similar cytotoxic 
effects against p53 WT and mutant solid cancer cell lines. Two of the most sensitive cell lines 
towards CX-5461 were PANC-1 and A375 which have either mutated p53 status or wild type 
with IC50 values of 35nM and 53nM respectively. The IC50 values for cell lines harbouring p53 
mutations ranged from 35.73nM to 656.1nM.  
 
Of the fifteen cell lines studied in the cell panel to determine sensitivity towards CX-5461, 
three representations of sensitivity were selected for further analysis using combination 
treatments. These cell lines include A375 melanoma (53nM - sensitive), LN18 glioblastoma 
(104nM - moderately sensitive) and CaSki (408nM - relatively resistant) cervical cancer cell 
lines.   
 
Table 3.1: IC50 values of the cell panel exposed to CX-5461 for 96 hrs alongside their individual p53 gene status.  
IC50 values were calculated using graph pad using non-linear regression analysis. Experiments were performed in 
triplicates for each cell line  
Cell Line IC50 nM p53 Status 
PANC-1 35.73 Mut 
A375 53.56 WT 
G-361 55.45 WT 
PEO1 98.89 Mut 
LN18 104.1 Mut 
A549 169.2 WT 
HCT-116 178.3 WT 
SKMEL – 28 188.1 WT 
SCaber 215.8 Mut 
SiHa 229.3 WT 
BXPC3 257.7 Mut 
CaSki 408 WT 
ZR-75-1 506.7 WT 
PSN-1 656.1 Mut 
PEO1-CarbR > 3200 Mut 
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3.3.1  CX-5461 induced cytotoxicity in BRCA1/2 deficient ovarian cancer cell line 
 
PEO1 (BRCA2 mutant) and PEO1CarbR (carboplatin resistant – BRCA2 wild type) cell lines 
were exposed to CX-5461 for 72hrs and viability following treatment was measured using 
MTS assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MTS Assay following CX-5461 treatment over 72hrs showed that PEO1 (BRCA2 mut) was 
significantly more sensitive to effects of CX-5461 compared to PEO1CarbR with IC50 values of 
99.7nM and > 3.2μM respectively (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Dose response curves of PEO1 (BRCA1/2 mut) and PEO1Cr (BRCA1/2 wt) ovarian cancer 
cell lines exposed to a range of CX-5461 doses 
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3.4 CX-5461 treatment in combination with radiotherapy in solid cancers 
 
Before combining radiation alongside CX-5461 treatment, it was important to establish how 
selected cell lines to be used in combination studies would respond to radiation alone as a 
single agent. MTS assays were used to assess cell viability following radiation exposure at 
room temperature. Low range single doses of X-rays were used ranging from 0 – 16Gy (for 
Methods please see Chapter 2 section 2.8) and cells were analysed for survival once control 
samples had reached approx. 80-90% confluency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results from Figure 3.4 indicate a dose dependent decrease in cell survival after 
exposure to increasing doses of radiation as assessed by MTS assay. A single dose of 6Gy 
was sufficient enough to reduce cell survival by 50% across all cell lines used in this 
experiment, 16Gy exposure was sufficient enough to kill almost all LN18 cells with CaSki and 
A375 cells showing survival between 10-20% at this dose. The dose responses of A375, LN18 
and CaSki cells to single dose X-rays are in agreement with previous reports in the literature 
(Ahmed, 1996, Zheng, 2004).  
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Figure 3.4: Single dose X-ray radiation MTS Dose response curve of A375, LN18 and CaSki cells. % viability following 
irradiation was measured once untreated control cells had reached approximately 80-90% confluency. 
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3.5 Combination treatment of CX-5461 and RT in A375 melanoma cells 
 
Dose response curves from experiments involving A375 cells treated in combination with 
CX-5461 and single dose X-rays are presented in Figure 3.5 Combination index values 
obtained from combination experiments are presented in Figure 3.6 
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Figure 3.5: MTS dose response curve of A375 cells exposed to CX-5461 in combination with a range of single dose X-rays 
  Radiation Dose Gy  	 2 4 6 8 16 
1600 1.96 1.22 1.94 3.06 3.97 
800 1.82 1.42 2.11 2.04 2.50 
400 1.31 1.01 1.39 1.08 1.59 
200 0.82 0.56 0.76 0.72 0.90 
100 0.71 0.4 0.59 0.59 0.54 
50 0.57 0.37 0.45 0.41 0.37 
25 0.91 0.52 0.39 0.33 0.27 
12.5 0.97 0.54 0.34 0.27 0.21 
6.25 1.01 0.53 0.28 0.20 0.15 
 
Figure 3.6: Loewe's combination index matrix for A375 cells treated in combination with RT and CX-5461 
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A375 cells were exposed to a range of CX-5461 doses alone or in combination with single 
dose X-rays and cell survival was measured using the MTS assay at 96hrs (Figure 3.5). The 
results from the MTS assay show a dose dependent decrease in cell survival following 
exposure to CX-5461 alone. When combined with X-rays, cell death was more pronounced 
with combinations of 4Gy x-rays & 6.25nM CX-5461 reducing cell viability to below 50% 
compared to 6.25nM drug alone which only reduced cell survival by 13% (Figure 3.5) and 
single dose X-rays dose of 4Gy alone which reduced survival by 50% (Figure 3.4). 
Isobologram analysis of combination treatments showed that the increased effectiveness of 
combination treatments where seen when low doses of CX-5461 (6.25nM – 100nM) were 
combined with high radiation doses between 6Gy-16Gy (Figure 3.5). Combination 
treatments of 4Gy & 100nM CX-5461 was markedly more effective at reducing cell viability 
(reduced to 10%) compared to combinations using the same drug concentrations but higher 
doses of radiation.  
 
Clonogenic assays were performed with A375 cells treated with CX-5461 and incubated for 
14 days. The plating efficiency of A375 cells was found to be 12.5% averaged across three 
experiments. Results from CFU assay are shown in Figure 3.6 and images of colonies from 
these experiments are shown in Figure 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Clonogenic assay of A375 cells treated with low dose CX-5461 reporting the survival fraction of 
cells able to form visible colonies. Incubation time 14 days. Each individual experiment was set up in 
triplicates and repeated three times.  
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To assess if CX-5461 displays any anti-proliferative properties the clonogenic assay was used 
to determine the replicative ability of cells treated with Cx-5461 to form visible colonies. The 
results showed a dose dependent decrease in the formation of visible colonies compared to 
untreated controls (Figure 3.6). Low doses of 3nM CX-5461 were sufficient to induce a 
reduction in colony formation and doses of 30nM were toxic enough to prevent the 
formation of any colonies in A375 cells (Figure 3.7). The data from Figures 3.4 and 3.6 show 
that CX5461 is cytotoxic towards A375 melanoma cells at the doses used and this 
cytotoxicity is further enhanced when combined with doses of radiation between 4-16Gy as 
well as displaying potent anti-proliferative properties. 
 
 
 
 
Control 
3nM CX 
10nM CX 
30nM CX 
Figure 3.8: A375 clonogenic assay, crystal violet staining of colonies following CX-5461 treatment and incubated for 14 
days. Each sample was plated in triplicates and each plate was repeated three times on separate occasions.  
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3.6 Combination treatment of CX-5461 and RT in LN18 glioblastoma cells 
 
Dose response curves from LN18 cells treated in combination with a range of CX-5461 doses 
in combination with X-rays are presented in Figure 3.9. Combination index values for 
synergistic/additive effects are presented in Figure 3.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Radiation Dose Gy  
 2 4 6 8 16 
400 0.84 0.94 0.69 0.70 0.57 
200 0.92 0.61 0.39 0.49 0.47 
100 0.79 0.65 0.40 0.37 0.35 
50 0.85 0.51 0.50 0.35 0.30 
25 1.18 0.58 0.46 0.31 0.18 
12.5 1.04 0.61 0.42 0.29 0.13 
6.25 0.58 0.40 0.24 0.17 0.06 
 
Figure 3.10: Loewe's combination index matrix for LN18 cells treated in combination with RT and CX-5461 
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Figure 3.9: MTS dose response curve of LN18 cells exposed to a range of CX-5461 doses in combination with single dose 
X-rays 
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LN18 cells were grown in 96 well plates at a density of 3x103 cells per well overnight. LN18 
cells were treated with a range of CX-5461 doses ranging from 0-3.25uM in combination 
with single dose X-rays between 0-16Gy, following radiation cells were incubated until 
control wells had reached 90% confluency. The MTS data showed a dose dependent 
decrease in cell survival when treated with CX5461 alone. The same effect was observed for 
LN18 cells treated with radiation alone (Figure 3.4). Combination index values suggested 
that the most synergistic combinations of treatment were in the region of low drug range 
(6.25nM-100nM) and X-ray doses between 6-16Gy (Figure 3.10). 
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Colony formation assay (CFU) results from LN18 and single dose CX-5461 exposure are 
shown in Figure 3.11. Images of colonies from the CFU experiment are shown in Figure 3.12. 
The plating efficiency of LN18 cells was found to be 15% averaged across three experiments.  
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Figure 3.11: Clonogenic assay of LN18 cells exposed to low doses of CX-5461 and incubated for 14 days before 
staining of colonies with crystal violet. Each independent experiment was performed in triplicates and repeated 
three separate times. Survival fraction was calculated as SF = # of colonies formed following treatment / # of 
cells seeded x plating efficiency for LN18 
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CX-5461 displayed strong anti-proliferative effects against LN18 cells (Figure 3.11). The 
colonies formed by LN18 cells were smaller in size in comparison to A375 or CaSki cells and 
crystal violet staining showed that doses of 3nM CX-5461 were sufficient to reduce the 
number of visible colonies formed and doses of 30nM resulted in complete loss of colony 
formation (Figure 3.12).  
 
 
 
 
 
 
Figure 3.12: LN18 cells clonogenic assay in 6-well plates showing the number of colonies stained by crystal violet 
following CX-5461 treatment. For clonogenic assays, each condition was set up in triplicates and each experiment 
was repeated three times on separate occasions using cells with different passage numbers. 
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3.7 Combination treatment of CX-5461 and RT in CaSki cervical carcinoma cells 
 
Dose response curves from CaSki cells treated in combination with CX-5461 and single dose 
X-rays are shown in Figure 3.13. Combination index values obtained from isobologram 
analysis of combination treatment in CaSki cell line are presented in Figure 3.14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Loewe’s combination index matrix for CaSki cells treated in combination with RT and CX-5461 
 
  Radiation Dose (Gy)  
 2 4 6 8 16 
1600 1.84 1.65 1.7 1.64 1.63 
800 1.24 1.29 1.25 1.2 1.27 
400 0.9 0.92 0.87 0.9 1.04 
200 0.67 0.68 0.67 0.66 0.79 
100 0.5 0.54 0.57 0.52 0.67 
50 0.38 0.39 0.44 0.45 0.62 
25 0.28 0.31 0.36 0.36 0.56 
12.5 0.21 0.21 0.25 0.34 0.51 
6.25 0.15 0.2 0.23 0.33 0.55 
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Figure 3.13: MTS dose response curve of CaSki cells exposed to a range of CX-5461 doses in combination 
with exposure to single dose X-rays 
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Of the cells lines used to study the effects of combining RT alongside the inhibition of RNA 
Pol I transcription, CaSki cells showed the greatest synergistic effects. Exposure to radiation 
alone showed a dose dependent decrease in cell viability (Figure 3.4). When treated with 
CX-5461 alone for 96hrs, MTS assay measurements reported an IC50 value of 408nM (Figure 
3.2). Combination treatments showed that low doses of CX-5461 & 4Gy X-rays was sufficient 
to reduce cell survival by 50% (Figure 3.13). CI values reported synergy in the low nanomolar 
range as well as in the lower doses of radiation used (2-6Gy). The highest level of increased 
effectiveness of combination treatments was seen using CX-5461 doses between 6.25nM – 
50nM when combined with radiation doses of 2, 4 or 6Gy (Figure 3.14).  
 
The results from clonogenic experiments involving CX-5461 and CaSki cells are shown in 
Figure 3.15. The plating efficiency of CaSki cells was found to be 11.6%, averaged across 
triplicate experiments.  
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Figure 3.15: Clonogenic assay of CaSki cells exposed to low doses of CX-5461 to assess the replicative ability 
of single cells to form individual colonies. Cells were incubated for 14 days before staining of colonies with 
crystal violet. 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clonogenic assay results showed that low doses of CX-5461 inhibited the formation of 
colonies in a dose dependant manner (Figure 3.15). Noticeable reduction in colony 
formation could be observed at doses of 10nM CX-5461 and crystal violet staining of 
colonies was significantly reduced at doses of 30nM compared to untreated controls (3.16).  
 
From combination experiments involving CX-5461 and single dose X-rays, CaSki cell line 
showed the highest levels of increased effectiveness from combining both drug and 
radiation in the low drug and low radiation dose range. This was followed by A375 where 
the most significant interaction between drug and radiation was seen in low drug and 
medium single dose X-ray range and LN18 cell line which showed that the most effective 
combinations involved low dose CX-5461 and high dose (16Gy) X-ray exposure. 
 
 
 
 
Control 
Figure 3.16: Crystal violet staining of CaSki cells grown in 6-well plates following CX-5461 
treatment 
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3.8 Ki67 expression as a marker for cellular proliferation in cells treated with CX-5461 
 
Ki67 is a cellular marker associated with proliferation. Levels of Ki67 expression in non-
treated and CX-5461 treated samples were measured using flow cytometry (488nm) over 
the course of 72hrs (for Methods see chapter 2 section 2.19). Each sample was run in 
duplicate on the day of analysis and each separate experiment was repeated three times on 
separate occasions.  Results of Ki67 expression following 24hrs CX-5461 treatment are 
shown in Figure 3.17, at 48hrs in Figure 3.18 and at 72hrs in Figure 3.19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24hr Untreated Control 500nM CX 1μM CX 
Figure 3.17: Histogram plots showing populations expressing Ki67 and side scatter plots showing changes in cell population 
following CX-5461 treatment at 24hrs 
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48hrs Ki67 expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72hrs KI67 expression: 
 
 
 
 
 
 
 
 
 
 
 
 
At each individual time point of 24hr, 48hr and 72hrs, samples treated with CX-5461 showed 
lower expression of Ki67 compared to control samples in a manner which was dose 
dependant (Figure 3.19). This effect was significantly noticeable in samples analysed at 24hr 
and 72hrs. Side scatter plots showed a decrease in populations staining positive for Ki67 
following Cx-5461 treatment as indicated by red circles. 
 
 
48hr Untreated Control 500nM CX 1μM CX 
72hr Untreated Control 500nM CX 1μM CX 
Figure 3.18: Histogram plots showing populations expressing Ki67 and side scatter plots showing changes in cell population 
following CX-5461 treatment at 48hrs 
Figure 3.19: Histogram plots showing populations expressing Ki67 and side scatter plots showing changes in cell population following 
CX-5461 treatment at 72hrs 
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Figure 3.20: Ki67 expression in control and drug treated CaSki cells as determined by flow cytometry. P value 0.0001 = 
****, 0.0002 = *** and 0.0015 = ** 
 
The results showed that the reduction in KI67 expression was statistically significant 
compared to untreated controls (p-value < 0.05 at each time point over the course of 72hrs 
in a dose dependant manner (Figure 3.20). In future experiments involving Ki67 expression 
in response to CX-5461 treatment, cell plating requires further optimisation as the low level 
of Ki67 initially detected in untreated controls could be due to the initial high density 
seeding of cells. A lower initial seeding density would allow for more cells to remain in log 
phase and show a higher level of Ki67 expression in actively cycling cells.  
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3.9 Discussion 
 
The results presented in this chapter show that CX-5461 produces potent cytotoxic effects in 
solid cancer cell lines and that this effect is enhanced in a synergistic manner when 
combined alongside radiation therapy. Of the entire cell lines used to assert the cytotoxicity 
of CX-5461, all produced an IC50 value in the nanomolar range (Table 3.1). No clear 
relationship could be established between the p53 status of individual solid cancer cell lines 
used in these experiments and their respective response to CX-5461 exposure, findings 
which are in line with the pilot study published by Drygin et al, (Figure 3.2). Drygin et al  
(2011) and Hein et al (2011) both showed that CX-5461 was most potent against wild type 
p53 cells which were derived from haematological malignancies (median IC50 = 12nM) 
compared to median IC50 values of 94nM in p53 mutated haematological malignancies, 
164nM in p53 WT and mutated solid cancers (265nM) and normal cells (5mM). 
 
It has been reported recently in the literature that CX-5461 displays synthetic lethality 
towards tumours with BRCA1/2 deficiencies (Xu et al, 2017). CX-5461 and its related 
compound CX-3543 both induced DNA damage which was dependent on BRCA1/2 mediated 
homologous recombination and DNA-PK non-homologous end joining pathway for repair. 
CX-5461 was highly toxic towards BRCA2 knockdown HCT-116 cells compared to BRCA2 wt 
isogenic cells and induced greater apoptosis in BRCA2 knockdown cells compared to WT 
cells (xu et al, 2017). These findings are in line with our data in PEO1 ovarian cancer cell lines 
where PEO1 (BRCA2 mut) cell line (Sakai et al, 2009) was highly sensitive to CX-5461 
compared to its PEO1CarbR counterpart (Figure 3.3).  
 
 Many anti-cancer drugs which aim to kill cancer cells rely on the status of the tumour 
suppressor p53 to be intact to induce p53 dependent cell death. The data presented in this 
chapter is in line with previous authors suggesting that CX-5461 cytotoxicity is independent 
of p53 status in solid cancers and thus could potentially be a useful agent to treat cancers 
which harbour p53 mutations.   
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There are numerous ways in which it is possible to measure several aspects of cell 
proliferation, mitochondrial function and cell viability. Cell proliferation assays provide 
direct and accurate measurements of the number of actively dividing cells within a 
population. Cell viability assays, in contrast to cell proliferation assays, are used to 
determine the number of ‘healthy’ cells within a population by assessing specific indicators 
of metabolically active cells such as mitochondrial function and unlike cell proliferation 
assays, cell viability assays are unable to distinguish between quiescent/senescent and 
actively cycling cells.  
 
To determine cell viability following exposure to CX-5461, the authors of the initial study 
involving CX-5461 used Alamar Blue and CyQUANT viability and proliferation assays. Alamar 
Blue (Resazurin) is a weak fluorescent dye which is irreversibly reduced to a pink coloured 
resorufin substrate which can be used as an oxidation-reduction indicator for cell viability 
assays.  This irreversible reaction from resazurin to sesorufin has been shown to be 
proportional to aerobic respiration (Gonzalez-Pinzon et al, 2012). 
 
CyQUANT cell proliferation assay is a fluorescent assay used to determine cell proliferation 
and cytotoxicity. This assays is used to measure DNA content within cells through the action 
of CyQUANT GR cyanine dye which emits a strong fluorescent signal when bound to cellular 
nucleic acids. CyQUANT assay does not measure metabolic activity compared to tetrazolium 
assays (MTT/MTS) which means samples can froze until analysis and data can be obtained at 
various time intervals following termination of experiments.  
 
The cell viability data presented in this thesis was determined using a tetrazolium based 
colorimetric assay (MTS) in contrast to Alamar blue. MTS is a short term assay which 
measures mitochondrial metabolic activity (similar to Alamar blue) through the reduction of 
tetrazolium salts by metabolically active cells, the coloured formazan product is detected 
and measured using a spectrophotometer. This is assay is suitable for short term 
experiments (< 5 days).  
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Some disadvantages of using MTS assays include the inability to distinguish between 
senescent and dividing cells since senescent cells are also metabolically active and also the 
assay is not suitable for drugs which may alter the metabolic activity of cells following 
exposure  such as (Phloretin, FX11, 2-Deoxyglucose and C75 (Jang et al, 2013). Another 
drawback to using tetrazolium salt based viability assays (XTT/MTT/MTS) is the presence of 
phenol red in cell culture medium used to dilute tetrazolium reagents, fatty acids as well as 
serum albumin which have been reported to misrepresent data obtained from MTT/MTS 
assays over extended incubation periods (Huang et al, 2004).  
 
Cell proliferation data presented in this thesis was obtained using clonogenic assays and 
ki67 expression analysis using flow cytometry in contrast to Drygin et al, who only used 
CyQUANT assay to determine the anti-proliferative effects of CX-5461. The clonogenic assay 
is the standard assay to determine the proliferative capacity of a single cell and therefore is 
a suitable end point assay to determine CX-5461’s anti-proliferative effects. Some 
drawbacks to using the clonogenic assay include the length of incubation (around 14 days) 
and potential risk of contamination as well as the fact that some cell lines do not form 
colonies. In combination with clonogenic assays, cell proliferation can also be assessed by 
measuring the expression of Ki67 levels since Ki67 is a interphase protein which is present in 
all phases of the cell cycle excluding G0 (senescence) (Bruno et al, 1992).  
 
CaSki cells, which are positive for Human Papilloma Virus (HPV 16+) carry two major 
oncogenes, E6 and E7 which bind to and target tumour suppressor’s p53 and pRb for 
ubiquitin-mediated degradation (Zur, 2000). p53 plays a fundamental role in in sensing 
genotoxic and cytotoxic stresses and under normal conditions is tightly regulated by MDM2 
and by ubiquitin mediated degradation (Micheal & Oren, 2002). In cervical cancer cells, E6 
has displaced the mdm2 protein (Hengstermann, 2002) and it has been reported that 
abolition of E6 can restore p53 function (Butz et al, 2000). 
 
Previously, docetaxel (DOC) has been shown to radio-sensitize CaSki cells to radiation 
treatment (Pradier et al, 2001). Combinations of platinum agents alongside radiation 
treatment (5Gy) have also been reported to show synergistic effects in SiHa cervical cancer 
cell lines (Koivusalo et al, 2002).   
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CaSki cells have also been shown to be resistant to treatment by cisplatin, 5-fluoruracil and 
radiation treatment (Saxena et al, 2005). Radio-sensitizing effects in CaSki cells have also 
been reported using a PI3K kinase inhibitor LY294002 by Lee  et al (2006) who reported that 
treatment alone with LY294002 did not decrease overall cell survival but pre-treatment with 
LY294002 at 6, 2 or 0.5 hours before radiation compared with post treatment produced 
more radio-sensitization (P < 0.0001).  
 
In the present study, CX-5461 combined with X-rays was shown to be synergistic in all cell 
lines used in combination studies (A375, LN18 & CaSki). Synergistic interactions were most 
evident in combinations involving CaSki cells in the low drug/low radiation range compared 
to A375 and LN18 in which combination index values reported synergy in the low drug/high 
radiation range (Figures 3.6, 3.10 and 3.14). Other studies which report synergy in CaSki 
cells involve treatment with cisplatin and E6/E7 SiRNA combinations which show that in 
vitro, long term exposure of HeLa cells to cisplatin & E6/E7 SiRNA induced cellular 
senescence and apoptosis and in vivo, E6/E7 specific SiRNA potentiated the anti-tumour 
efficacy of cisplatin via the induction of apoptosis, senescence and antiangiogenesis (Jung et 
al, 2011). 
 
The synergy observed in CaSki cells is important since the ideal clinical setting for cancer 
treatment and management is to deliver the lowest dose of radiation and/or chemotherapy 
possible to the patient to minimise any adverse side effects and maximise cytotoxicity in the 
target area. Since CX-5461 is currently in phase 1/2 clinical trials in Canada for breast cancer 
BRCA1/2 mutant cell lines (Clinical trial identification: NCT02719977), in vitro studies 
identifying synergistic combinations of treatment modalities including CX-5461 could inform 
the direction of such trials.  
 
Clonogenic assays revealed that CX-5461 possessed a potent anti-proliferative profile. Doses 
as low as 30nM were sufficient to prevent the formation of any visible colonies and doses of 
10nM were sufficient to reduce the number of observed colonies relative to untreated 
controls and A375, LN18 and CaSki cell lines (Figures 3.7, 3.11 & 3.15).  
 
 
118 
 
The anti-proliferative effects of CX-5461 have been noted by Hu et al, who showed that CX-
5461 greatly reduced the colony formation capacity of BRCA2-/- HCT116 cells (Hu et al, 
2017) and also by Ye et al who found marked inhibition of mouse aortic smooth muscle cells 
in a concentration dependent manner following CX-5461 treatment (Ye et al, 2017). The 
anti-proliferative effects of CX-5461 have also been reported to be independent of p53 WT 
or KO status in isogenic myeloma cell line models (Lee et al, 2017) as well as by Li et al who 
demonstrated in the anti-proliferative effects of CX-5461 in a range of glioma cells (Li et al, 
2018) 
 
Flow cytometry data revealed that a marker of cellular proliferation, Ki67, was significantly 
reduced in CX-5461 treated samples at time points of 24hrs, 48hrs and 72hrs relative to 
control samples (Figure 3.20). These findings are in line with those of Rebello et al (2016) 
who reported a reduction of Ki-67 expression in Hi-MYC tumours but not in PTEN-null (low 
MYC) tumours following CX-5461 treatment. The authors also showed that combinations of 
CX-5461 alongside CX-6258 (pan-PIM kinase inhibitor) also reduced Ki67 expression in Hi-
MYC mice.  
 
Importantly, a reduction at 24hrs implies that the anti-proliferative effects of CX-5461 take 
place early following exposure. Statistical analysis of Ki67 expression data suggests that 
treatments with 1μM Cx-5461 at 24hrs, 48hrs and 72hrs caused a significant change in Ki67 
expression relative to controls (P-value 0.0001). Treatment with 500nM CX-5461 was shown 
to be significant at 24hrs (p-value 0.0001) and at 48hrs (0.0002). Taken together the data 
obtained from clonogenic assays and Ki67 expression analysis suggest that CX-5461 induces 
potent anti-proliferative effects following exposure before any signs of cell death (cleaved 
effector caspases and cleaved PARP). 
 
Cell lines treated in combination with CX-5461 and radiation were probed for markers of 
apoptosis (cleaved PARP), cell cycle control (p27kip1), p53 induction and DNA damage 
(gH2AX) via western blot analysis. Marked changes were observed in the aforementioned 
markers and these data will be introduced and explored further in Chapters 4 and 5.  
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In conclusion, the data presented in this chapter shows that CX-5461 exerts potent cytotoxic 
effects as evaluated in a panel of solid cancer cell lines with IC50 values ranging from 35nM 
to > 3.2 μM. Importantly, we report novel findings to support the synergistic interaction of 
combining the inhibition of RNA Pol I transcription through the use of CX-5461 alongside X-
ray radiation in A375, LN18 and CaSki solid cancer cell lines with CaSki cervical cancer being 
the most synergistic. CX-5461 as a single agent displays potent anti-proliferative profile as 
demonstrated through colony formation assays and KI-67 profiling following CX-5461 
treatment.  
 
Cell viability following exposure to treatments involving combinations of radiation (x-rays) 
and CX-5461 was determined using MTS assay. This method of analysis of cells which have 
been exposed to radiation has some drawbacks. Firstly, since MTS assays measures the 
metabolic activity of a cell, cells which have been exposed to radiation may only cycle 
through the cell cycle and successfully divide once or a couple of times before they 
eventually die, these cells destined for death will provide a signal which could be 
misinterpreted as cells which a completely viable and not dyeing therefore could result in 
misinterpretation of cell viability data. Secondly, the MTS assay is a single time point assay 
which is performed after a defined time following irradiation therefore survival fraction data 
can only be obtained from one set of data.   
 
This could cause the loss of some information regarding growth performance resulting in 
misinterpretation of survival fractions. Clonogenic assays on the other hand are more 
suitable to assess the replicative capacity (proliferation) of a cell following exposure to 
radiation alone or in combination with drug treatment since they are long term assays (> 5 
days) and include the capacity to eliminate cells not capable of sustained proliferation as 
cells which have been exposed to lethal doses of radiation exhibit prolonged cycles which 
may only last a few cycles (Chu et al, 2002).  
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In conclusion, the data presented in this chapter met the aims originally set out at the 
beginning of Chapter 3. A broad spectrum of sensitivity was displayed through exposure to 
CX-5461 in a range of solid cancer cell lines with IC50 values ranging from 35nM in the most 
sensitive cell line (PANC-1) to >3200nM in the most resistant cell line (PEO1-CarbR). When 
CX-5461 was combined alongside single dose X-ray treatment, the highest level of increased 
effectiveness of combination treatment at inducing cell death as measured by the metabolic 
proliferation assay MTS was seen in CaSki cell line followed by A375 and LN18. The anti-
proliferative effects of CX-5461 were reported through the use of clonogenic assays and 
KI67 expression through flow cytometry.   Clonogenic assay showed that doses above 10nM 
were sufficient to prevent the formation of any visible colonies and treatment with CX-5461 
also showed a reduction in Ki67 expression relative to untreated controls highlighting the 
anti-proliferative effects of CX-5461. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Molecular mechanisms associated with CX-5461 induced 
cytotoxicity as a monotherapy and combined therapy in solid 
cancers (Part 1) 
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4. Molecular mechanisms associated with CX-5461 induced cytotoxicity in solid cancers 
 
Across all multicellular organisms exists a tightly regulated balance between the increase in 
cell mass (growth) and the removal and recycling of damaged cells. The maintenance of this 
balance is imperative for the normal development and homeostasis of the organism (Guo et 
al, 1999). Cell death is a relevant process because it plays an important role in the 
development of an organism as well as acting as a defence mechanism against diseases 
including cancer (Long et al, 2012).  
 
Previous experiments involving CX-5461 have reported the activation of apoptosis, 
autophagy and/or senescence in different cancer cell line models. For example, Bywater et 
al (2012) studied a murine model of spontaneous lymphoma driven by MYC (regulator of Pol 
I and ribosome biogenesis) and reported the rapid onset of apoptosis which was dependent 
on p53 in Eu-myc B lymphoma cells. The same group also reported the selectivity of CX-5461 
towards cancerous cells by showing that normal B cells isolated from the bone marrow of 
wild type mice treated with CX-5461 in vivo with doses sufficient to kill Eu-myc B cells did 
not result in nucleolar disruption or activation of p53 or apoptosis despite showing signs of 
reduced Pol I transcription (Bywater et al, 2012).  
 
Further work by Drygin et al (2011) reported findings which contrasted the modes of cell 
death after exposure to CX-5461 reported by Bywater et al, (2012). The authors studied the 
effects of CX-5461 in a range of solid cancer cell lines and found that p53 dependent 
apoptosis was not the main route of cell death; they further reported the induction of 
autophagy as well as cellular senescence. No changes in apoptotic markers were seen after 
exposure to CX-5461 and also the possibility of necrotic cell death was ruled out. These 
findings coupled with the detection of B-galactosidase, a widely used marker for the 
induction of senescence, showed that CX-5461 induced inhibition of rRNA synthesis in solid 
cancers leads to cellular senescence and autophagy (Drygin et al, 2011).  
 
 
 
 
 
123
Programmed cell death (PCD) can be considered as a mechanism of tumour suppression and 
is triggered in normal cells to remove unnecessary, aged or damaged cells which if not 
removed could be harmful to the living system (Fuchs et al, 2011). The three forms of 
programmed cell death include autophagy, programmed necrosis and apoptosis each of 
which can be clearly distinguished by their morphological features within a cell (Tan et al, 
2009). PCD can also be further extended to include senescence and mitotic catastrophe as 
modes of cell death in response to anticancer agents (Singh et al, 2010). The Nomenclature 
Committee on Cell Death propose four major modes of apoptosis: (i) intrinsic apoptosis by 
death receptors; (ii) extrinsic apoptosis by dependence receptors; (iii) caspase dependent 
intrinsic apoptosis; and (iv) caspase-independent intrinsic apoptosis (Galluzzi et al, 2012). 
 
Apoptosis is important in the context of cancer intervention due to the ability of malignant 
cells to evade this signal-mediated self-destructive process (Hannahan & Weinburg, 2000).  
A schematic diagram depicting the intrinsic and extrinsic pathways of apoptosis is presented 
in Figure 4.1.  Caspases are a group of endoproteases whose activation is strictly controlled 
through their production as inactive zymogens which gain their catalytic function following 
cellular signalling events, promoting their accretion into dimer or macromolecular 
complexes. The activation of caspases functions to activate or inactive substrates which 
facilitate the signalling cascade for the controlled dissemination of cellular components.  
 
Apoptotic caspases can be classified into two categories through their mechanism of action; 
Initiator caspases (caspase -8 & -9) and executioner caspases (caspase -3, -6 & -7). The 
former are involved in the activation of executioner caspases which go on to degrade key 
structural proteins and activate enzymes which results in the appearance of key apoptotic 
hallmarks such as membrane blebbing and DNA fragmentation (Mcllwain et al, 2013).  
 
 Both the intrinsic and extrinsic pathways converge through activation of common late stage 
factors such as executioner caspase 3 but can also be triggered through other mechanisms. 
The extrinsic pathway is activated upon binding of death ligands with their respective death 
receptors located within the plasma membrane such as Fas, TNF-R (tumour necrosis factor 
receptor) and TRAIL (tumour necrosis factor related apoptosis inducing ligand)].  
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These receptors then cause the activation of FADD (FAS associated death domain) or TRADD 
(tumour necrosis factor receptor type 1 associated death domain) which leads to caspase 8 
mediated activation of the end stage of the apoptotic pathway.  
 
The intrinsic pathway can be activated through various factors such as DNA damage, 
chemical agents or radiation exposure and is characteristic of mitochondrial dysfunction 
whereby cytochrome c is released from the mitochondria into the cytoplasm which then 
leads to the formation of the apoptosome which activates caspase 9 ultimately converging 
to the common activation of the executioner caspase 3.  
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Figure 4.1: Schematic representation of the intrinsic and extrinsic apoptotic pathways 
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The process of ribosome biogenesis has been outlined in Chapter 1 and includes the roles of 
specific riboproteins (RPL11, RPL5 etc) which under normal physiological conditions aid in 
the production of mature ribosomal subunits (Boisvert et al, 2007). Under conditions of 
cellular stress, such as those imposed by chemical agents, the same riboproteins are 
involved in the activation of a p53-dependent nucleolar stress response, through the 
MDM2-RPL11 pathway (Bursac et al, 2014) which facilitates the induction of apoptosis. 
 
In solid cancers, the apoptotic cell death pathway is sometimes compromised through the 
cancer cells ability to modulate the apoptotic pathways at levels of transcription, translation 
and post translational control. Cancer cells may evade apoptotic commitment through 
increasing/decreasing expression of anti or pro apoptotic genes, or they may inhibit the 
process of apoptosis through the stabilizing or destabilizing of anti or pro apoptotic 
proteins. Post translation modifications such as phosphorylation of anti or pro apoptotic 
proteins which may alter their function is also another mechanism by which cancer cells can 
evade programmed cell death (Fernald & Kurokawa, 2013).   
 
Autophagy is a highly conserved catabolic process in which cellular constituents (including 
organelles) are delivered to cytoplasmic lysosomes for degradation and the products of 
which are recycled by the cell. Currently there are three main types of autophagy reported 
in mammalian cells known as macroautophagy, microautophagy and chaperone mediated 
autophagy (Glick et al, 2010). 
 
Autophagy is important in the context of cancer due to cancer cells ability to exploit this 
mechanism to overcome the nutrient limiting conditions and to facilitate tumour growth. 
Recent studies have shown that autophagy can modulate the tumour microenvironment by 
promoting angiogenesis which can aid in the delivery of nutrients to cancerous sites (Yang et 
al, 2015). Therefore as well as acting as a cryoprotective mechanism as mentioned above, 
autophagy can also serve as an alternative cell death mechanism (Meijer & Codogo, 2004).  
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The complete process of autophagy can be divided into several distinct stages which include 
induction, vesicle nucleation, autophagosome membrane elongation, fusion and 
degradation (Figure 4.2). Induction of autophagy is controlled by the mammalian target of 
rapamycin complex 1 (mTORC1) which is able to sense and integrate stress signals from a 
variety of sources which include perturbations in growth factors, amino acids, hypoxia and 
ATP levels.  Under normal cellular conditions, active mTORC1 represses autophagy by 
prohibiting the assembly of the autophagy initiating kinase complex which is comprised of 
ULK1 (human homologue of ATG1), Atg13, FIP2000 and Atg101 (Jung et al, 2009; 
Mizushima, 2010).  
 
Stress induced inactivation of mTORC1 permits the assembly of the ULK1 complex and the 
autophagy cascade is initiated. Ensuing induction, autophagy signals are committed to the 
phagophore forming regions in phosphatidylinositol-3-phosphate (PI3P) which can be 
derived from a number of pre-existing membrane sources which include the endoplasmic 
reticulum, endosomes, golgi stacks and plasma membrane (Reggiorri et al, 2005; Hailey et 
al, 2010; Ruvikumar et al, 2010). The nucleation of phagophores is driven by the Beclin1-
associated PI3P-kinase III complex (He et al, 2010).  
 
The growth and sealing of autophagosome membranes is controlled by two ubiquitin-like 
conjugation systems LC3-phophatidylethanolamine (PE) conjugation and Atg12-Atg5 
conjugation (Yang et al, 2010). Following cleavage, LC3 is conjugated to the membrane lipid 
(PE) to form LC3-II following processing by Atg7 and Atg3. 
 
Although the majority of the machinery involved in autophagy is recycled within the cytosol, 
a small proportion of LC3-II is retained within the autophagosome membrane until fusion 
with lysosomes. Maturation of the autophagosome with the endosome-lysosome network 
facilitates the formation of an autolysosome which then breaks down autophagic cargo, 
along with the inner membrane of the autophagosome through the action of lysosomal acid 
hydrolases and proteases (Ganley, 2013; Bento et al, 2016). 
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Senescence refers to the limited replicative capacity of a cell which is no longer committed 
to the cell cycle but is still metabolically active. Two types of senescence prevent infinite 
proliferation - stress induced senescence and replicative senescence (He et al, 2017). The 
former involves several stress stimuli such as DNA damage, damage to chromatin structure 
and oxidative stress as well as oncogene activation. Replicative senescence occurs due to 
the failure of DNA polymerase to successfully duplicate the ends of chromosomes known as 
telomeres which leads to telomeric DNA sequence loss as the cell cycles through each round 
of division This ability to induce growth arrest is a distinguishing feature between healthy 
cells and tumour cells presumed to function as a barrier to prevent the accumulation of 
mutations and possibly the formation of cancer (He et al, 2017).  
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The combination index (CI) values obtained from combining CX-5461 and X-rays in CaSki 
cells suggested that low doses of CX-5461 combined with low doses of radiation were most 
synergistic (Chapter 3 Figure 3.13). To explore this synergy further, low doses of radiation 
(4Gy) were combined with low and high doses of CX-5461 (500nM and 1μM) for 48hrs, 
72hrs and 96hrs. Cell death was measured using flow cytometry using the Annexin V/PI 
assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A representative example histogram from an Annexin V/PI assay is shown in Figure 4.3. 
Viable cells (green staining) do not bind to Annexin V-FITC or to propidium iodide (PI; red 
staining)) as reflected in the lower left quadrant. Cells undergoing early stages of apoptosis 
with exposed phosphatidylserine (PS) but intact cell membranes only bind Annexin V-FITC 
and do not bind to PI and fluorescence from these cell populations is reflected in the 
bottom right quadrant. Cells that have undergone later stages of apoptosis bind to both 
Annexin V-FITC and also to PI and are reflected in the upper right quadrant. Cells only 
staining positive for PI have undergone necrosis and appear in the upper left quadrant 
(Figure 4.3).  
 
 
 
PI
 Lo
g 
Annexin V-FITC Log 
Viable Early Apoptosis 
Late Apoptosis Necrosis / End  
stage Apoptosis 
Figure 4.3: Schematic diagram illustrating the different cell populations following drug 
treatment as measured by flow cytometry using Annexin V-FITC / PI assay 
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Apoptotic cells exhibit distinct morphological features such as cell shrinkage, membrane 
blebbing and nuclear fragmentation. Early stages of apoptosis cause distinct changes to the 
cell membrane such as the externalisation of PS through the action of activated caspases on 
membrane bound scramblase. During apoptosis scramblase causes translocation of PS to 
the outer membrane surface I contrast to necrosis where PS residues remain internalised 
but the cell membrane itself ruptures.  
 
Annexin V-FITC is a naturally membrane impermeable ligand for PS and can therefore be 
easily used to identify early apoptotic cells by binding to externalised PS. A point to note is 
that following membrane rupture which is a feature common to both necrosis and late 
stage apoptosis, Annexin does have the capacity to bind to any internal PS residues. To 
circumvent this, propiduim iodide which is also membrane impermeable is used to counter 
stain DNA following membrane rupture. Therefore cells only staining positive for Annexin V-
FITC are undergoing early apoptosis and cells staining positive for both Annexin V-FITC and 
PI are undergoing necrosis or late stage apoptosis.  
 
The Annexin/PI assay was used to assess levels of apoptosis (if any) in samples which were 
treated with CX-5461 alone, radiation alone or in combination. Combination treatments 
were set up in T25 culture flasks and analysed at 48hr, 72hr and 96hr time points with CX-
5461 being added to the cells 1hr prior to radiation. Cells were seeded at densities of 5x105 
cells per flask for 48hr experiments, 4x105 cells per flask for 48hr experiments and 3x105 
cells per flask for 96hr experiments.  
 
The flow cytometry data from each time point will be presented below along with a bar 
chart summarising the surviving populations in each sample. One way ANOVA statistical 
analysis test was used to determine any statistical significance when comparing groups. 
Values < 0.05 were considered as statistically relevant to reject the null hypothesis. 
Statistically significant differences from untreated controls are marked by asterisks. 
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4.1 Study Objective 
 
The targeting of a subcellular organelle in combination with radiation & CX-5461 will 
enhance tumour cell killing effects 
 
Hypothesis 
The induction of apoptosis is enhanced in solid cancer cells following combination 
treatment an RNA polymerase I inhibitor alongside radiation therapy 
 
How does CX-5461 induce cell death in solid cancers? 
 
 
The objective of this chapter was to determine how treatment with CX-5461, alone, or 
combined with radiation can induce cell death in solid cancer cell lines  
 
In order to investigate the modes of cell death, the following experiments were conducted: 
• Western blot probes for markers of autophagy (LC3 & p62) 
• Flow cytometry using Cyto-iD Autophagy Assay to detect the presence of any 
autophagolysosome formation (end stage autophagy) 
• Confocal microscopy of samples stained for markers of autophagy (LC3) following 
CX-5461 treatment 
• Western blot probes for markers of caspase dependent apoptosis (cleaved PARP and 
caspase-3) 
• Flow cytometric analysis using Annexin V-FITC/PI assay of cells undergoing apoptosis 
following CX-5461 or combination treatment 
• Senescence associated β-galactosidase assay (SA-β-gal) to detect the presence of any 
cells entering the senescent state following CX-5461 treatment using bright field 
microscopy 
 
 
 
 
 
 
 
 
132
4.2 CX-5461 treatment of A375 cells and autophagy induction 
 
Western blot analysis was performed at several time points (24hrs & 48hrs) in A375, LN18 
and SKMEL and at 24hrs, 48hrs and 72hrs in CaSki cells for markers of autophagic flux. 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) and SQSTRM/p62 were used to 
determine the formation of autophagolysosomes and end stage autophagy. The p62 protein 
serves as a link between LC3 and ubiquitin substrates and p62-bound polyubiquitinated 
proteins become incorporated into the completed autophagosome and are degraded in 
autolysosomes and can therefore serve as readout of autophagic degradation. For all 
western blots used in the study to detect autophagy LC3 control extracts were purchased 
from Cell Signalling Technologies UK (#11972). LC3 control extracts included +ve control 
HeLa cells treated with 50μM chloroquine overnight or untreated HeLa cells as a-ve control. 
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Figure 4.4: Western blot analysis of A375 lysates treated with a low dose (100nM) and high dose (500nM) CX-5461 
for 24hrs and 48hrs and probed for markers of autophagic flux. Rabbit Anti LC3 1:1000, Rabbit Anti p62 1:1000, 
Mouse GAPDH 1:2000. LC3 II:I ratios and also p62 densitometry plots are also shown . * P-value = < 0.05, ** P-value 
= <0.01 and *** P-value = < 0.001. Doses of CX-5461 used to treat A375 reflected the IC50  (100nM) value and a lethal 
cytotoxic dose of 500nM. 
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Western blot analysis of A375 showed that following CX-5461 treatment at both 48hrs and 
72hrs, a complete conversion of LC3I to LC3II was not observed. At 24hrs a reduction of p62 
was observed in drug treated samples relative to controls and at 48hrs p62 levels could 
faintly be detected in A375 lysates (Figure 4.4). Flow cytometry analysis of A375 cells 
showed little induction of autophagy at 24hrs (as measured by the presence of 
autophagolysosomes), Rapamycin (a known inducer of autophagy) did little to induce 
autophagy at 24hrs but at 48hrs a more noticeable effect of both rapamycin and CX-5461 
was observed (Figure 4.5).  
 
Both doses of CX-5461 (100nM & 500nM) induced greater formations of 
autophagolysosomes compared to the positive control and untreated control, a threefold 
increase in autophagolysosomes in samples treated with 500nM CX-5461 was reported 
(Figure 4.5). At 72hrs, CX-5461 treatment showed a three-fold (100nM) and six-fold (500nM) 
increase in autophagolyosomes compared to untreated control and rapamycin treated 
positive controls.  
 
 
 
 
Figure 4.5: Cyto-iD autophagy assay detecting presence of autophagolysosomes following CX-5461 treatment 
over 72hrs.. Where * are not shown p-value >0.05 therefore not significant, **  p-value < 0.01 and **** p-value = 
< 0.0001 
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4.3 Treatment of LN18 cells with CX-5461 and autophagy induction 
 
LN18 cells were seeded in 6-well plates at a density of 1x105 cells per well and drug treated 
for 24hr and 48hrs. Following treatment cells were harvested using traditional methods and 
lysates were prepared using RIPA buffer and Halt protease inhibitors followed by sonication 
and total protein content was measured using BCA assay. Following electrophoresis and 
transfer, membranes were probed for rabbit anti-LC3 (1:1000), rabbit anti-p62 (1:1000) and 
mouse anti-GAPDH (1:2000). Goat anti-rabbit HRP and goat anti-mouse-HRP conjugated 
secondary antibodies were used at a dilution of 1:2000. 
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Figure 4.6: Western blot analysis of LN18 lysates treated with a low dose (500nM) and high dose (1uM) CX-5461 and 
probed for markers of autophagic flux. Rabbit Anti LC3 1:1000, Rabbit Anti p62 1:1000, Mouse GAPDH 1:2000. LC3 II:I ratios 
and also p62 densitometry plots are also shown. Where * are not shown p-value >0.05 therefore not significant. * P-value = 
<0.05 and *** P-value = <0.001. 
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Western blot analysis of LN18 glioblastoma cells showed that at both 24hrs and 48hrs Cx-
5461 treatment, a lack of complete conversion of LC3I to LC3II was observed, this was 
accompanied by incomplete downregulation of p62 (Figure 4.6) which can be seen to be 
upregulated  at 24hrs in LN18 cells treated with 1uM CX-5461 relative to untreated control. 
This data is in agreement with data obtained by flow cytometry analysis of 
autophagolyosomes in rapamycin and drug treated samples were no significant fold 
increase could be observed at both 24hrs and 48hrs treatment relative to untreated 
controls.  At 72hrs however, Cyto-iD autophagy assay reported a 2.5 and 3 fold increase in 
samples treated with 500nM and 1μM Cx-5461 compared to rapamycin and untreated 
controls (Figure 4.7).  Since p62 can bind to LC3 and serve as a selective substrate for 
autophagy, accumulation of p62 can serve as an indicator of autophagy suppression 
(Komatsu et al, 2007). The data for LN18 cells suggests a lack of complete autophagy 
turnover at 24hrs and 48hrs following CX-5461 treatment as differences in the ratios of LC3 
II:I were found to not be significant p-value > 0.05. 
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Figure 4.7: Cyto-iD autophagy assay displaying the presence of autophagolysosomes following CX-5461 
treatment. Where * are not shown p-value >0.05 therefore not significant. *** p-value = < 0.001 and **** p-
value = < 0.0001 
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4.4 Treatment of SKMEL-28 cells with CX-5461 & autophagy induction 
 
SKMEL-28 cells were seeded in 6-well plates and processed for western blot analysis as 
mentioned in section 4.3 LC3 and p62 expression in SKMEL-28 cells exposed to 1μM and 
2μM CX-5461 is presented in Figure 4.8 alongside LC3 II:I ratios and p62 expression levels 
relative to untreated control samples. An overload of protein content in individual lanes on 
the western membrane blot is visible in Figure 4.8a, this was overcome by reducing the 
amount of protein content loaded into each well when separating proteins using 
electrophoresis and also by reducing the exposure time of the western membrane to the 
chemiluminescent substrate used to image western blot membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
+v
e 
-v
e 
24
hr
 U
TD
 C
TL
 
1u
M
 C
X-
54
61
 
2u
M
 C
X-
54
61
 
48
hr
 U
TD
 C
TL
 
1u
M
 C
X-
54
61
 
2u
M
 C
X-
54
61
 
LC3 
p62 
GAPDH 
SKMEL-28 
 
S K
M
E L
-2
8  
4 8
h  
C T
L  
S K
M
E L
-2
8  
4 8
h  
1 u
M
 
S K
M
E L
-2
8  
4 8
h  
5 u
M
 
0
1
2
3
4
S K M E L -2 8  4 8 h r  L C 3  D e n s ito m e tr y
L
C
3
 I
I:
 I
 R
a
ti
o
S K
M
E L
-2
8  
4 8
h r
 C
T L
S K
M
E L
-2
8  
4 8
h r
 1
u M
S K
M
E L
-2
8  
4 8
h r
 2
u M
0 .0
0 .5
1 .0
1 .5
S K M E L -2 8  4 8 h r  p 6 2  E x p re s s io n
F
o
ld
 C
h
a
n
g
e
Figure 4.8: A - Western blot analysis of SKMEL-28 lysates treated with a low dose (1uM) and high dose (2uM) CX-
5461 and probed for markers of autophagic flux. B – Densitometry analysis of SKMEL 48hr westerns showing LC3 
II:I ratios and p62 expression relative to untreated control. Where * are not shown p-value >0.05 therefore not 
significant. * p-value = < 0.05, ** p-value < 0.01, *** p-value = < 0.001 and **** p-value = < 0.0001. 
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4.5 SKMEL-28 Cyto-iD Autophagy Detection 
Following treatment with CX-5461 over 72hrs, SKMEL-28 cells were analysed using flow 
cytometry to monitor autophagic activity at the cellular level. Results are presented as 
histogram overlay. The colours in Figure 4.9 are representative of untreated control (black), 
rapamycin positive control (red), 1μM CX-5461 (blue) and 2μM CX-5461 (pink).   
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Figure 4.9: (Above) Histogram overlays of SKMEL-28 cells treated with 10uM rapamycin, 1uM CX-5461 and 
2uM CX-5461. (Below) Cyto-iD autophagy assay displaying the accumulation of autophagolyosomes 
following rapamycin and CX5461 treatment. Where * are not shown p-value >0.05 therefore not significant. 
* p-value = < 0.05, *** p-value = < 0.001 and **** p-value = < 0.0001 
 
SKMEL-28 24hrs SKMEL-28 48hrs SKMEL-28 72hrs 
Shift to the 
right 
indicates 
autophagy 
increase 
* * 
*** 
***
* 
Fluorescence Intensity Fluorescence Intensity Fluorescence Intensity 
 
 
138
Western blot analysis for markers of autophagy in SKMEL-28 cells showed that at 24hrs CX-
5461 treatment, an incomplete conversion from LC3I to LC3II was observed alongside a lack 
of p62 degradation (Figure 4.8). At 48hrs CX-5461 treatment however, a complete 
conversion of LC3I to its conjugated form LC3II was observed (p-value < 0.05) alongside a 
reduction in p62 levels (p-value < 0.001). Treatment with CX-5461 at 48hrs showed an 
increase in LC3 II:I ratios (Figure 4.8) as well as degradation of p62 as shown by a reduction 
in p62 protein levels (Figure 4.8) which support the process of autophagic flux.  The Western 
blot data are in agreement with the Cyto-iD autophagy assay as measured by flow 
cytometry where at 24hrs treatment, no significant changes could be seen in either samples 
treated with rapamycin or CX-5461 treatment with respect to end stage autophagolysosome 
formation (p-value > 0.05).  At 48hrs, a 2.5 fold increase was observed in rapamycin treated 
samples, as indicated by the red curve in Figure 4.9, as well as a fourfold increase in CX-5461 
treated samples (blue and pink curves), this data is in agreement with LC3/p62 western 
blots at the same time point (Figure 4.8). This effect was more pronounced at 72hrs where 
rapamycin had a clear effect on SKMEL-28 cells and CX-5461’s effect was greater (p-value < 
0.001) compared to rapamycin control (p-value <0.05) and untreated control (Figure 4.9).  
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4.6 Treatment of CaSki cells with CX-5461 & autophagy induction 
 
CaSki cells were seeded in 6-well plates and processed for western blot analysis as 
previously mentioned in section 4.3. LC3 and p62 expression in CaSki cells exposed to a sub 
lethal dose of 1μM and lethal dose of 5μM CX-5461 are presented in Figure 4.10b alongside 
LC3 II:I ratios and p62 expression levels over 72hrs shown in Figure 4.10c.  A flow diagram 
describing the process of setting up CaSki cells for western blot analysis is shown in Figure 
4.10a. 
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Figure 4.10a – Flow diagram of CaSki cells prepared for western blot probing of autophagy markers. b) Western blot 
analysis of CaSki lysates treated with a low dose (1uM) and high dose (5uM) CX-5461 and probed for markers of 
autophagic flux over 72hrs 
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Figure 4.10c – LC3 II:I ratios and p62 expression levels relative to untreated controls. Where * is not shown p-value 
>0.05 therefore not significant.  ** p-value = < 0.01, **** p-value = < 0.0001 
** ** ***
**** 
 
 
141
4.7 Cyto-iD Autophagy Detection in CaSki cell line 
Following treatment with CX-5461 over 72hrs, CaSki cells were analysed using flow 
cytometry to monitor autophagic activity at the cellular level. Results are presented as 
histogram overlay. The colours in Figure 4.11a are representative of untreated control 
(black), rapamycin positive control (red), 1μM CX-5461 (blue) and 5μM CX-5461 (pink).   
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Figure 4.11: A - Flow cytometry-based profiling of Cyto-iD Autophagy Detection in CaSki cells. CaSki cells were untreated, 
or treated with 10uM Rapamycin, 1uM Cx-5461 or 5uM CX-5461 for 24hr, 48hr or 72hrs. B - – Cyto-iD autophagy assay 
displaying the presence of autophagolysosomes following CX-5461 treatment. Where * are not shown p-value >0.05 
therefore not significant.  ** p-value = < 0.01. 
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C 
Figure 4.12: Confocal microscopy of CaSki cells treated with 1uM CX5461 for 48 hours and stained for rabbit 
anti-LC3 (Green), DNA counter stain DAPI (Blue). All images taken at 40x objective. A - Untreated control, B - 
10uM Rapamycin, C - 1uM CX-5461 
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Western blot analysis for markers of autophagy induction in CaSki cells showed that of the 
four cell lines investigated for the induction of autophagy, CaSki cell line was the most 
proficient. With respect to complete autophagy flux, a complete conversion of LC3I to LC3II 
as well as a reduction in p62 levels at 24hrs, 48hrs and 72hrs (Figure 4.10). Densitometry 
analysis of LC3 bands showed an increase in LC3 II:I ratios over 72hrs (p-value < 0.0001) 
(Figure 4.10) as well as a reduction in p62 levels normalised to untreated controls (p-value < 
0.001) (Figure 4.10).  The Western blot data showing the induction of autophagy is in 
agreement with flow cytometry data which shows the accumulation of autophagolyosomes 
induced by both rapamycin as well as by CX-5461 as early as 24hrs post treatment through 
to 48hrs (Figure 4.11). At 72hrs, rapamycin did not seem to have much of an effect at 
inducing end stage autophagy but CX-5461 still had an effect at this time point (4.11). 
Confocal microscopy showed diffuse cytoplasmic distribution of LC3I in untreated control 
samples (figure 4.12a) and the presence of distinct LC3II puncta in positive control samples 
treated with rapamycin (Figure 4.12b) and CX-5461 treated samples (Figure 4.12c) at 48hrs 
post drug treatment. Taken together, the Western blot data accompanied with the flow 
cytometry analysis of autolysosome accumulation in combination with confocal microscopy 
support the claim that CaSki cells undergo complete autophagic flux in response to CX-5461 
treatment.  
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4.8 CX-5461 single agent treatment and the induction of apoptosis 
The induction of apoptosis in solid cancer cell lines treated with CX-5461 was measured 
using Annexin V-FITC/PI assay at either 48hrs or 72hrs post CX-5461 treatment as well as 
using Western blot probes for markers of caspase dependent apoptosis (PARP cleavage). 
Cleaved caspase 3 was also attempted but no visible bands could be detected in blots (data 
not shown). Annexin Assays were performed in A375, LN18 and CaSki cells following CX-
5461 treatment. Z-VAD-FMK, a known pan-caspase inhibitor was also used in conjunction 
with CX-5461 to see if the presence of Z-VAD-FMK prevented caspase dependant cell death 
as measured by flow cytometry.  
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4.9 LN18 & CX-5461 treatment alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LN18 cells treated with a low and high dose of CX-5461 caused an increase in positive 
Annexin V-FITC/PI staining (Figure 4.13). Although some little background apoptosis was 
observed in the untreated control sample, the populations of cells in late stage apoptosis 
increased from 3.4% in untreated controls to 25.5% in LN18 cells treated with 300nM CX-
5461. Western blot analysis showed no cleavage of PARP at either 48hr or 72hrs as shown in 
Figure 4.13b, this indicates that cell death via apoptosis may be occurring in a caspase 
independent manner.  
 
A) LN18 
72hr CTL 150nM CX 300nM CX 
Figure 4.13: A- Annexin V-FITC assay of LN18 cells treated with low and high doses of CX-5461 for 72hrs B – Western blot 
probes for whole and cleaved PARP, p53 and GAPDH loading control using lysates prepared at 48hrs and 72hrs following 
CX-5461 treatment. 
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4.10 A375 & CX-5461 treatment alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A375 cells treated with CX-5461 over 72hrs showed a change in Annexin V-FITC/PI staining 
but this effect was not as pronounced as observed for LN18 cells over the same time period. 
The percentage of cells undergoing end stage apoptosis increased from 0.5% in untreated 
controls to 9.9% in samples treated with 200nM CX5461 (Figure 4.14). This implies that 
there was a reduction in healthy viable cell population not undergoing apoptotic cell death 
from 98.7% in untreated control to 74.3% in A375 cells treated with 200nM CX-5461.  At 
48hrs following CX-5461 treatment, feint cleavage of PARP could be detected in lysates 
prepared with 100nM CX-5461 and slightly stronger cleaved PARP could be detected in 
lysates treated with 500nM CX-5461 (Figure 4.14).  
a) A375 72hr CTL 100nM CX 200nM CX 
Figure 4.14: A - Annexin V-FITC assay of A375 cells treated with low and high doses of CX-5461 for 72hrs B - B – Western 
blot probes for whole and cleaved PARP, p53 and GAPDH loading control using lysates prepared at 48hrs and 72hrs 
following CX-5461 treatment. 
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4.11 CaSki & CX-5461 treatment alone 
CaSki cells treated with a low, medium and high dose of CX-5461 showed a significant 
increase in Annexin V-FITC/PI staining in a dose dependant manner (Figure 4.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48hr CTL 500nM 
1μM 5μM 
Figure 4.15: Annexin V-FITC/PI assay of CaSki cells treated with a range of CX-5461 doses for 48hrs B- B – Western 
blot probes for whole and cleaved PARP, p53 and GAPDH loading control using lysates prepared at 48hrs and 72hrs 
following CX-5461 treatment. 
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Cell populations undergoing late stage apoptosis increased from 0% in untreated control to 
42.2% in 500nM CX-5461 treated samples, 67.7% in samples treated with 1μM CX-5461 and 
to 89.8% in samples treated with a high dose of 5μM CX-5461 after 48hrs (Figure 4.15).  At 
48hrs treatment with CX-5461 did not induce strong bands representative of PARP cleavage 
although very feint bands can be seen, at 72hrs however cleaved PARP bands can more 
clearly be seen in drug treated lysates (Figure 4.15).  
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4.12 Z-VAD-FMK & CX-5461 treatment 
Benzyloxycarbonyl-phenylalanyl-alanyl-fluoromethyl ketone (Z-VAD-FMK) is a known potent 
inhibitor of cysteine proteases and also selectively irreversibly binds to the catalytic site of 
caspase proteases and can inhibit the induction of caspase-dependant apoptosis. A 
tolerable dose of 50μM Z-VAD-FMK was obtained from performing a dose response MTS 
assay to determine any Z-VAD-FMK associated toxicity before being used in conjunction 
with CX-5461 (Figure 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A375 72hr Z-VAD-FMK 
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Figure 4.16: A - Dose response assay of A375 cells treated with increasing concentrations of Z-VAD-FMK caspase 
inhibitor to assess non-toxic doses. B - Annexin V-FITC/PI assay of A375 cells treated with CX-5461 for 72hrs with 
or without Z-VAD-FMK 
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Treatment with CX-5461 in A375 cells for 72hrs induced a marked apoptotic response as 
determined by high Annexin and PI staining (Figure 4.16). % survival in the absence of Z-
VAD-FMK was reported as 99.5% untreated control, 1μM CX-5461 56.2% and 2μM CX-5461 
20%. In the presence of 50μM Z-VAD-FMK, the % or surviving cells increased in drug treated 
samples, from 56.2% -ZVAD to 61.9% +ZVAD in samples treated with 1μM CX-5461 and from 
20% (-ZVAD) to 55.1% (+ZVAD) in samples treated with 3μM CX-5461 (Figure 4.16).  
Further optimisation of the MTS experiment involving Z-VAD and CX-5461 would require 
MTS assays to be performed using a fixed concentration of Z-VAD-FMK alongside varying 
concentrations of CX-5461. Growth curve optimisation would ensure that cells are being 
measured for viability when they are in the most active part of the growth phase. Using 
Annexin/PI assay as an end point assay would provide more reliable results regarding the 
viability of cells following treatment since the MTS assay only measures metabolic activity 
and therefore cannot provide a completely accurate readout of cell viability since some 
viable cells within the screened population may viable but not displaying high rates of 
metabolism. The MTS assay could also be accompanied alongside the lactate 
dehydrogenase assay (LDH) since the soluble cytosolic LDH enzyme is released into surround 
cell culture medium upon cell damage or cell lysis following apoptotic or necrotic cell death.  
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4.13 CX-5461 treatment and the induction of cellular senescence in A375 cells 
 
Cellular senescence is a state where normal cells lose their capacity to proliferate when 
challenged by a variety of cellular stresses.  Β-galactosidase can be used as a marker to 
detect any cells which have entered into a senescent state. Β-galactosidase has been found 
to be highly expressed in cells undergoing senescence compared to cells cycling through the 
cell cycle (Debacq-Chainiaux 2009). Senescent cells were detected using Senescence 
Associated β-galactosidase Assay (SA-β-Gal) (for methods see Chapter 2 section 2.18). 
Following 48hrs treatment with 1μM CX-5461, cells were incubated overnight with SA-β-GAL 
detection solution and imaged using bright field microscopy the next day. Cells which have 
entered into the senescent stage of the cell cycle and have stained positive for SA-β-Gal are 
marked by red arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17a: A375 cells (untreated control above, CX-5461 1uM treated below) stained for the presence of B-galactosidase 
following 48hr CX-461 treatment. Cells which have entered into the senescent state are marked by red arrows. Image taken 
with 20x objective. 
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In an attempt to quantify the amount of cells staining positive for SA-β-Gal in Figure 4.17, 
100 cells were scored by eye in three untreated control images and three drug treated 
images. The values obtained were then plotted as fold increases compared to untreated 
controls and shown in Figure 4.18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells staining positive for SA-B-Gal following CX-5461 treatment were scored by hand using 
a bright field microscope. To improve the accuracy of quantifying cells undergoing 
senescence using the SA-B-Gal staining kit, imaging software analysis tools such as ‘region of 
interest’ would provide a more robust and repeatable quantification of cells staining 
positive for SA-B-Gal activity.  
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Figure 4.18: The fold increase in cells staining positive for SA-B-Gal following CX-5461 treatment for 
48hrs. Unpaired t-test p-value of **** < 0.0001. 
**** 
Figure 4.17b: Enlarged images of A375 cells untreated (left) and CX-5461 treated 
for 48hrs showing SA-B-Gal positive stained cells (blue). 
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4.14 Apoptotic response of cancer cells following combination treatment using CX-5461 & 
X-rays - CaSki 48hr CX-5461 and X-rays combination treatment 
 
CaSki cells were exposed to low and high doses of CX-5461 in combination with 4Gy and 8Gy 
single dose X-ray exposure. CX-5461 was administered on the same day as radiation 
exposure (1hr before) and cells were incubated for 48hr, 72hr and 96hrs. Cell death 
following combination treatment was analysed using Annexin/PI assay using flow 
cytometry. A flow diagram illustrating the process of setting up the combination treatment 
is shown in figure 4.19 and the data from the 48hr combination treatment is presented in 
figure 4.20. 
 
 
Figure 4.19: Schematic flow diagram showing the preparation of samples for combination treatment involving CX-5461 and 
X-rays to determine the mode of cell death 
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Figure 4.20: Low dose combination treatment of CaSki cells treated with either drug alone or in combination 
with 4Gy and 8Gy X-rays 
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Annexin V assay at 48hrs showed that CX-5461 treatment alone caused a shift in cell 
populations to stain positive for Annexin V-FITC as well as PI indicating that late stage 
apoptosis is occurring in these cell populations at 48hrs (Figure 4.20). Combining CX-5461 
alongside radiation was more cytotoxic than CX-5461 or radiation individually (Figure 4.20 & 
4.21). Treatment with X-rays alone at low doses of 4Gy did show a modest reduction in cell 
survival (cell survival reduced to 71.2%) this effect was more pronounced using 8Gy where 
cell survival decreased to 49.9%.  
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Figure 4.21: % of surviving populations following 48hr combination treatment in CaSki cells. ** p-
value < 0.01, *** p-value < 0.001, *** p-value < 0.0001 
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4.15 CaSki 72hr CX-5461 and X-rays combination treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
72hr Control 500nM 1μM 
4Gy 4Gy & 500nM 4Gy & 1μM 
8Gy 8Gy & 500nM 8Gy & 1μM 
97% 69.3% 55.9% 
86.4% 55.1% 39.4% 
62.8% 43.4% 21.9% 
Figure 4.22: 72hr Low dose combination treatment of CaSki cells treated with either drug alone or in combination with 4Gy and 
8Gy X-rays 
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Combination treatments analysed at 72hrs showed that treatment with CX-5461 alone did 
cause a slight change in cell populations staining positive for Annexin/PI (Figure 4.22) but 
this effect was not as pronounced compared to CX-5461 alone treatment at 48hrs. Radiation 
alone treatment also showed a reduction in cell survival following 4Gy exposure (86.4%) and 
8Gy exposure (62.8%) relative to untreated controls (97%). Combining CX-5461 with 4Gy 
radiation was more effective at inducing late stage apoptosis compared to drug treatment 
alone (CX-5461 500nM alone surviving population 69.3%, CX-5461 500nM & 4Gy X-rays 
surviving population 55.1%) (Figures 4.22 & 4.23). An increase in Annexin/PI positive 
staining was further enhanced when 4Gy radiation was combined with 1μM CX-5461 and 
8Gy radiation with both 500nM and 1μM CX-5461 doses (Figure 4.22 and 4.23).  
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Figure 4.23: % of surviving cell populations following 72hr low dose combination treatment. ** 
p-value < 0.01, *** p-value < 0.001, *** p-value < 0.0001 
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4.16 CaSki 96hr CX-5461 and X-rays combination treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72hr Control 500nM 1μM 
4Gy 4Gy & 500nM 4Gy & 1μM 
8Gy 8Gy & 500nM 8Gy & 1μM 
Figure 4.24: 96hr Annexin/PI plots for CaSki cells treated in combination with CX-5461 and 4Gy and 8Gy X-rays 
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Combination treatments analysed at 96hrs showed that treatment with CX-5461 alone 
caused significant changes in cell populations staining positive for Annexin/PI (Figure 4.24). 
Cell survival was measured at 57% of the CX-5461 alone treated population for 500nM CX-
5461 and 30.4% for 1μM CX-5461 doses at 96hrs, results which are in line with the dose 
response data at the same time point using MTS assay (Chapter 3 Figure 3.2). Exposure to 
radiation alone reduced cell survival in a dose dependent manner (Untreated viable 
population 98.3%, 4Gy X-rays viable population 88.4%, 8Gy X-rays viable population 61.8%). 
Cell death via end stage apoptosis was more pronounced when CX-5461 was combined with 
X-rays and doses of 4Gy and 8Gy compared to either CX-5461 or X-rays treatment alone. 
Drug treatment with 500nM Cx-5461 reduced survival to 57% at 96hrs, combined with 4Gy 
X-rays survival was reduced to 32% and when the same CX-5461 dose was combined with 
8Gy X-rays survival was further reduced to 18.3% (Figure 4.25). This highlights there may be 
enhanced interactions between CX-5461 and X-rays at inducing cell death in CaSki cell line. 
 
Figure 4.25: % of viable cell populations following 96hr combination treatments in CaSki cells. ** p-
value < 0.01, *** p-value < 0.001, *** p-value < 0.0001 
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4.17 Scheduled treatment of CX-5461 in combination with X-rays in CaSki cell line 
 
Previous experiments involving combination treatments involved treating cells with CX-5461 
on the same day as irradiation. To see if scheduled administration of CX-5461 showed any 
increased cytotoxic effects AnnexinV/PI assay was used to measure cell death via apoptosis 
in samples treated either 24 hours before radiation, on the same day as radiation or 24 
hours post radiation. A schematic diagram showing the process of sample preparation for 
scheduled dosing of CX-5461 in combination with X-rays is shown in figure 4.26 
 
 
Figure 4.26: Schematic flow diagram of the steps involved in scheduled dosing of CX-5461 in combination with X-ray 
treatment. End point cell death assay used was Annexin/PI via flow cytometry 
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Pre 24hr treatment with CX-5461 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CaSki cells received a single dose of 4Gy X-rays for 72hrs alone or in combination with either 
500nM or 1uM CX-5461 which was added to the flasks 24hrs pre-radiation treatment. CX 
treatment alone did affect the membrane integrity of cells as shown by annexin and PI 
positive staining in Figure 4.27 compared to the untreated control, this effect was 
significantly more pronounced when combined with radiation which increased the 
annexin/PI positive cell population from 14.4% to 37.5% (Figure 4.27). These data suggest 
that pre-treatment of CaSki cells with CX-5461, following low dose X-ray radiation could 
radio-sensitise the cells when combined with X-ray treatment.  
 
 
 
 
 
 
 
 
 
 
 
Control 500nM 1uM 
4Gy 4Gy & 500nM 4Gy & 1uM 
Figure 4.27: 72hr Annexin V assay of CaSki cells pre-treated with CX-5461 for 24hrs hours followed by 4Gy X-ray 
irradiation 
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Same day CX-5461 Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CaSki cells were simultaneously treated with CX-5461 & X-rays. CaSki cells were drug treated 
1 hour before exposure to 4Gy X-rays. Annexin data reports at 72hrs show that treatment 
with CX-5461 alone at doses of 500nM and 1uM modestly decreased the non-apoptotic 
population to 93.2% & 90.9% respectively. CX-5461 combined with 4Gy radiation 
significantly decreased the population of non-apoptotic cells with externalized PS to 68.5% 
and 63.1% showing that CX-5461’s cytotoxic effects are enhanced when combined with 4Gy 
radiation treatment (Figure 4.28).  
 
 
 
 
 
 
 
 
 
 
Control 500nM 1uM 
4Gy 4Gy & 500nM 4Gy & 1uM 
Figure 4.28: 72hr Annexin V assay of CaSki cells treated simultaneously with CX-5461 & 4Gy X-rays 
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Post 24hr treatment with CX-5461 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CaSki cells received a single dose of 4Gy x-rays for 72hrs alone or in combination with either 
500nM or 1uM CX-5461 which was added to the flasks 24hrs post-radiation treatment. No 
significant effects could be noticed with Post 24hr treatment of CX-5461 alone or in 
combination with x-rays (Figure 4.29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 500nM 1uM 
4Gy 4Gy & 500nM 4Gy & 1uM 
Figure 4.29: 72hr Annexin V assay of CaSki cells treated with CX-5461 24hrs after receiving 4Gy X-ray irradiation 
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Pre-24hr treatment with CX-5461 followed by radiation treatment was found to be most 
significant compared to treatment with CX-5461 on the same day as radiation or 24hrs post 
radiation (p-value = < 0.0001). Combinations treatments involving 500nM CX-5461 and 4Gy 
radiation were most significant when CX-5461 was administered 24hrs prior to cells 
receiving radiation (p-value < 0.0001).  
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Figure 4.30: % surviving populations following scheduled treatment of CX-5461. All conditions received 
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4.18 Discussion 
 
The data from our experiments show that complete autophagic flux is observed in the CaSki 
cell line over the course of 24hrs 48hrs and 72hrs as measured by a complete conversion of 
LC3I to LC3II and reduction in p62 levels in samples treated with CX-5461 alone (p-value < 
0.0001) (Figure 4.10a). The conversion of nonlipidated LC3I to its lipidated form, LC3-II, 
represents LC3-1 conjugation with phosphatidylethanolamine (PE) and the amount of LC3-II 
is closely correlated with the number of autophagosomes, which can serve as an indicator of 
autophagosome formation (Kabeya et al, 2000). LC3-II is itself also degraded by the process 
of autophagy, therefore LC3-II turnover alone cannot serve as a solid indicator of autophagic 
flux. p62 (SQSTM1/sequestosome 1) can bind to LC3 and acts as a selective substrate for 
autophagy.  
 
p62 and p62 bound proteins are incorporated into autophagosomes and are also degraded 
when fused with autolysosomes, which together with LC3-II turnover can serve as a reliable 
readout for autophagic flux since inhibition of autophagy is correlated with increased levels 
of p62 (Bitto et al, 2014). 
 
The conversion of LC3 to LC3II is further confirmed through increased ratios of LC3 II:I 
conversion and confocal microscopy at 48hrs where LC3II puncta are clearly visible following 
CX-5461 treatment as measured against rapamycin treated controls in CaSki cells (Figure 
4.10c). Autophagic flux, which is defined as a measure of autophagic degradation could also 
be observed in SKMEL-28 cells over 48hrs (p-value < 0.01) (Figure 4.8) although a lack of 
autophagic flux proficiency was observed in A375 and LN18 cell lines through western blot 
analysis (Figure 4.4 and Figure 4.6) through a lack of complete conversion from LC3-I to LC3-
II alongside increased p62 levels in CX-5461 treated samples.  
 
The fusion of autophagosome with lysosomes marks the end stage of the autophagy 
process, where internal cargo is degraded by lysosomes (Yang and Klionsky, 2009 & Glick et 
al, 2010), and the presence of such autophagolysosome was confirmed using flow 
cytometry in CaSki, SKMEL, A375 and LN18 cells at over the course of 72hrs following CX-
5461 treatment (Figures 4.5, 4.7, 4.9 & 4.11).  
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The effect of CX-5461 can be seen to be more effective than the positive control rapamycin 
treated samples (p-value - < 0.0001), a known inducer of autophagy. Taken together, with 
respect to the induction of autophagy following CX-5461 treatment, our data are in 
agreement with other authors who also report the induction of autophagy in solid cancer 
cell lines following exposure to CX-5461 (Drygin et al, 2011, Li et al, 2016, Li et al, 2018).  
 
Several authors have also reported findings which state that treatment with CX-5461 causes 
cancer cell lines derived from solid tumours to enter in a senescent state (Drygin et al, 2011; 
Quin et al, 2016 & Cornelison et al, 2017). SA-β-GAL (senescence associated β-galactosidase) 
is a hydrolase enzyme which catalyses hydrolysis of β-galactosides at a pH of 6.0 and this 
process strictly takes place within senescent cells and is distinct from acidic β-galactosidase 
activity which takes place at a pH of 4.0 in all cells (Debacq-Chainiaux F et al, 2009).  
 
 In A375 cells treated for 48 hours with CX-5461 and stained for SA-β-gal overnight, we 
could also detect a significant increase (p-value < 0.0001) in SA-β-GAL +ve senescent cells in 
populations of 1uM CX-5461 treated A375 cells compared to untreated controls (Figure 4.17 
and 4.18).  
 
To assess the mode of cell death following CX-5461 only treatment, LN18 and A375 cells 
were drug treated for 72hrs followed by measurement of apoptosis induction using Annexin 
V-FITC/PI assay. Both cell lines (A375 and LN18) showed an increase in cell populations 
staining positive for Annexin V-FITC as well as PI following CX-5461 treatment (Figures 4.13 
& 4.14). Positive Annexin V-FITC staining represents exposure of phosphatidylserine (PS) on 
the outer membrane of cells and positive PI staining represents the ability of PI to 
transverse the compromised cell membrane and bind to nuclear DNA, together, positive 
Annexin V-FITC and PI staining represent cells undergoing end stage apoptosis (Figure 4.3).  
 
A375 and LN18 cells showed a reduction in viable cell populations following CX-5461 
treatment (A375 98.7% untreated to 74.3% 200nM CX5461 / LN18 89.5% untreated to 
60.1% 300nM CX-5461) (Figure 4.13 and 4.14) over 72hrs.   
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Treatment of A375 cells in the presence of a pan caspase inhibitor (Z-VAD-FMK) reduced the 
cytotoxic effects of CX-5461 as measured by Annexin/PI assay indicating that in A375 cells 
the induction of end stage apoptosis may be through caspase-dependent mechanisms 
(Figure 4.16).  
 
Induction of apoptosis was also observed in CaSki cells following 48hr CX-5461 alone 
treatment. End stage apoptosis (positive Annexin and PI staining) was observed in a dose 
dependent manner in CX-5461 treated samples (Figure 4.15). However no cleavage of PARP 
could be detected at 48hrs in CaSki lysates treated with 500nM or 1μM CX-5461 although 
feint cleaved PARP bands could be seen at 72hrs (Figure 4.15). 
 
Previous studies involving CX-5461 have reported that treatment with CX-5461 induces p53 
dependant apoptosis in haematological malignancies only (Bywater et al, 2011). In solid 
cancers cell death has primarily been reported to be via autophagy and senescence in A375 
and MIA PaCa-2 cells by Drygin et al and also in osteosarcoma cells by Li et al (Drying et al, 
2011, Li et al, 2016).  
 
The results obtained involving CX-5461 and the induction of apoptosis are in agreement 
with the more recent reports in the literature which have also shown that apoptosis can be 
induced in HCT116 cells colorectal carcinoma cells (Xu et al, 2017) as well as in a range of 
glioma cells (Li et al, 2018) following CX-5461 treatment.  
 
Combination treatments involving CX-5461 and X-rays were analysed at 24hrs, 48hrs and 
72hrs in CaSki cells. Cells were treated with 500nM and 1μM Cx-5461 doses alone or in 
combination with 4Gy and 8Gy X-rays. 
 
At 48hrs, treatment with CX-5461 did induce late stage apoptosis as measured by Annexin 
V-FITC/PI staining in CaSki cells, and this effect was seen to be more pronounced when 
combined with 4Gy and 8Gy X-rays (Figure 4.20 and 4.21).  Combinations of 500nM CX-5461 
with 4Gy and 8Gy X-rays were seen to be statistically significant (P-values < 0.0001) 
indicating that these combinations show synergistic effects compared to each agent alone.   
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Lee et al also measured apoptosis at 48hrs using flow cytometry in multiple myeloma cell 
lines and found strong Annexin-V staining at 48hrs in both p53 WT and mutant myeloma cell 
lines (Lee et al, 2017).  
 
Data from 72hr and 96hrs combination treatments showed a cytotoxic response from all 
combinations used but this effect was not as strong as that observed at 48hrs (Figures 4.22 - 
4.25) Radiation alone did little to induce apoptosis but a small reduction in surviving 
populations was noticeable in a dose dependent manner and this trend, with respect to 
radiation alone treatment, was observed across all three time points. Combinations of 4Gy 
and 8Gy X-rays with 500nM or 1μM CX-5461 significantly reduced cell survival compared to 
either drug or radiation alone (P-value < 0.001). 
 
The data obtained from combination treatments show that CX-5461 has the capacity to 
induce cell death by apoptosis as measured by Annexin V-FITC/PI assay as early as 48hrs 
post drug treatment and that this cytotoxicity is enhanced when combined with low doses 
of radiation. These findings are in contrast to the original publication by Drygin et al, (2011) 
who reported that they could not detect any signs of cell death by apoptosis cells in their 
panel of solid cancer cell lines at 48hrs. 
 
The authors did not attempt to measure apoptosis by flow cytometry, the absence of 
apoptosis was reported through a lack of PARP and caspase 3/7/8/9 cleavage by western 
blot analysis and importantly these measurements were only taken at 24hrs and 48hrs post 
24hr CX-5461 treatment.  
 
Although both Western blot and flow cytometric techniques are highly sensitive, flow 
cytometry as a readout for the detection of apoptosis is advantageous over Western blot 
analysis due to high speed analysis (depending on flow rate), measurement of both single 
cells and large number of cells, measurement of multiple parameters and quantification of 
fluorescence intensities as well as identifying small populations of cells and the ability to 
sort predefined cell populations.  
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Western blots on the other hand can be time consuming and several factors can affect the 
western blot result such as the type of transfer method used, membrane use (PVDF/NC), the 
type of blocking buffer used, probing techniques as well as potential cross reactivity of 
antibodies.  
 
Western blot data has shown that in A375 and CaSki cells, cleavage of PARP is possible at 
48hrs and 72hrs in samples treated alone with CX-5461 (Figures 4.14 and 4.15) or in 
combination treatment in CaSki cells involving X-rays (Figures 4.20 and 4.22) indicating late 
stage caspase-dependant apoptosis can be induced following CX-5461 treatment alone or in 
combination with radiation.  
 
Comparisons between single agent CX-5461 treatment at doses of 500nM compared to 
combination treatment involving 4Gy/500nM and 8Gy/500nM CX-5461 were found to be 
more effective than use of either agent in isolation. At time points of 48hrs, 72hrs and 
96hrs, all single agent CX-5461 vs combination treatments reported a p-value of < 0.0001 
indicating that the difference in these two approaches is highly significant. This data is in 
line with the combination index matrices for CaSki cell line which show that the highest 
synergistic interactions occur when low dose CX-5461 is combined with low dose X-rays.  
 
Scheduled administration of CX-5461 did show that pre-24 hour’s treatment with CX-5461 
prior to radiation was more effective at increasing the cytotoxicity of CaSki cells when 
combined with radiation compared to treatment with CX-5461 on the same day or 24hrs 
post radiation treatment (P-value < 0.0001) (Figures 4.27, 4.28, 4.29 and 4.30). This could be 
due to lack of viable ribosomes available to synthesise repair proteins which under normal 
circumstances would aid in the repair of radiation induced damage forcing the cells into a 
senescent state or inducing cell cycle arrest.  
 
Pradier et al, (2001) also performed scheduled dosing of docetaxel in combination with 
radiation in CaSki cells. In their experiments, the team treated CaSki cells with DOC 24hrs 
pre irradiation and 24hrs post irradiation and reported sensitizer enhancement ratios (SER) 
of 1.44 for 24hr pre DOC treatment and 1.17 for 24hr post DOC treatment.  
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SER (sensitizer enhancement ratio) is defined as the ratio of radiation doses in the absence 
and in the presence of the drug which produce the same biological effect. The higher the 
SER the more effective the sensitizer. An SER of 1.0 indicates no activity. Although SER’s 
obtained for ZMK-1 cells were higher compared to CaSki cells in their study, the ratios 
obtained for CaSki cells do support argument for radio-sensitization of CaSki cells with 24hr 
pre-treatment with DOC (Pradier et al, 2001).  
 
The data presented in this chapter highlights the synergistic interactions of combining CX-
5461 alongside radiation treatment. Induction of apoptosis is increased when the two 
modalities are combined and this effect is seen over the course of 96hrs. This chapter also 
provides evidence CX-5461 can induce apoptosis in solid cancer cells which can be detected 
at 48hrs. However, since no striking cleavage of PARP could be detected using western 
blots, this apoptotic response may be through caspase independent mechanisms. 
Preliminary data suggests that pre-treatment with CX-5461 for 24hrs prior to radiation 
exposure can radio-sensitize cells to the effects of radiation. CX-5461 possess the capacity to 
induce autophagy and senescence in solid and this could serve as a protective mechanism 
for cells which have entered the senescent state to reduce energy expenditure and recycle 
cellular components for energy.  
 
With respect to assessing CX-5461 induced cytotoxicity, Drygin et al used Western blot 
analysis to probe for markers of caspase dependant apoptosis following drug treatment 
such as whole and cleaved PARP and whole and cleaved caspase 3, 7, 8 and 9 following 24hr 
drug exposure as well as employing the Terminal deoxynucleotidyl transferase dUTP nick 
end labelling technique (TUNEL) (Drygin et al, 2011).  
 
The present work in this thesis also looked at markers of end stage apoptosis using Western 
blot analysis probing for cleaved PARP and cleaved caspase-3 as well as using Annexin/PI 
assay through the use of flow cytometry to determine the mode of cell death following CX-
5461 treatment. The Annexin/PI method allows for the detection of cells which may be 
undergoing early/late apoptosis as well as necrosis. Using this method in combination with 
Western blot probes for end stage apoptosis can provide deeper insights into the 
mechanism surrounding CX-5461 induced apoptosis.  
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Other methods which could be employed to further investigate apoptotic cell death 
following CX-5461 treatment include assessment of cell morphology alterations using light 
microscopy and time lapse microscopy by means of cell staining methods (Darzynkiewicz et 
al, 1997), plasma membrane alterations using LDH activity assay (Decker & Lohmann-
Matthes, 1988) or through the detection of specific regulators of apoptosis such as 
intracellular cytochrome c (Waterhouse & Trapani, 2003)  or Bcl2 family members , Fas and 
FasL targets  through the use of monoclonal antibodies against the above-mentioned 
targets (Menyhart et al,  2016). 
 
Results presented in this chapter are in agreement with the hypothesis proposed in section 
4.1. Combination experiments involving CX-5461 and single dose X-rays decreased non-
apoptotic cell populations in CaSki cell line over the course of 96hrs compared to single 
agent treatment alone as reported by Annexin/PI assay via flow cytometry.  
 
The objective of this chapter was to determine the mode of cell death following CX-5461 
exposure alone or in combination with x-rays in solid cancer cell lines. The data obtained 
showed that CX-5461 treatment alone induced autophagic flux most proficiently in CaSki cell 
line followed by SKMEL-28 with A375 and LN18 cell lines showing the least autophagic 
proficiency. Conversion of LC3I to LC3II and reduction in p62 levels via Western blot analysis 
was observed over the course of 72hrs in CaSki cell line. This was accompanied through the 
detection of autophagolysosomes in CaSki cell line via immunostaining of LC3 puncta using 
confocal microscopy. Flow cytometry analysis using Cyto-iD autpphay detection kit showed 
that high doses of CX-5461 treatment were sufficient to induce autophagolysosomes 
formation in CaSki, SKMEL-28, A375 and LN18 cell lines. Annexin/PI assay revealed that 
exposure to CX-5461 treatment alone induced end stage apoptosis as marked by high PI and 
Annexin staining in CaSki, A375 and LN18 cell lines and this effect was effectively increased 
when CX-5461 was combined with single dose X-rays in CaSki cell line. CX-5461 induced 
senescence was also observed in A375 cell line following treatment with CX-5461 over 
48hrs. Taken together, the data presented in this chapter suggests that treatment with CX-
5461 can induce autophagy, senescence and end stage apoptosis in solid cancer cell lines 
and importantly, end stage apoptosis is increased when CX-5461 is combined with single 
dose X-ray exposure compared to treatment with either modality alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Molecular mechanisms associated with CX-5461 induced cytotoxicity 
as a monotherapy and combined therapy in solid cancers (Part 2) 
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5. Molecular mechanisms underlying combination treatment involving CX-5461 and 
radiation therapy in solid cancer cell lines 
 
Many chemotherapeutic agents inhibit cell proliferation and/or induce apoptosis in cancer 
cells by stabilizing and activating the tumour suppressor protein TP53 (p53) (Vogelstein et 
al, 2000 and Johnstone et al, 2002). TP53, nicknamed ‘the guardian of the genome’ is a 
known transcription factor which facilitates the expression of genes controlling cellular 
processes such as cell growth, proliferation, survival and programmed cell death (Lane, 
1992).  It has been reported that cellular stresses such as DNA damage and the activation of 
oncogenes lead to fluctuations in ribosome biogenesis which can in turn also activate p53 
function (Diesenroth et al, 2010; Zhang & Lu et al, 2009 and Mayer & Grummt, 2005).  
 
Accumulation of p53 and its increased stability following cellular stresses is a consequence 
of reduced proteasome degradation by MDM2 (Haupt et al, 1997 and Hu et al, 2012). The 
reduced affinity of p53 for MDM2 is caused by phosphorylation of p53 by ATM protein 
kinase following DNA damage (Gajjar et al, 2012). MDM2 mediates its effects on p53 
through two mechanisms; firstly through direct binding with p53 thus impairing interactions 
with basal Pol II transcription machinery and secondly through altering p53 stability through 
E3 ubiquitin ligase activity and targeting p53 for nuclear export and 26s proteosomal 
degradation (Kubbutat et al, 1997). 
 
With respect to perturbations in ribosome biosynthesis leading to p53 stabilization, 
evidence in the literature suggests that several ribosomal proteins, usually involved in 
ribosome biogenesis processes, bind to MDM2 thus preventing its inhibitory effects on p53 
(Diesenroth et al, 2010). Stabilization of p53 through the use of rRNA inhibitors such as 
actinomycin D (Zhang et al, 2003), 5-fluoruracil (5-FU) (Sun et al, 2007) and mycophenolic 
acid (Sun et al, 2008) have also been documented. Silencing of RNA polymerase I expression 
and TIF-1A has also been reported to stabilise p53 through the RP-MDM2 interaction 
pathway (Donati et al, 2011 and Yuan et al, 2005). The major riboproteins thought to be 
involved in the inactivation of MDM2 are RPL5 (Dai et al, 2004), RPL11 (Zhang et al, 2003) 
and RPL23 (Dai et al, 2004).  
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A schematic representation of the p53 stabilization and RP-MDM2 pathways under normal 
conditions and under conditions of nucleolar stress are depicted in Figure 5.1 and 5.2. 
Mechanisms by which nucleolar stress can be activated include inhibition of rRNA synthesis, 
impaired rRNA processing and imbalances in riboprotein levels (Sazuki et al, 2012). 
Oncogenic stress (Ras, c-myc activation) ARF is responsible for relieving p53 degradation 
from MDM2 by inhibiting MDM2 E3 ligase activity. Following DNA stress such as radiation, 
drug exposure or oxidative stress, ATM and ATR phosphorylate p53 and MDM2 which blocks 
their interaction and promotes p53 accumulation.  
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Figure 5.1: The nucleolar stress response. Above, under normal conditions, riboproteins are assembled with 
rRNA into 40s and 60s subunits inside nucleolus. p53 levels are supressed through MDM2 binding which 
targets p53 for ubiquitination and degradation. Adapted from Hein et al, 2013. 
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Figure 5.2: Under conditions of nucleolar stress, ribosome production is halted, riboproteins released into 
nucleoplasm. Riboproteins and 5.8s rRNA interact with MDM2 to prevent p53 binding. Increased RPL11 
mRNA increases RPL11 and MDM2 binding stabilizing and ­ p53 induction. Adapted from Hein et al, 2013. 
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The DNA damage response pathway serves to sense DNA damage, delay cell cycle 
progression and attempt any repairs or induce programmed cell death if the damage is too 
intensive (Goldstein et al, 2015). The sensing and response to DNA damage is mediated by 
the phosphatidylinositol 3-kinase-like kinase (PI3K) family which includes ATM, ATR and 
DNA-PK kinases (Blackford and Jackson, 2017). Activated ATM plays a crucial role in 
initiating the cellular signalling cascade in response to DNA double stranded breaks by 
phosphorylating a series of downstream targets involved in cell cycle checkpoints leading to 
the inactivation of cyclin/cyclin dependent kinase complexes resulting in cell cycle arrest 
(Shaltiel, 2015).  
 
The G1 checkpoint serves to prevent the replication of and damaged DNA.  It is well 
established that responses to double strand breaks in G1 phase involves ATM and its target 
Chk2 which facilitate the stabilization of p53. P53 then induces transcriptional activation of 
p21Cip1 (member of CIP/KIP family of CDK inhibitors) which in turn binds to and inhibits 
cyclin E/CDK2 complex. This inhibition causes the cell cycle arrest of cells at the G1/S 
transition (Harper et al, 1993 and Harper et al, 1995).  
 
p27kip1 belongs to the same family as p21Cip1 of CDK inhibitors (Denicourt, 2001) and its roles 
have mainly been attributed to in G1 phase progression inhibition and the induction of 
quiescence in response to anti-proliferative signalling (Kiyokawa et al, 1996). It is important 
to note that quiescence occurs due to a lack of nutrition and growth factors compared to 
senescence which takes place due to aging and severe DNA damage (Terzi et al, 2016). Cell 
cycle control is also regulated by p27kip1 which is not a transcriptional target of p53. This is 
done mainly through phosphorylation of p27kip1 at residue Ser-140 by ATM kinase which 
leads to p27kip1 stability following DNA double strand breaks (Cassimere et al, 2016). 
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5.1 Aims & objectives 
 
The targeting of a subcellular organelle with CX-5461 in combination with radiation will 
enhance tumour cell killing effects 
 
The objective of this chapter was to determine if treatment with CX-5461, alone, or 
combined with radiation can induce DNA damage in solid cancer cell lines and to determine 
any effects on cell cycle progression  
 
In order to investigate the modes of cell death, the following experiments were conducted: 
 
• Western blot analysis of DNA damage using gH2AX as marker for DNA damage in 
samples treated with CX-5461 alone or in combination with radiation 
• Confocal microscopy of gH2AX foci in CX-5461 treated samples 
• Flow cytometric cell cycle analysis using propidium iodide staining to determine cell 
cycle progression following CX-5461 and combination treatment including p53 and 
p27kip1 expression via western blot analysis 
• Transient silencing of nucleophosmin (NPM1) using siRNA in CaSki cells to determine 
if silencing of NPM1 increases sensitivity to CX-5461 using flow cytometry  
• qPCR analysis to determine the effects of CX-5461 on the transcription of 45s pre-
rRNA in CaSki and A375 solid cancer cell lines 
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5.2         CX-5461  induced DNA damage in CaSki cell line 
 
CaSki cells treated with 1μM or 5μM CX-5461 induced the expression of the DNA damage 
marker gH2AX in a time and dose dependent manner (Figure 5.3). Western blot analysis of 
gH2AX expression at time points of 48hrs and 72hrs was found to be statistically significant 
compared to untreated controls (p-value < 0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon the induction of double stranded DNA breaks (DSB), H2AX molecules become rapidly 
phosphorylated by PI3 kinases (ATM, ATR and DNA-PK) and the induction of gH2AX is one of 
the earliest events detected in cells following exposure to DNA damaging agents as it has 
been reported that gH2AX induction appears within minutes and reaches a maximum after 
30 minutes (Rogakou et al,, 1999), in light of this early induction of gH2AX a 24hr analysis of 
lysates exposed to CX-5461 is also required to determine the early onset of CX-5461 induced 
DSB DNA damage. 
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Figure 5.3: Western blot analysis of CaSki samples treated with either CX-5461 alone for 48hrs and 72hrs and 
probed for p-H2AX DNA damage marker. *** p-value = < 0.001, **** p-value = < 0.0001. Positive control HeLa cells  
treated with 50µM chloroquine, negative control HeLa unteated (CST Technology – 11972) 
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Lysates produced from CaSki cells treated in combination with 1μM CX-5461 and single dose 
X-rays were also probed for gH2AX expression over the course of 48hrs and 72hrs (Figure 
5.4). CaSki cells treated in combination with X-rays at 48hrs showed modest increase in 
gH2AX expression in combination lysates with the highest expression found in samples 
treated with 1μM CX-5461 (p-value <0.05) or 8Gy X-rays (p-value < 0.0001). At 72hrs, the 
expression of gH2AX was found to increase in a dose dependent manner, levels of gH2AX 
could be strongly detected in lysates treated in combination (p-value < 0.0001) and these 
expression levels were higher compared to CX-5461 alone or radiation alone (Figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visualization of gH2AX foci following 1μM CX-5461 treatment over 48hrs and 72hrs in CaSki 
cells using confocal microscopy is presented in Figure 5.5 and Figure 5.6. 
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Figure 5.4: Western blot analysis of p-H2AX DNA damage marker in CaSki cells treated in combination with 4Gy and 
8Gy X-rays over 72hrs. Relative expression of p-H2AX for each sample compared to untreated controls is also shown. 
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5.3 Confocal microscopy of CX-5461 induced gH2AX foci in CaSki cell line 
 
 
   
 
 
 
 
 
48hr 
Untreated 
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Figure 5.5: Confocal microscopy of CaSki cells treated with 1uM CX-5461 for 48hrs and stained for a DNA 
damage marker H2AX (anti rabbit 1:1000) and goat anti-rabbit 488 (1:2000). Blue represents nuclear DNA 
and green foci represent sites of double stranded DNA breaks.  
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Figure 5.6: 72hr Confocal microscopy of CaSki cells exposed to 1uM CX-5461 for 72hrs and stained for p-H2AX (anti 
rabbit H2AX 1:1000, goat anti-rabbit secondary Alexa fluor-488 1:2000), DAPI (Blue). Images taken using 40x 
objective. Blue colour represents nuclear DNA and green foci represent sites of double stranded DNA breaks.  
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48hr treatment in CaSki cells with 1μM CX-5461 induced significant double stranded breaks 
as visualised in Figure 5.5 compared to untreated control samples. DNA double stranded 
breaks could also be detected significantly in samples imaged at 72hrs (Figure 5.6).  
Although very little background p-H2AX staining could be detected in control sample, this 
was significantly lower compared to drug treated samples.   
 
In an attempt to quantify the number of CX-5461 g-H2AX induced DNA damage foci, three 
drug treated images and two control images were selected and from each image the 
number of red, green and blue pixels were recorded. From this the ratio of green to blue 
pixels was calculated using pixel analysis (Microsoft Excel). The values obtained from the 
three drug treated images and two control images were averaged and presented in Figure 
5.7. Green puncta visible in Figure 5.5 & 5.6 represents sites of DNA damage where g-H2AX 
has bound and blue pixels represent genomic DNA as counterstained by DAPI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of image analysis software such as ImageJ and Metamorph to detect and quantify 
CX-5461 induced g-H2AX Foci would provide a more robust method of analysis over the 
measurement of the ratios of individual pixels since the ratio of green to blue pixels is not 
directly related to the number of g-H2AX foci (autofluorescence).  
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Figure 5.7: Ratio of green to blue pixels in untreated and 1uM CX-5461 treated CaSki cells. Green:blue ratio 
represents the amount of green pixels which correspond to sites of double strand DNA breaks as marked by 
g-H2AX relative to the amount of blue pixels which represent nuclear DNA. Higher green:blue represents 
more DNA damage.  
G
re
en
:B
lu
e 
Pi
xe
l R
at
io
  
 
 
183
5.4 CX-5461 induced DNA damage in A375 melanoma cell line 
 
A375 cells treated with 100nM or 500nM CX-5461 for 48hrs and 72hrs as well as in 
combination with 4Gy/8Gy X-rays and probed for gH2AX levels using western blot analysis 
are presented in Figure 5.8. These doses were selected to reflect the sensitivity of A375 cell 
line towards CX-5461 as shown in Chapter 3 Figure 3.2.  
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Figure 5.8: Western blot analysis of p-H2AX DNA damage marker in A375 samples treated with CX-5461 alone for 48/72hrs 
and in combination treatment (CT) with 4Gy and 8Gy X-rays over 48hrs. Densitometry analyses of gH2AX levels in CX-5461 
treated samples and from combination treatment samples are presented below western blot images. **** p-value = 
<0.0001. 
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Treatment with CX-5461 induced double stranded DNA breaks in samples treated alone with 
CX-5461 at 48hrs. This effect was seen to be reduced at 72hrs although feint bands for H2AX 
could be detected (Figure 5.8). Since A375 is one of the more sensitive cell lines towards CX-
5461, cell survival at 72hrs is greatly reduced which could explain the lack of H2AX detected 
at this time point. When CX-5461 was combined with X-rays, H2AX marker could be 
detected in all samples, expression of H2AX was found to be higher in samples treated with 
CX-5461 alone and in combination with 4Gy and 8Gy X-rays compared to 4Gy/8Gy 
treatment alone indicating that combination treatment is more effective at inducing 
genomic damage compare to either CX-5461 or X-rays alone (Figure 5.8).  
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5.5 CX-5461 induced DNA damage in LN18 glioblastoma cell line 
 
Lysates produced from LN18 cells were treated with 500nM or 1uM CX-5461 for 48hrs and 
72hrs as well as in combination with 4Gy/8Gy X-rays and probed for gH2AX levels using 
western blot analysis. LN18 cell line represent a medium sensitivity towards CX-5461 from 
the panel of cell lines investigated in Chapter 3.  Treatment with CX-5461 alone induced 
strong H2AX expression in a manner which was dose and time dependent (Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In figure 5.9, a high level of gH2AX can be detected in the 72hr control compare to the 48hr 
control. This could be due to overcrowding of cells which would result in contact inhibition 
and reduction in oxygen available to the cells as well as a decrease in nutrient availability 
which could lead to the induction of double stranded DNA breaks being detected in the 
untreated 72hr control sample.  
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Figure 5.9: Western blot analysis of LN18 cells exposed to CX-5461 over 72hrs and probed for p-H2AX DNA damage marker 
along with the corresponding densitometry measurements of samples normalized to untreated control. **** p-value = 
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In lysates prepared from combination treatments at 48hrs, gH2AX induction could be 
strongly seen in only samples treated in combination with CX-5461 and X-rays relative to 
untreated, CX-5461 alone or X-ray alone treatments (Figure 5.10). 
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Figure 5.10: Western blot analysis of LN18 cells exposed to CX-5461 in combination with 4Gy and 8Gy X-rays and probed 
for p-H2AX DNA damage marker along with the corresponding densitometry measurements of samples treated with CX-
5461 alone or combination treatments (CT) normalized to untreated control. **** p-value = 0.0001. 
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5.6 CX-5461 induced cell cycle arrest 
 
CaSki and A375 cell lines were grown in T25 flasks at a density of 5x105 cells per flask and 
drug treated with CX-5461 for 48hrs before being analysed using flow cytometry for any cell 
cycle associated effects.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment with CX-5461 alone for 48hrs induced a G2/M arrest in CaSki cells. The 
percentage of cells in G2/M in untreated samples increased from 28% to 49% (Figure 5.11). 
When treated with radiation alone with single doses of 4Gy, 10Gy and 16Gy a dose 
dependent increase in cells arrested in G2/M transition was observed (Figure 5.13). 
Combination treatments involving CX-5461 and X-rays showed complete abolition of cell 
cycle (Figure 5.14).   
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Figure 5.11: Cell cycle analysis and propidum iodide (PI) staining of CaSki cells following 48hr CX-5461 
treatment. The percentages of cells of in each stage of the cell cycle following CX-5461 treatment are shown 
below cell cycle histograms 
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Western blot analysis was used to probe for markers involved in progression through the 
cell cycle. p53 is a known tumour suppressor and involved in both the G1/S and G2/M cell 
cycle check points, The activation of p53 following DNA damage results in the expression of 
proteins which play important roles in cell cycle arrest, repair and apoptotic cell death 
(Bargonetti & Manfredi, 2002).  p27kip1 is a cyclin dependant kinase inhibitor involved in 
preventing the activation of cyclin E or cyclin D complexes from adding phosphate residues 
to the retinoblastoma protein, which is required to progress through the G1 phase of the 
cell cycle, increased levels of p27 cause cells to arrest in the G1 phase  of the cell cycle 
(Abukhdeir & Park, 2008).  
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Figure 5.12: Western blot analysis of cell cycle markers p27kip1 and p53 in CaSki cells exposed to CX-5461 over 72hrs. 
The relative expression levels of each markers are also shown. ** p-value = < 0.01, **** p-value = < 0.0001. 
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Western blot analysis revealed a p53 induction in CaSki cells following CX-5461 treatment. 
This effect was seen to be more pronounced at 48hrs although induction of p53 at 72hs was 
also detected (Figure 5.12). At both 48hrs and 72hrs, treatment with Cx-5461 induced 
positive expression of p27kip1 in samples treated with 1μM or 5μM CX-5461 compared to 
untreated controls which is indicative of cell cycle blockade through the G1/S checkpoint 
(Figure 5.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190
5.7 Effect of radiation alone on cell cycle progression in CaSki cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Cell cycle analysis of CaSki cells exposed to single doses of X-rays alone (4Gy, 10Gy and 16Gy) 
for 48hrs (above). Graphic representation of cells in each stage of the cell cycle in untreated control and 
radiated samples (below). 
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5.8 Effects of combination treatment on cycle progression in CaSki cells 
 
To study the effects of combination treatment on the progression of CaSki cell through the 
cell cycle a low doge of 4Gy X-rays was combined with 1μM CX-5461 for 48hrs and cellular 
DNA was stained using propidium iodide and analysed using flow cytometry (figure 5.14). 
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Figure 5.14: Cell cycle analysis of CaSki cells treated with 1uM Cx-5461 in combination with 4Gy, 10Gy and 
16Gy X-rays for 48hrs 
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5.9 CX-5461 induced cell cycle arrest in A375 cells 
 
A375 cells exposed to 1uM CX-5461 for 48hrs and analysed for cell cycle associated effects 
(Figure 5.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Cell cycle analysis of A375 melanoma cells exposed to 1uM Cx-5461 for 48hrs (above). Percentage of A375 
cells in each stage of the cell cycle following treatment with CX-5461 
G0 - 0.5% 
G1 - 60.5% 
S - 9.5% 
G2M - 28% 
G0 - 8% 
G1 - 33% 
S - 7% 
G2M - 51% 
G
0
G
1 S
G
2M
0
2 0
4 0
6 0
8 0
A 3 7 5  4 8 h r  C e ll C y c le
S ta g e  o f C e ll C y c le
C o n tro l
1 u M  C X
Untreated Control 
Nu
m
be
r o
f c
el
ls 
Propidium iodide Propidium iodide 
Nu
m
be
r o
f c
el
ls 
%
 o
f C
el
ls 
1µM Cx-5461 
 
 
193
A375 cells were probed for p52 and p27 cell cycle arrest markers following 48hr and 72hr 
CX-5461 treatment (Figure 5.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In A375 cell line, a G2/M cell cycle arrest was also observed following single agent CX-5461 
treatment (Figure 5.15). Cell populations in the G2/M transition increased from 28% in 
untreated controls to 51% in samples treated with 1μM CX-5461. At both 48hr and 72hr 
time points, a strong p53 induction was observed in drug treated samples relative to 
untreated controls (Figure 5.16). With respect to p27kip1, a reduction in expression was 
observed at 48hrs in A375 cells treated with 500nM CX-5461 but at 72hrs the expression of 
p27kip1 was found to increase (Figure 5.16).  
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Figure 5.16: Western blot analysis of cell cycle markers p27kip1 and p53 in A375 cells treated with CX-5461 over 
72hrs. **** p-value = 0.0001, *** p-value = 0.0001 
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5.10 Nucleophosmin (NPM1) Silencing 
 
Nucleophosmin is a prominent multifunctional nucleolar protein involved in a wide range of 
cellular processes such as ribosome biogenesis, mRNA processing, chromatin remodelling, 
embryogenesis and autophagy (Box et al, 2016). Since NPM1 is involved in ribosome 
biogenesis, a process which is a key target of CX-5461, transient silencing of NPM1 in CaSki 
cell line was investigated following CX-5461 treatment.  
 
Using Non-coding and NPM1 directed transient SiRNA (Dharmacon), CaSki cells were 
silenced for NPM expression for 72hrs before being drug treated with 500nM CX-5461 for a 
further 72hrs. Cell death was analysed using flow cytometry and Annexin V-FITC/PI Assay. 
Knockdown of NPM1 was confirmed via western blot analysis (Figure 5.19). 
  
Experiments involving combination treatments with CX-5461 and X-rays showed a marked 
reduction in NPM1 expression compared to single agent treatment alone (Figure 5.17). 
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Figure 5.17: Western blot analysis of NPM1 expression following single agent CX-5461 treatment over 72hrs (left) 
and NPM1 expression in CaSki cells treated in combination with XC-rays over 48hrs 
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Histogram plots from 72hr Annexin V-FITC/PI assay of NPM1 silenced cells treated with 
500nM CX-5461 are presented in figure 5.18: 
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Figure 5.18: Annexin V-FITC/PI staining of CaSki cells silenced for NPM1 expression and drug treated with CX-5461 
(500nM) for 72hrs. Controls are corrected to 100%, NC and SiRNA drug treated treated samples are expressed as a 
percentage relative to their respective controls 
78.8% 
100% 
100% 
73.8% 
Annexin V-FITC Annexin V-FITC 
Annexin V-FITC Annexin V-FITC 
Pr
op
id
iu
m
 io
di
de
 
Pr
op
id
iu
m
 io
di
de
 
Pr
op
id
iu
m
 io
di
de
 
Pr
op
id
iu
m
 io
di
de
 
 
 
196
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transient silencing of NPM1 appeared to sensitise CaSki cells to the effects of CX-5461 
(Figure 5.18 & 5.19). In the presence of non-coding SiRNA control, treatment with CX-5461 
reduced cell survival to 73.2%, in NPM1 silenced CaSki cells, treatment with 500nM CX-5461 
reduced survival to 66% over 72hrs drug treatment. Comparison between non coding SiRNA 
drug treated CaSki cells and NPM1 SiRNA drug treated cells showed a significant (**) 
difference in sensitivity towards CX-5461 treatment with a p-value 0.0047 using one way 
ANOVA Tukeys multiple comparison test. The transient knockdown of NPM1 was confirmed 
through western blot analysis where lysates produced from untreated CaSki control, Non-
coding SiRNA and NPM1 SiRNA treated samples were probed for anti-mouse NPM1 (Santa 
Cruz 1:500). A complete knockdown of NPM1 can be visualised in Figure 5.19 
NPM1 
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48hr Control 2 
48hr Non Coding SiRNA 
48hr NPM
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Figure 5.19: % survival of CaSki cells treated with non-coding SiRNA and NPM1 SiRNA followed by 
500nM CX-5461 treatment for 72hrs. **** p value <0.0001. Western blot analysis of NPM1 
knockdown in CaSki cell lysates produced 48hrs after silencing, GAPDH loading control is shown. 
**** **** 
** 
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5.11 Quantitative polymerase chain reaction (qPCR) analysis of pre-45s rRNA expression in 
A375 and CaSki cell lines 
 
qPCR analysis was performed in A375 and CaSki cell line to validate the target of CX-5461. 
Since CX-5461 is a RNA polymerase I inhibitor, it was important to establish if treatment 
with CX-5461 does indeed target genes which are only under the control of RNA polymerase 
I such as 45s pre-rDNA transcripts which are responsible for the production of ribosomal 
subunits. 
 
Quantitative PCR analysis was performed on cDNA produced from CaSki cells treated with 
500nM CX-5461 and 1uM CX-5461 over the course of 72hrs. cT values were normalised 
against the housekeeping gene β-actin.  
 
RNA was extracted at 24hrs post CX-5461 treatment from A375 and CaSki cells followed by 
cDNA synthesis and qPCR was performed for 45s pre-rRNA expression (Figure 5.20). 
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Figure 5.20: 24hr qPCR analysis of 45s pre-rRNA expression in A375 and CaSki cell lines. P-value = < 0.0001. 
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qPCR analysis of 45s pre-rRNA expression was done at 24hrs, 48hrs and 72hrs in CaSki cells 
(Figure 5.21). Each sample was set in triplicates and repeated on three separate occasions. 
cT values were normalised against the housekeeping gene β-actin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21: Time course analysis of 45s pre-rRNA expression in CaSki cells treated with CX-5461. Comparison of 
control vs drug treated samples **** p-value = 0.0001. 
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5.12  Discussion 
 
We report that treatment with CX-5461 in solid cancer cell lines such as CaSki, A375 and 
LN18, alone or in combination with X-rays induces DNA damage (Figures 5.3, 5.4, 5.5, 5.6, 
5.8 & 5.9) through the formation of double stranded DNA breaks which are marked by 
gH2AX foci and imaged using confocal microscopy. gH2AX is a marker for DNA damage and 
following phosphorylation is known to localise to sites of DNA damage (Kuo et al, 2008).  
 
In CaSki, A375 and LN18 cell lines, treatment with CX-5461 alone resulted in significant 
increases in gH2AX levels as measured by western blot analysis (p-value < 0.0001) (Figures 
5.3, 5.8 and 5.9) relative to untreated controls.  Combination treatments were also 
statistically more significant at inducing DNA double strand breaks compared to either CX-
5461 or X-rays treatment alone (p-value = < 0.0001) (Figures 5.4, 5.8 and 5.10). This 
demonstrates that CX-5461 combined with X-rays is more effective at inducing DNA damage 
compared to the additive effects of the treatments. This data is in agreement with earlier 
findings presented in Chapter 3. 
 
The presence of gH2AX at sites of DNA damage can be considered as a kind of sensor which 
then functions to activate the DNA damage response pathway. Previous studies in the 
literature have also reported the induction of DNA damage following exposure to CX-5461 
(Xu et al, 2017 & Quin et al, 2016). Interestingly, Quin et al showed that gH2AX foci 
formation or induction of gH2AX at the protein level was not observed following short term 
exposure to CX-5461 (6hr) however long term exposure (48hrs) resulted in the observation 
of gH2AX foci in BJ-T cells treated with 1μM Cx-5461 (Quin et al, 2016), this is in agreement 
with our findings of gH2AX induction at times points of 48hrs and 72hrs CX-5461 treatment 
(Figure 5.5, 5.6 and 5.7). The authors also noted that the presence of gH2AX foci did not 
coincide with reduction in rDNA transcription or nucleolar morphology alterations following 
CX-5461 treatment rather it coincided with an increase in β-galactosidase staining which 
suggests that the formation of gH2AX foci is an indirect and delayed response to CX-5461 
treatment.   
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Xu et al reported the increased presence of gH2AX foci in both HCT-116 and U2OS solid 
cancer cell lines following 100nM CX-5461 treatment for 24hrs and also in SKOV3ip1 
epithelial ovarian cancer cells when treated with 500nM CX-5461 (Cornelison et al, 2017). 
Increased phosphorylation of gH2AX reported by Xu et al and Quin et al was shown using 
western blotting consistent with the increase in p-gH2AX observed in cell lysates produced 
from A375, CaSki and LN18 cells following exposure to CX-5461 (Figure 5.3, 5.8 & 5.9).  
 
g-H2AX in general, represents the presence of double stranded DNA breaks. Strong evidence 
supports quantitative correlation between DNA double strand break induction following 
exposure to ionizing radiation and the formation of g-H2AX foci (Rothkamm et al, 2012). 
Other reports have shown that the formation of g-H2AX foci as well as induction of pan-
nuclear g-H2AX signalling are a cellular response to stresses other than ionizing radiation. 
Therefore the g-H2AX signal has been shown to be stronger at sites of DNA double strand 
breaks compared to undamaged chromatin regions (Meyer, 2013). 
 
The nucleolar response to double stranded breaks is mediated by ATM activity (Marechal 
and Zou, 2013) and DSBs occurring within regions of rDNA repeats are repaired through the 
non-homologous end joining pathway (Harding et al, 2015).  
 
With respect to cell cycle perturbations, CX-5461 treatment alone in CaSki and A375 
induced marked G2/M arrests, preventing the completion of mitosis (Figures 5.11 & 5.15). 
These results are in line with previous studies that also report G2/M arrests following 
exposure to CX-5461 in several cell lines including ovarian cancer (Cornelison, 2017), acute 
myeloid leukaemia  (Hein et al, 2011), glioblastoma (Li et al, 2018), osteosarcoma (Li et al, 
2016) and also in advanced prostate cancer cells (Robello et al, 2016). Exposing CaSki cells to 
radiation alone also induced a marked G2/M arrest (Figure 5.13) but in combination with 
CX-5461 a catastrophic abolition of cell cycle activity was observed (Figure 5.14). 
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The cell cycle arrest within the G2M phase of the cell cycle caused by CX-5461 is also the 
most radiosensitive stage of the cell cycle. This cell cycle arrest could explain the synergy 
between CX-5461 since cells are primed in the stage of cell cycle where exposure to 
radiation will have the most cytotoxic effects. 
 
In cultured cortical neurons, Kalita et al (2008) showed that inhibition of rRNA through 
camptothecin (topisomerase I inhibitor) treatment reduced transcription of rRNA and 
caused nucleolar stress which led to the stabilization of p53 and the induction of p53-
dependent apoptosis.  
 
In haematological malignancies, similar stabilization of p53 and p53-dependent induction of 
apoptosis has also been reported (Bywater et al, 2012) following treatment with CX-5461.  
Previous studies involving solid cancers cell lines looked at p53 levels following CX-5461 
treatment in A375 cells (Drygin et al, 2011).  
 
The same group reported that in A375 cells, CX-5461 modestly increased p53 at doses which 
were up to 10-fold higher than the IC50 (58nM) obtained for Pol I transcription inhibition in 
A375 cells.  In the present study, CX-5461 treatment induced the expression of the tumour 
suppressor protein p53 in CaSki and A375 cells which are both p53 wt (Figures 5.12 & 5.16). 
Our results are in agreement with Drygin et al with respect to the induction of p53 in A375 
cells following CX-5461 treatment but we found that this induction is possible at far lower 
doses such as 100nM and 500nM CX-5461 at the same time point of 48hrs (Figure 5.16). 
 
In CaSki cells, p27kip1 expression was seen to increase at 48hrs and 72hrs following high dose 
CX-5461 treatment alone (p-value 0.0001) (Figure 5.12), this was accompanied by significant 
increase in p53 stabilization (p-value 0.0001) only over 48hrs period indicating that CX-5461 
induces strong cell cycle arrest response. p53 expression at 72hrs was not found to be 
statistically significant (p-value > 0.05).  In A375, at 48hrs in CX-5461 alone treated samples, 
p27kip1 expression was found be significantly reduced alongside significant increase in p53 
expression (Figure 5.16). This could mean a lack of G1/S blockade at 48hrs although p53 has 
been stabilized.  
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Studies have identified more than 250 proteins, some previously unknown, to be associated 
with the nucleolus (Anderson et al, 2002). Of these nucleolar proteins, nucleophosmin 
(B23/NPM1), a multifunctional protein known to be involved in ribosome biogenesis, 
genomic stability and DNA repair and autophagy (Gisendi et al, 2006; Lindström et al, 2011 
and Katagiri et al, 2015) is of particular interest due to its over expression in ovarian cancer 
cell lines (PEO1 & PEO1 Carboplatin resistant) reported in an in-depth proteomic mass 
spectrometry study (Cruz et al, 2017).   
 
A recent study has highlighted the importance of NPM1 in solid cancers (Chen et al, 2018). 
The authors conducted a meta-analysis of the prognostic significance of NPM1 within solid 
cancers. Their findings showed that high NPM1 levels correlated with poor overall survival in 
solid cancers and also increased expression of NPM1 was associated with tumour 
aggressiveness (Chen et al, 2018). This highlights the potential value of NPM1 as a 
prognostic marker in solid cancers.   
 
Analysis of NPM1 expression in CaSki cells via western blot analysis showed that NPM1 
expression was reduced at 48hrs following CX-5461 treatment (Figure 5.17) and 
combination treatment with radiation showed reduced NPM1 expression compared to 
either drug or X-ray treatment alone. Based on this observation we investigated the effects 
of NPM1 silencing in CaSki cells in an effort to clarify any role of NPM1 is mediating the 
cytotoxicity of CX-5461. 
 
We observed that transient silencing of NPM1 in CaSki cells increased the sensitivity of drug 
treated NPM1 silenced CaSki cell line (p-value < 0.05) towards the effects of CX-5461 
compared to non-coding (scramble) control cells under the same conditions (Figure 5.18) 
indicating that the presence of NPM1 may play a protective role towards the cytotoxic 
effects of CX-5461. Previously, Loubaeu et al (2014) showed that NPM1 supported prostate 
tumour cell migration, colony formation and invasion and that silencing through specific 
NPM1 targeted short hairpin RNA (shNPM1)  in lymph node carcinoma prostate cells lead to 
the decrease in growth of tumours grafted in nude mice (Loubeau et al, 2014).  
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Silencing was coupled with the loss of ability of LNCaP cells to form with a decrease in 
proliferative capacity accompanied by 30% decrease in BrdU incorporation which was 
associated with a 60% reduction in proliferating cell nuclear antigen (PCNA) mRNA levels, a 
key marker for cellular proliferation.  
 
Olausson et al (2015) also silenced NPM1 in human astritic glioma cells. The team found 
that in U251MG, U1242MG and U343MGa C12:6 glioma cells depletion of NPM1 had 
modest effects on cell viability which was accompanied by alterations in nucleolar 
morphology. When NPM1 depleted glioma cells were cultured with low doses of ActD (μM), 
NPM1 depleted cells were more sensitive to apoptosis compared to non-NPM1 depleted 
cultures (Olausson et al, 2015) which are in agreement with our findings.  
 
The chemosensitisation of CaSki cells using combination treatment has also previously been 
reported. Faried et al (2006) showed that pre-treatment with rapamycin followed by 
treatment with paclitaxel significantly enhanced the sensitivity of CaSki cells to the effects of 
paclitaxel through increased apoptotic cell death. In A375 and CaSki cells, a reduction of 45s 
pre-rRNA expression was observed at 24hrs in samples treated with 500nM and 1μM Cx-
5461 (Figure 5.20). The results from the 24hr qPCR experiment were in agreement with the 
data obtained by Drygin et al where they too observed a decrease in 45s pre-rRNA 
expression in A375 cell line (Drygin et al, 2011). The pilot study did not include CaSki in their 
qPCR panel. We therefore looked at the expression of 45s pre-rRNA in CaSki cells over the 
course of 72hrs CX-5461 treatment. 
 
 qPCR analysis showed that over the course of 72hrs, treatment of CaSki cells with CX-5461 
reduced the transcription of 45s pre-rRNA in a dose dependent manner (Figure 5.21) (p-
value < 0.0001). These data support the argument that CX-5461 inhibits the transcription of 
genes under the control of RNA Polymerase I, since levels of β-actin and GAPDH were 
unaffected, and these genes are under the transcriptional control of RNA Polymerase II.  
 
 
 
 
204
The data presented in this chapter highlights the role of CX-5461 in inducing DNA damage 
following CX-5461 treatment. When combined with radiation, the induction of DNA damage 
as measured by gH2AX expression was found to be significantly higher (p-value <0.001) 
compared to the effects of each agent alone. Treatment with CX-5461 induces marked G2M 
cell cycle arrests and when combined with X-rays complete abolition of the cell cycle is 
observed. Cell cycle effects were associated with marked induction of p53 alongside p27kip1 
expression which are associated with cell cycle arrest and G1/S stage arrest. The silencing of 
a prominent nucleolar protein NPM1 sensitised CaSki cells towards the effects of CX-5461 
indicating that NPM1 may play a protective role in the presence of CX-5461. Taken together, 
CX-5461 is a powerful anti-cancer agent capable of inducing apoptosis, DNA damage, 
autophagy and senescence in solid cancer cells. When combined with radiation, the 
cytotoxic effects of CX-5461 are greatly enhanced in solid cancers.  
 
The results obtained in this chapter are in agreement with the hypothesis proposed in 
section 5.1. Combination treatment involving CX-5461 and X-rays induced stronger gH2AX 
signals via western blot analysis compared to treatment with either agents alone in CaSki, 
A375 and LN18 cell lines. Distinct gH2AX foci could be observed using confocal microscopy 
following CX-5461 single agent treatment alone in CaSki cell line at both 48 and 72hrs. Since 
the induction of gH2AX foci is an early occurring event following DNA DSBs it is important to 
also establish levels of gH2AX induction at both 12hrs and 24hr post CX-5461 treatment.  
 
Flow cytometry analysis revealed that CX-5461 treatment induced G2/M arrests in both 
A375 and CaSki cell lines, when CX-5461 was combined with X-rays this resulted in complete 
abolition of the cell cycle. Silencing of NPM1 modestly increased the sensitivity of CaSki cell 
line towards CX-5461 and qPCR experiments confirmed the selectivity of CX-5461 towards 
genes under the transcriptional control of RNA polymerase I exclusively. Altogether, CX-
5461 treatment alone and in combination induces DNA damage and treatment with CX-
5461 induces a cell cycle arrest in the most radiosensitive stage of the cell cycle (G2/M), this 
could explain the increased effectiveness of combining CX-5461 with X-ray treatment where 
the cells which are stalled in G2/M following drug treatment are unable to repair the SSBs 
and DSBs induced by X-ray exposure due to a lack of ribosome availability to produce the 
necessary repair proteins involved in the DNA damage response pathways.   
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6.  Conclusion and Future work 
 
 
This study aimed to assess the cytotoxic effects of targeting RNA Pol I transcription in solid 
cancer cell lines through exposure to CX-5461 alone or in combination with X-ray radiation to 
assess whether combination treatment achieves any synergistic anti-cancer effects in solid 
cancer cell lines. This treatment modality has the potential to limit toxic side effects through 
the use of low dose radiation exposure and low drug dose administration to help sustain and 
improve clinical responses for solid cancers such as cervical cancer (CaSki) and skin melanoma 
(A375).  
 
Increased transcription of rRNA coupled with an increase in ribosome biogenesis is a common 
feature to all rapidly proliferating cancer cells.  Over the last decade, several candidates which 
target RNA Pol I transcription have been investigated and show promising results.  
Radiotherapy is a major route of treatment for cancer patients and has been used in 
combination with several classes of chemotherapy drugs to treat a range of cancers. Little 
evidence exists in the literature investigating the effects of combining the use of RNA Pol I 
inhibition in combination with photon radiotherapy. The work described herein identifies 
some key aspects of RNA Pol I associated cytotoxicity in solid cancers through treatment with 
CX-5461 alone and in combination with X-rays.  
 
The long term treatment and management of solid cancers intrinsically involves limited 
chemotherapeutic options since it is often the case that patients develop resistance to anti-
cancer agents such platinum or taxane based drugs. It is therefore imperative to identify and 
understand the interaction of novel agents which have the potential to be used in conjunction 
with standard therapy regimens e.g. surgery and radiation therapy with the aim of improving 
clinical outcomes and also minimising chemo/radiotherapy associated side effects.  
 
The results presented in this thesis revealed a marked response in solid tumour cell lines when 
treated with CX-5461 in combination with radiation exposure involving synergistic 
interactions. Drug treatment caused the activation of G2M cell cycle arrest, senescence, 
induction of autophagy, DNA damage coupled with the induction of apoptosis, which was 
dependent on the cell line under investigation. 
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6.1 CX-5461 is a potent cytotoxic agent in solid cancer cell lines with a marked anti-
proliferative profile 
 
 
A panel of fifteen solid cancer cell lines were evaluated for CX-5461 associated cytotoxic 
effects using MTS cell proliferation assay (Section 3.3). Cells were treated with a range of CX-
5461 doses for 96hrs and the IC50 obtained are presented in Section 3.3. Treatment of a panel 
of cell lines with CX-5461 resulted in broad range sensitivity in solid cancer cell lines with the 
most sensitive being PANC-1 pancreatic and A375 melanoma cell lines. Of the cell lines used 
this study, IC50 values obtained for A375 (IC50 53.58nM) and HCT-116 (IC50 178.3nM) cell lines 
were in agreement with those reported previously by Drygin et al (A375 IC50 58nM & HCT-116 
IC50 162nM) who included both solid cancers as well as haematological malignancies in their 
cell panel (Drygin et al, 2011). Previously, it has been shown that CX-5461 exerts specific 
toxicity towards BRCA2 deficiencies in cancer cells (Xu et al, 2017). PEO1 (BRCA2 Mut) was 
found to be significantly more sensitive to the effects of CX-5461 compared to PEO1-CarbR 
(BRCA2 wt). This selectivity of CX-5461 can be exploited to treat highly aggressive tumours 
based on BRCA status. 
 
BRCA1 and BRCA2 are human genes which encode tumour suppressor proteins which are 
involved in the repair of damaged DNA ensuring the stability of a cells genetic material. BRCA1 
is a pleiotropic (having multiple effects) DNA damage response protein which functions in 
both cell cycle checkpoint activation as well as DNA repair, BRCA2 is a known mediator of the 
homologous recombination DNA repair pathway (Roy et al, 2012). Mutations in either 
BRCA1/BRCA2 genes can lead to the improper repair of damaged DNA which can lead to 
additional genetic alterations resulting in the formation of cancerous growth of cells. In light 
of these findings involving CX-5461 toxicity in BRCA2 deficient cell lines, a wider panel of cell 
lines constituting of wild type and mutant BRCA2 status gene profile (through gene silencing 
and BRCA2 overexpression) would provide deeper insights into the mechanism surrounding 
the specific toxicity of CX-5461 towards cancers harbouring BRCA2 mutations.  
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Of the cell lines included in the CX-5461 sensitivity panel, eight cell lines were wild type for 
p53 status and seven cell lines had reported mutated p53 status (Section 3.3). We found no 
difference in the sensitivity towards CX-5461 based on the status of p53 of the solid cancer 
cell lines. This finding is also in agreement with Drygin et al (2011) who also reported no 
statistical significance in sensitivity towards CX-5461 of solid cancer cell lines based on their 
p53 status. In haematological malignancies such as acute myeloid leukaemia however, p53 
status did seem to play a role in determining sensitivity with wild type p53 cell lines being 
more sensitive towards CX-5461 and p53 mediated induction of apoptosis (Bywater et al, 
2012).  This lack of specificity of CX-5461 towards p53 status could be exploited in the clinic 
to treat cancers with mutated p53 status, since mutated p53 status is often associated with 
drug resistance (Heintz et al, 2017).   
 
CX-5461 prevents the binding of SL-1 to the pre initiation complex at the promoter region of 
rDNA genes therefore preventing the binding of RNA Pol I to promoter regions thus 
preventing the transcription of rRNA. Drygin et al, showed in A375 cells that treatment with 
CX-5461 reduced the transcription of 45s pre-rRNA transcripts via qPCR analysis (Drygin et al, 
2010), our results confirm this reduction in 45s pre-rRNA transcription (Section 5.20) in A375 
cells. We extended the qPCR analysis to CaSki cell line where over 72hrs qPCR results showed 
that CX-5461 also significantly inhibited pre-45s rRNA transcription (p-value 0.0001) (Section 
5.21) showing that CX-5461 is selective for genes under the control of RNA pol I. RNA 
polymerase I is an important target in the context of cancer intervention over RNA Pol II and 
III since RNA pol I is highly expressed in cancer cells and is driven by increased rates of Myc  
ERK signalling pathways, rRNA transcription mediated by RNA pol I as well as increased rates 
of protein synthesis required to sustain the high growth demands (White, 2005).  
 
Clonogenic assays and Ki67 staining by flow cytometry revealed the potent anti-proliferative 
effects of CX-5461 towards solid cancer cell lines (Section 3.5, 3.6, 3.7 and 3.8). Ki-67, with a 
half-life of ~60-90 minutes is a protein found in all active stages of the cell cycle apart from 
the G0 phase (Scholzen et al, 2000 and Sun et al, 2018). The expression of Ki-67 has been 
associated with the proliferative capacity of intrinsic cell populations in malignant tumours 
and can therefore be used as a marker for tumour aggressiveness (Brown & Gatter, 2002).  
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In A375, LN18 and CaSki cells, low nanomolar doses of CX-5461 were sufficient to prevent the 
formation of any colonies from single cells (Section 3.5, 3.6, 3.7). These results are in line with 
Xu et al who also reported strong anti-proliferative effects of CX-5461 in isogenic BRCA2 
knockout and wild type HCT-116 cells (Xu et al, 2017). Hein et al have also reported anti-
proliferative effects of CX-5461 in leukemia initiating cell populations as measured by 
clonogenic assay (Hein et al, 2017).  
 
Over the course of 72hrs, the levels of Ki-67 could be seen to decrease in a dose dependent 
manner (Section 3.8). A reduction in Ki-67 has also been reported following CX-5461 
treatment in Hi-MYC prostate tumours (Rebello et al, 2016). Taken together, our results are 
in agreement with the anti-proliferative effects reported in the literature with respect to 
exposure of CX-5461 towards solid cancer cell lines.  
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6.2  The cytotoxic effects of CX-5461 are enhanced when combined with X-ray radiation 
therapy 
 
 
Of the solid cancer cell lines used in the cell panel to assess CX-5461 induced cytotoxicity, 
three cell  lines with High sensitivity (A375), medium sensitivity (LN18) and low sensitivity 
(CaSki) were selected to be used in combination treatment experiments involving CX-5461 
and single dose X-rays (Section 3.4, 3.5, 3.6 and 3.7). Exposure of A375, LN18 and CaSki cells 
to single dose X-rays for 96hrs showed a dose dependent decrease in survival as measured by 
MTS assay (Section 3.3). The dose responses of A375, LN18 and CaSki cells towards single 
dose X-rays exposure are in line with previous reports in the literature (Ahmed 1996; Zheng 
2004).  
 
Combination experiments involving treatment of A375, LN18 and CaSki cells with a range of 
Cx-5461 doses in combination with single dose X-ray exposure revealed synergistic 
interactions in all three cell lines. Combination index values showed that CX-5461 was most 
synergistic with X-rays in CaSki cervical cancer cells (Section 3.7) followed by A375 melanoma 
cells (Section 3.5) and least synergistic in LN18 glioblastoma cells (Section 3.6).  
 
 
Combination index values in CaSki cells showed that the highest synergy was seen in the low 
drug range (6.25nM to 50nM CX-5461) and in the low dose radiation range (2Gy-6Gy) (Section 
3.7).  Compared to A375 and LN18 where combination index values indicated the most 
synergistic interactions to involve low drug doses and high radiation doses (Section 3.5 and 
3.6). As CaSki cells are wild type for p53 status, activation of the nucleolar stress response, as 
a consequence of inhibiting RNA Pol I transcription, could lead to the interaction of RPL11 
with HDM2, releasing and stabilising p53 to activate cell cycle arrest and the induction of 
apoptosis (Yang, 2018 & James et al, 2014).  
 
The high synergy observed in CaSki cell line between CX-5461 and X-ray irradiation could be 
explained in terms of a deficit in DNA repair proteins available to the cell following treatment 
with CX-5461 and exposure to X-rays. Exposure to ionising radiation can cause indirect effects 
(reactive oxygen species generation), direct effects (DNA damage) as well as non-targeted 
effects (radiation induced bystander effect RIBE) (Mavragani et al, 2016).  
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Reactive oxygen species (ROS) are free radicals and reactive molecules derived from 
molecular oxygen. Examples include superoxide anion, peroxide, Hydroxyl radical, Hydroxyl 
ion and nitric oxide. ROS are produced as by products from aerobic respiration during 
mitochondrial electron transport or by oxidoreductase enzymes. Exogenous ROS can be 
produced from tobacco smoke, pollutants, drugs, xenobiotics and radiation. Endogenous ROS  
are produced intracellularly through multiple mechanisms which are dependent upon the cell 
and tissue type, with the major producer of ROS being the NADPH oxidase complexes found 
within membranes, mitochondria, the endoplasmic reticulum and peroxisomes (Muller, 2000 
and Han et al, 2001). 
 
The detection and subsequent repair of these aforementioned cellular stresses activate a 
variety of responses in irradiated cells which are initiated by the DNA damage response and 
DNA damage repair pathways to repair the damage, activate apoptosis or initiate and immune 
response. All these processes require the production of proteins specific to each pathway to 
be produced on demand, in the case of rRNA transcription inhibition, a lack of fully functioning 
ribosomes facilitate the promotion of cell death since ionizing radiation induced damage 
cannot be repaired.  
 
Combination treatment in CaSki cells was more effective at inducing cell death via apoptosis 
compared to using each agent alone (Section 4.14). This trend was seen over the course of 
48hrs (Section 4.14), 72hrs (Section 4.15) and 96hrs (Section 4.16) where combination 
treatments involving CX-5461 and 4Gy/8Gy X-rays induced greater apoptosis compared to 
using CX-5461 or X-rays alone over the same time periods. The scheduled treatment of CX-
5461 in CaSki cells was also investigated (Section 4.17). The results showed that 24hr-
pretreatment with CX-5461 following 4Gy radiation exposure was more effective at reducing 
cell survival compared to treatment with CX-5461 on the same day as radiation treatment or 
24hrs post radiation. 
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Combination treatments over 48hrs and 72hrs showed an increase in Annexin C-FITC/PI 
staining which is indicative of the induction of end stage apoptosis as PS has been externalised 
and able to bind to Annexin V-FITC and PI which is membrane impermeable and is able to 
enter the cell through the ruptured membrane and bind to DNA. When combination lysates 
were probed for markers of caspase dependent apoptosis (PARP), detection of cleaved PARP 
at 48hrs could only be detected in samples which received doses of radiation alone (Section 
4.14), little cleavage of PARP could be observed for samples treated with CX-5461 alone or in 
combination with X-rays. At 72hrs, modest bands of cleaved PARP could be detected in CX-
5461 alone treated samples or in combination treatment lysates. This hints at the possibility 
that cell death via apoptosis may be occurring via caspase-independent mechanisms.  
 
Cell cycle analysis of CaSki cells treated in combination with 4Gy, 10Gy and 16Gy X-rays 
alongside 1uM CX-5461 showed a complete abolition of cell cycle activity (Section 5.8) 
compared to CX-5461 treatment alone over the same time period in CaSki which induced a 
G2M cell cycle arrest (Section 5.6). In A375 cells, CX-5461 single agent treatment also induced 
a G2M cell cycle arrest (Section 5.9). A blockage during the G2M transition has been reported 
in previous studies involving treatment with CX-5461 (Cornelison, 2017; Hein, 2017; Li et al, 
2018; Li et al, 2016 and Robello et al, 2016). A G2M checkpoint arrest is a common result of 
genotoxic damage employed to prevent the entry into mitosis following DNA damage (Liang, 
2009). 
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6.3 CX-5461 treatment induces apoptosis, autophagy and senescence in solid cancer cell 
lines 
 
 
Initial studies involving CX-5461 reported the induction of p53 dependent apoptosis in 
haematological malignancies (Bywater et al, 2012) and in solid cancers cell death was 
primarily reported to be through autophagy and senescence (Drygin et al, 2010). Cell death 
analysis using Annexin/PI assay has shown that treatment in solid cancers with CX-5461 can 
induce apoptosis as measured by flow cytometry as well as the detection of autophagy and 
cellular senescence in solid cancer cell lines through LC3II-LC3I conversion and p62 
sequestration as measured by western blot analysis and senescence associated β-
galactosidase activity using bright field microscopy respectively. 
 
In LN18, A375 and CaSki cell lines, end stage apoptosis was detected through the use of 
Annexin V-FITC/PI assay. In all three cell lines, drug treated samples show higher populations 
of cells staining positive for both Annexin V-FITC and PI staining compared to untreated 
controls (Section 4.9 – 4.11).   For LN18 cells, although shift in cell populations could be 
observed no cleavage of PARP could be detected in lysates probed for whole and cleaved 
PARP at 48hrs or 72hrs (Section 4.9).  
 
In CaSki cells, a shift in viable cell population to end stage apoptosis was accompanied by 
detection of cleaved PARP at both 48hrs and 72hrs (Section 4.11). A375 cells too displayed 
modest cleavage at PARP at 48hrs following CX-5461 treatment (Section 4.10), in the 
presence of a pan-caspase inhibitor Z-VAD-FMK cells populations undergoing end stage 
apoptosis was reduced (Section 4.12) indicating that in A375 melanoma cells caspase 
dependent apoptosis is the cause for CX-5461 induced cell death 
 
Cellular senescence following CX-5461 treatment has been reported in A375 and MIA PaCa-2 
cells following treatment with 300nM CX-5461 for 24hrs (Drygin et al, 2010) and in primary 
immortalized human fibroblast cells (BJ-T) with 1μM CX-5461 for 72hrs (Quin et al, 2016). Our 
experiments in A375 cells are in line with these findings where treatment with CX-5461 for 
1μM CX-5461 for 48hrs caused a twelve fold increase in cells staining positive for β-
galactosidase (Section 4.13).  
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Under normal conditions where cell cycle progression is unhindered, the progression through 
the G1/S checkpoint into the S and G2 phase of the cell cycle as well as progression through 
M-phase is reliant upon several factors which must be in check before the cell commits to the 
process of cell division. These factors include cytoplasmic to nuclear ratio, sufficient 
concentration of proteins necessary for the synthesis of DNA and duplication of DNA, 
successful repair of any mutations before duplication, correct copy number of chromosomes, 
accurate alignment of chromosomes and microtubule assembly (Bell & Dutta 2002).  
 
A reduction in protein synthesis through rRNA transcription inhibition by CX-5461 results in a 
lack of fully functioning ribosomes available in G1 to synthesise all the proteins necessary to 
carry out all of the functions mentioned above. This means cellular contents excluding 
chromosomes cannot be successfully duplicated in order to successfully enter into S phase. 
This lack of availability of cellular components could then lead the cell to enter into the 
senescent state, where the cell is not committed to divide and has the potential to re-enter 
G1 upon relief from ribosome biogenesis inhibition. If the latter is not achieved, the cell can 
then activate the cell death cascade.   
 
The tumour suppressor protein p53 is an important regulator of cellular stress responses and 
induces the transcription of specific genes involved in cell cycle arrest, DNA repair, senescence 
and apoptosis (Prives & Hall, 1999).  Under normal physiological conditions p53 is maintained 
at low levels through its interaction with E3 ubiquitin ligase (MDM2) (Kruse & Gu, 2009). In 
wild type p53 cells, under conditions of nucleolar stress (following rDNA transcription 
inhibition or nutrient deprivation), riboproteins from the small and large ribosome subunits 
such as RPL11, translocate to the nucleoplasm take on other functions which result in the 
stabilisation of p53 through the interaction of RPL11-MDM2 complexes which causes the 
upregulation of p53 and its target genes resulting in cell cycle arrest and activation of 
apoptosis (Dez & Tollervey, 2004). The lack of apoptotic induction following RNA Pol I 
inhibition could be a result of mutated p53 genes or truncated p53 proteins which are unable 
to activate the p53 dependent nucleolar stress response pathway thus preventing the 
activation of the apoptotic cell death cascade.  
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The induction of autophagy was assessed in A375, SKMEL, LN18 and CaSki cell lines. 
Autophagy was investigated through monitoring the conversion of LC3I-LC3II coupled with 
p62 degradation alongside flow cytometry analysis of formation of autophagolysosome. Any 
cells undergoing autophagy following CX-5461 treatment were imaged for LC3-II puncta using 
confocal microscopy.  
 
Significant conversion of LC3I-LC3II was observed in CaSki lysates probed at 24hrs, 48hrs and 
72hrs (Section 4.6). Complete conversion of LC3I-LC3II was also observed in SKMEL-28 cells 
at 48hrs (Section 4.5). In both cell lines this conversion was accompanied with a decrease in 
p62/SQSTRM levels which indicates that the process of autophagic flux is taking place 
(Klionsky et al, 2016). CaSki cells seemed to be the most autophagy proficient with clear LC3-
II puncta being visualized using confocal microscopy imaging (Section 4.6 – 4.7) when 
compared to rapamycin treated positive control samples, a known inducer of autophagy 
(Meijer & Codogno 2004). 
 
In A375 cells and LN18 cell lines, an incomplete conversion of LC3-I to LC3-II was noted 
alongside a lack of degradation of p62 in LN18 and A375 cells (Section 4.2 and 4.3) indication 
a lack of complete autophagic process where p62 itself is incompletely degraded by 
autophagolyosomes which usually marks the completion of autophagic flux. Flow cytometry 
analysis using Cyto-iD Autophagy Assay kit (Enzo) showed that CX-5461 was more effective at 
inducing end stage autophagy compared to rapamycin treated cells in CaSki (Section 4.7) and 
SKMEL (Section 4.5) cell lines in a time and dose dependent manner. The induction of 
autophagy following CX-5461 treatment could serve as a survival mechanism by which the 
cell attempts to lower its energy consumption demands following inhibition of rRNA 
transcription since the process of ribosome biogenesis is a huge energy consuming process 
(Granneman and Tollervey 2007).  
 
Several forms of DNA damage are marked by phosphorylation of histone gH2AX at Ser139 
residues by ATM and ATR kinases (Huen & Chen 2008). Detection of DNA damage in CaSki, 
A375 and LN18 cell lines exposed to CX-5461 treatment was marked by significantly increased 
detection of gH2AX in a time and dose dependent manner (p-value 0.0001) (Section 5.3, 5.4 
and 5.5).  
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In combination treatments involving CaSki cells, CX-5461 induced DNA damage was higher 
compared to single agent treatments alone. This is in agreement with the data obtained from 
our combination index values which show synergistic interactions between CX-5461 and X-
rays. DNA damage was then visualized using confocal microscopy of gH2AX foci in CaSki cells 
at 48hrs and 72hrs following CX-5461 treatment (Section 5.3). Quantification of green pixels 
(gH2AX foci) relative to blue pixels (DAPI stained DNA) (Section5.3) in drug treated images 
compared to untreated images show significantly higher ratios of green>blue pixels and this 
is in agreement with densitometry analysis of gH2AX western protein band measurements 
which show increases in gH2AX levels in drug treated samples  (Section 5.2, 5.4 and 5.5).   
 
NPM1 is a multifunctional nucleolar protein which is involved in ribosome biogenesis, mitotic 
spindle assembly, chromatin remodelling, embryogenesis, DNA repair and autophagy (Box et 
al, 2016).  To illustrate the multiple interactions of NPM1 analysis from the STRING functional 
protein association network shows the known interactions of NPM1 from curated databases 
and experimentally determined interactions as well as predicted interactions from gene 
neighbourhoods, gene fusions and gene co-occurrences (Figure 6.1) (https://string-
db.org/cgi/network.pl?taskId=olIqhguyAvC2, accessed 16-8-18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.1: STRING analysis of known and predicted proteins interacting with NPM1 
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Preliminary data shows that silenced NPM1 CaSki cells did seem to be more sensitive towards 
the effects of CX-5461 compared to non-coding SiRNA treated samples following 72hr 500nM 
CX-5461 treatment (Section 5.10). In order to completely ascertain if knockdown of NPM1 
does indeed sensitise cells to the effects of CX-5461, overexpression of NPM1 would need to 
be investigated to determine any NPM1 associated cyto-protective effects. Previous studies 
have shown that knockdown of NPM1 sensitises glioma cells to Act D exposure and in prostate 
cancer cells silencing of NPM1 was seen to decrease their proliferative capacity. In conclusion, 
although transient silencing showed increased sensitivity to CX-5461 exposure, further work 
is required to elucidate the mechanism behind this observation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218
6.4 Future work 
 
Detection of apoptotic cell death was measured using flow cytometry using Annexin V-FITC/PI 
assay as well as through the detection of cleaved caspase-3 and cleaved PARP. This was 
assuming that any apoptosis taking place was caspase dependent. Since Western blot analysis 
showed very little cleavage of PARP and no detectable cleavage of caspase-3, caspase 
independent mechanisms may be responsible for activating the apoptotic cascade. Caspase 
independent mechanisms of cell death can be initiated by active (apoptosis inducing factor 
(AIF)) or through passive mechanisms such as adenosine triphosphate (ATP) depletion. 
Apoptotic associated DNA fragmentation is mediated through the translocation of AIF and 
endonuclease G to the nucleus following mitochondrial outer membrane protein release 
(Pradelli, 2010). The detection of AIF and endoG relocation using confocal microscopy could 
aid in detecting any caspase indepenedent associated effects following CX-5461 treatment as 
well as measuring ATP levels.  
 
Micro array assays involving pathways related to apoptosis (intrinsic & extrinsic), autophagy 
(autophagy related genes) as well as PI3K/Akt/mTOR (pro-survial)  pathway would provide 
insights into the expression of genes involved in these processes following treatment with CX-
5461.  
 
To confirm if cells are indeed transcriptionally inactive following CX-5461 treatment, 
visualisation of the translocation of upstream binding factor (UBF), an essential component 
of the RNA Pol I transcription framework, to the nucleolar caps would aid in a reduction in 
rDNA transcription alongside qPCR data.  
 
Since the majority of work involving CX-5461 has been done in vitro apart from Bywater et al 
(2012) who used a mouse model to study the effects CX-5461, using animal models to further 
explore the effects of combination treatment involving CX-5461 and X-rays and the effects on 
tumour size and volume would provide further insights into the synergy between CX-5461 
and radiation treatment.  
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Further cell cycle analysis would include measuring levels of cyclin A and cyclin B since these 
cyclins are involved in the transition from S phase in G2 phase of the cell cycle as well as 
monitoring levels of mitosis promoting factor (MPF) which associates with cyclin B to progress 
through m-phase. An observed increase in cyclin A and reduction in cyclin B alongside MPF 
levels would confirm the findings of G2M arrest following CX-5461 treatment.  
 
It has previously been reported that p21CIP1/WAF1 and also p16INK4a proteins levels are 
upregulated during replicative senescence (Stein et al, 1999), measurement of these markers 
could provide molecular insights into the induction of senescence observed in solid cancer 
cell lines following CX-5461 treatment. To establish if autophagy is a cytotoxic response to CX-
5461, pre-treatment with lysosomal inhibitors such as Pepstatin A, which inhibits lysosomal 
enzymes, followed by CX-5461 treatment would determine if autophagy is the route of cell 
death.   
 
Further work would also include to study the effects of CX-5461 in a non-cancerous 
phenotype. This would allow investigation into the selective cytotoxicity of CX-5461 towards 
cancer cells over healthy cells. Taken together, the future work proposed would provide 
deeper mechanistic understandings into the synergistic interactions of CX-5461 with radiation 
as well providing a route to treat cancers with p53 and BRCA mutations.  
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